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Abstract
Knisley, Kyle James. M.S., Department of Chemistry, Wright State University, 2013.
Libraries from Libraries Approach to the Synthesis of Arylidene Oxindoles.

A libraries from libraries combinatorial chemistry approach was employed to
synthesize fluorinated derivatives of both oxindoles and isatins as potential
pharmaceuticals or targeting agents for imaging purposes related to cancer or
Alzheimer’s disease. Synthesis for these fluorinated derivatives are described by routes
involving, either: a) N-alkylation of 5-substituted isatins followed by Wolff-Kishner
reduction to the corresponding oxindoles and final Knoevenagel condensation with aryl
aldehydes, or; b) Wolff-Kishner reduction of the isatins followed by condensation and
finishing with the N-alkylation of the aldol products. In specific cases, a “click” reaction
followed the N-alkylation of the aldol products to form the isatin 1,2,3-triazole which
could be utilized to perform radiochemistry with a [18F]-radiolabel for the imaging of
cancer. The strategy for the synthesis of such potential inhibitors was guided by SAR
studies of peptide based inhibitors, as well as small-molecule inhibitors based upon the
isatins scaffold. Previously, it was shown increasing functionality by adding 3 points of
variability with the incorporation of an electron-withdrawing group such as a chlorine
atom at the C-5 position allowed for increased potency of the oxindole derived inhibitors.
Herein, a library of arylidene oxindoles was synthesized utilizing 3 points of variability
with the incorporation of the electron-withdrawing group fluorine. Furthermore, a novel
i
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alternative synthesis was established for the creation of arylidene oxindoles which
allowed for increased functionality through the incorporation of N-propargyl inhibitors.
Finally, the ability to create N-propargyl compounds lead to the synthesis of isatin 1,2,3triazoles was also explored for the possibility as potential imaging agents for cancer.

ii
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Introduction
In recent years the drug discovery process has relied to some extent on the
precepts of combinatorial chemistry1 as a means of rapidly synthesizing and evaluating
diverse libraries of compounds for biological activity. Such compound libraries are
centered about scaffolds which can be defined as the “core portion of a molecule common
to all members of a combinatorial library.”2 Certain chemical structures (often polycyclic
heterocycles) have been found to be particularly attractive scaffolds for drug discovery
libraries as they are often capable of binding as ligands to multiple, unrelated classes of
protein receptors and have been defined as privileged structures.3 One such family of
privileged structures includes the benzo-fused nitrogen heterocycles, including indole (1)4
and its oxidized congeners isatin (2) and oxindole (3).

It is generally appreciated that libraries developed around such privileged
structures should “yield medicinally active compounds with high hit rates at significantly
reduced library size compared to large classical libraries obtained from combinatorial
chemistry efforts based on non-privileged templates.”5 As this thesis relates to the
construction of fluorinated derivatives of both oxindoles and isatins as potential
1
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pharmaceuticals or targeting agents for imaging purposes related to cancer or
Alzheimer’s disease, a brief overview of the diverse biological activities of these
heterocycles is presented herewith.
Oxindole
Oxindole (indolin-2-one, 3) is a reduced derivative of the isatin family and was
first synthesized by Baeyer at the end of the 19th century through the reduction of isatin.6
The chemistry and synthesis of oxindole was last reviewed by Sumpter in 1945.7 Given
the biological activity of this heterocyclic scaffold, much recent work has been devoted
to rapidly generating diversity by taking advantage of the reactive C-3 ketone carbonyl
group of isatin precursors in multicomponent reaction processes so as to afford the
corresponding spirocyclic oxindoles.8 Although the broad range of biological activities
exhibited by oxindoles warrant their inclusion into the classification of privileged
scaffolds, perhaps their most significant role is that of protein kinase inhibitors.9
Arylidene oxindoles were among the first structures identified as receptor tyrosine kinase
(RTK) inhibitors by SUGEN in 1998, wherein it was found that: (1) 3[(pyrrole)methylidenyl]indolin-2-ones are highly specific against the VEGF (Flk-1) RTK;
(2) 3-(substituted benzylidenyl)indolin-2-ones (e.g., 4) containing bulky groups in the
phenyl ring at the C-3 position showed high selectivity toward the EGF and Her-2 RTKs;
and, (3) pyrrolic compounds containing an extended side chain exhibited high potency
and selectivity when tested against the PDGF and VEGF (Flk-1) RTKs.10
Crystallographic evidence demonstrated that both the proton at the N-1 position and the
oxygen atom at the C-2 position of the indolin-2-one were found to be coordinated to the
2
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peptide backbone within the ATP binding pocket of these RTKs, and it was reasoned that
such bidentate hydrogen bonding between the indolin-2-one flat core in the adenine
binding site might serve to block entry of ATP in the site. Additionally, it was found that
alkylation at the N-1 position of the indolin-2-ones greatly decreases the inhibitor potency
of these oxindoles, and that the substitution around the indolin-2-ones may be key
determinants for the potency and especially specificity of the inhibitors. This recurring
(vide infa) “nitrogen-linked Michael acceptor”11 structural motif of general structure 4 is
found in many biologically active oxindoles, and has led to development of SU11248 (5(5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3carboxylic acid (2-diethylaminoethyl)amide (5) or Sunitinib.11

Sunitinib was developed as a tyrosine kinase inhibitor that would target both
vascular endothelial (VEGF) and platelet-derived growth factor (PDGF) RTKs because
of their critical roles in tumor growth and the fact that both RTKs have been found to be
expressed on tumor cells and affect tumor cell production.11 It was found to possess the
best inhibitory potency against the VEGF-R2 and PDGF-Rβ targets in biochemical and
cellular assays, displays solubility under both neutral and acidic conditions, and protein
binding properties in the presence or absence of serum or blood proteins.12 Sunitinib
also had very good oral bioavailability, was highly efficient in a number of preclinical
3
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tumor models and was so effective that it was placed into clinical phase I trials for the
treatment of cancer.12
It should also be mentioned that the synthetic sequence developed by SUGEN
remains the most commonly employed approach to arylidene oxindoles and involves an
initial Wolff-Kishner reduction of the C-3 carbonyl group of substituted isatins 6 (which
in general are more readily available) to the corresponding oxindoles 7 in refluxing
hydrazine hydrate, followed by an aldol type condensation with an appropriate aldehyde
in refluxing ethanol with a catalytic amount of piperidene.

Such arylidene oxindoles 8 (which can exist as a mixture of E/Z isomers) can
serve as potent protein kinase inhibitors9-22, exhibit moderate antitumor 23,24 and antiviral
activity (HIV),25 and can serve as caspase-3 inhibitors.26 As described earlier, oxindoles
are most often recognized as protein kinase inhibitors. Protein kinases are involved in a
number of diseases such as cancer, diabetes, and inflammation in which the protein
kinase-mediated cell signaling pathways are activated by these disease states. The human
genome encodes over 518 protein kinases that share a catalytic domain conserved in
sequence and structure but are vastly different in the way catalysis is regulated.9 Protein
kinase inhibitors are designed around the ATP binding pocket between two lobes within

4
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the kinase fold which when combined with less conserved surrounding pockets has
allowed for differences in kinase structure and flexibility in order to achieve selectivity.9
Benzylidene oxindoles with a phenolic group at C-3 represent another important
class of kinase inhibitors. Workers at Glaxo Wellcome first demonstrated the efficacy of
such analogues for the inhibition of cRaf1, a kinase required for Ras signal transduction
and the first enzyme in the mitogen-activated protein (MAP) kinase cascade consisting of
the three kinases cRaf1, MEK and ERK.13 The c-Raf protein kinase is one of three Raf
proteins possessed by mammals, the other two Raf proteins are known as A-Raf and BRaf. B-Raf is expressed primarily in the nervous system and is the most potent activator
of MEK, (A-Raf is the weakest), and c-Raf is expressed throughout the body. The Raf
proteins are involved in a signaling pathway that has been implicated in the promotion of
neuronal survival which exists as the Raf-MEK-ERK pathway. Researchers have
discovered that disruption of either c-Raf or B-Raf results in embryonic lethality.14
Workers at the University of Texas at Dallas later discovered that one of the Glaxo c-Raf
inhibitor compounds, GW5074 (5-iodo-3-[(3,5-dibromo-4-hydroxyphenyl) methylene]2-indolinone, 9)14 was a potent inhibitor of neurodegeneration both in cell culture and in
an animal model. It inhibits the death of cultured cerebellar granule and cortical neurons
induced by a variety of different apoptotic stimuli and also prevents striatal degeneration
and improves behavioral performance in mice treated with 3-nitropropionic acid which is
commonly used as an in vivo paradigm of Huntington’s disease.14 Although compound 9
represented the first demonstration of neuroprotection by pharmacological inhibition of cRaf, the major drawback to GW5074 lies in the fact that it is neurotoxic at concentrations
that are not much higher than those at which it is protective.
5
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Benzylidene oxindole derivatives possessing the (C=O)NH and the C-3 pyrrolyl
N-H moieties capable of making three hydrogen bonds with the backbone motif of the
kinase hinge region have also been demonstrated as inhibitors of cyclin-dependent
kinases (CDKs).15 CDKs play an important role in cell-cycle proliferation and are
attractive targets in cancer chemotherapy. An enamino analog GW8510 (10) was
discovered by Davis et al.17 The cyclin-dependent protein kinase has been linked to
neuronal apoptosis in which an abortive re-entry of neurons into the cell cycle occurs.
GW8510 was developed as an inhibitor of cyclin-dependent kinase 2 (CDK2) and
inhibits cerebellar granule neurons caused by switching them from high potassium (HK)
medium to low (LK) potassium medium. Johnson et al. showed that GW8510 was one
of seven 3-substituted benzylidene oxindoles that prevents LK-induced death of
cerebellar granule neurons.18 These findings demonstrate that the oxindole scaffold is
very effective for the development of neuroprotective compounds that could be utilized in
the treatment of neurodegenerative conditions.

6
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The casein kinase CK1 inhibitor IC261 (11) developed by Flajolet et al. is
another example of an oxindole derivative being utilized as a protein kinase inhibitor.19
The CK1 kinase inhibitor and -secretase are targets for therapeutic intervention in the
treatment of cancer and Alzheimer’s disease. Alzheimer’s disease is an illness that
prevents patients from managing their own lives and is accompanied by protein
aggregates in the brain largely composed of amyloid-β-peptide (Aβ) which are better
known as amyloid plaques. Aβ is generated by the degradation of the type I
transmembrane amyloid precursor protein (APP) by two aspartyl proteases, β- and

-

secretase. The -secretase is a target for therapeutics because it liberates various Aβpeptides with the lengths of 38, 40, and 42 amino acids. The toxicity of such amyloid
monomers is dependent upon the length of the peptides, in which case Aβ42 is the most
toxic and Aβ38 is non-toxic.20 IC261 was shown by Flajolet to be an ATP-competitive
casein kinase 1 (CK1 ) inhibitor and causes a significant reduction of Aβ40 and Aβ42.
Hottecke et al. attempted to analyze the relationship between CK1 kinase and

secretase

inhibitory activity.20 It was observed that cellular -secretase inhibition occurred at high
concentration of IC261 or through a metabolic activation of IC261. Variations of
IC261were synthesized and it was observed that subtle variations to the substitution
pattern caused a loss in the CK1 inhibition.

7
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Zhou et al. examined the antitumor activities of 3-substituted 1-(5-formyl
furfuryl) indolin-2-ones such as (Z)-5-bromo-1-(5-formylfurfuryl)-3-(4-nitro benzyli
denyl)indolin-2-one (12).23 In the development of 12, forty-two analogues were
synthesized and screened of which thirty one compounds were found to be highly potent
against human intestinal Caco-2 cell line. It was observed that EWG substitutions in the
molecules were favorable for their antitumor activities. Compound 12 was found to be
the most active with an IC50 value of 0.19 μM.23

Oxindole derivatives have also been shown to exhibit antiviral activity in the form
of non-nucleoside reverse transcriptase inhibitors (NNRTI). The main disease associated
with NNRTI is HIV/AIDS, the leading cause of death due to infectious disease in the
world. Treatment failures for this disease remain high due to the evolution of drugresistant viruses. The most commonly prescribed drugs for HIV are the NNRTI. Jiang et
al. synthesized 13 as a potential NNRTI, and although 13 was a very potent inhibitor for
HIV replication, it exhibited high clearance, low exposure, and low bioavailability25.

8
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The inhibitor was optimized by replacing the ester moiety with a tetrazole since
esters are known to be metabolically unstable, and using a 5-chloro- rather than a 5bromo-substituent. It was discovered that one form of the tetrazole was active while
another form was inactive depending on the position of the methyl group on the tetrazole
ring, and the incorporation of a 2-pyridinyl moiety in place of the tetrazole (e.g., 14),
exhibited EC50 values in the single digit nanomolar range (0.008 μM) suggesting that the
pyridine nitrogen is important in the interaction with the enzyme. Additionally,
incorporation of a methyl group at the meta-position of the 2-pyridyl ring of 14 increased
the inhibitory potency of the HIV inhibitor 15 to 0.005 μM. The study also
demonstrated that compounds 14 and 15 exhibited significantly improved exposure and
improved water solubility compared to that of compound 13 indicating they might be
better HIV replication inhibitors.25

As can be seen from the examples above, oxindole derivatives have been
employed in the treatment of a variety of pathological diseases ranging from cancer to
neurological disorders. There are numerous possibilities for a potential drug lead with
9
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the oxindole scaffold which makes it an interesting and popular starting point for many
researchers when searching for the next big discovery in the pharmaceutical world. Isatin
is also considered a privileged structure that presents similar features to those of oxindole
which is the reason it too is a very popular starting point as a drug lead.
Isatin
Isatin (2, 1-H-indole-2,3-dione)27 is a naturally occurring product found in a
variety of plants such as the genus Isatis and found as a metabolic derivative of
adrenaline in humans.28 Isatins are another member of a family of benzo-fused nitrogen
heterocycles which exhibit a range of pharmacological properties including both
antiprotozoal activities and anticancer activities.29,30 Previously, isatin derivatives were
associated with dye synthesis but recent reviews on isatin have shown that these
heterocycles exhibit a variety of beneficial effects towards many pathological and
physiological diseases.27 Due to the fact that various isatin derivatives are known to
possess extensive biological activity, the isatin scaffold is also considered a “privileged
scaffold”,31 and as such can serve as a convenient starting point in the search for new
receptor agonists and antagonists.

Iyer and co-workers demonstrated that simple N-Boc and N-Cbz-isatin analogues
(e.g., 16) acted as reversible, slow binding inhibitors of serine proteases and exhibited
selectivity for α-chymotrypsin over porcine pancreatic elastase.32 This is important
10
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because serine proteases have been associated with a number of pathological conditions
such as neurodegenerative diseases and arthritis and these findings demonstrated that
minor structural modifications of the isatin scaffold can lead to potentially useful
protease-specific inhibitors.

Webber and coworkers described an extensive study of isatin derived inhibitors
of HRV 3C protease, 33 and developed a new class of active, reversible, non-peptidic
inhibitors of this enzyme. The HRV 3C protease is responsible for the common cold,
therefore an inhibitor of this protease would allow for treatment of the common cold.
The structure activity relationship (SAR) studies showed that molecular recognition of
the carboxamide in the P1 subsite was an important aspect when considering the design of
the inhibitor. Also, it was determined that a carbonyl or a carbonyl isostere was required
at the C-5 position on the isatin scaffold for the most active HRV 3C protease inhibitors.
These findings allowed researchers to develop 1-benzo[b]thiophen-2-ylmethyl-2,3-dioxo2,3-dihydro-1H-indole-5-carboxylic acid amide (17) which was shown to be the most
potent inhibitor for this protease.

11
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Lindsley and coworkers discovered the first positive allosteric modulator (PAM)
of muscarinic acetylcholine receptor subtype 5 (M-5).34 These muscarinic acetylcholine
receptor subtypes participate in a variety of functions within many physiological
processes. Through the N-alkylation of the isatin scaffold, Lindsley was able to create the
first M-5 muscarinic acetylcholine receptor ligand in the form of 1-(4-methoxy-benzyl)5-trifluoromethoxy-1H-indole-2, 3-dione (18).34 SAR studies indicated that isatin
derivatives with a methoxybenzyl group at the N-position favored M-5 activity and the
trifluoromethoxy at the C-5 position favored a dual M-1/M-5 activity. Through
optimization of 18, it was discovered that replacement of the methoxy phenyl moiety
with a biphenyl ether moiety (e.g., 19) increased activity towards M-5 producing an EC50
value of 1.9 μM and exhibited decreased activity meaning it was selective against M1M4. Compound 19 was the most active and selective M-5 PAM to date.35

Through the work of Luhua and coworkers it was shown that isatin derivatives
could also be utilized as noncovalent (SARS) coronavirus 3C-like protease inhibitors.
12
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SARS coronavirus (severe acute respiratory syndrome) is a life threatening form of
atypical pneumonia.36 From the SAR studies it was concluded that a large hydrophobic
group placed at the N-1 position could fit in to a putative hydrophobic pocket leading to
high activity. It was also concluded that placing a carboxamide at the C-5 position of the
isatin scaffold made the molecule 3-4 times more active compared to the iodic
substitution in which iodine was utilized as a hydrophobic, electron affinitive group as
opposed to the carboxamide which can form multiple hydrogen bonds. The final
conclusion made by the group was that the C-3 oxygen formed a hydrogen bond to the
protein which was important for inhibition activity.36 These conclusions led to the
creation of 1-naphthalen-2-ylmethyl-2,3-dioxo-2,3-dihydro-1H-indole-5-carboxylic acid
amide (20) which was the most potent inhibitor of the SARS Coronavirus.

Biological Background
Recently, a new application for the isatin scaffold was discovered in the role of
caspase inhibitors. Caspases are cysteine aspartyl-specific proteases37 and regulate the
highly conserved mechanism of cell removal known as apoptosis (programmed cell
death).38,39 Apoptosis is essential in cell disposal as it serves to maintain homeostasis in
multi-cellular organisms. However, dysregulated apoptosis is believed to be involved in
13
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pathological conditions in humans such as cancer, autoimmune disorders and some
neurodegenerative disorders, such as Alzheimer’s, Parkinson’s, and Huntington’s
diseases.37 There are three groups of caspases; the first group is involved in
inflammation and includes caspases-1, -4, -5, and -13; the second group is the initiator
caspases which include caspases -6, -8, and -10; and the final group is the excutioner
caspases which include caspases 2,-3, and -7.40
Caspases are among the most specific of proteases.37 The nomenclature for
protease substrate cleavage is Pn, P1, P2, P3, P4, P4’, P3’, P2’, P1’, Pn’ which assigns amino
acid side chains of the peptide substrate and the nomenclature for the corresponding
bonding sites in the protease active site is Sn, S1, S2, S3, S3’, S2’, S1’, Sn’ subsites.41
Cleavage occurs at the amide bond between the P1 and P1’ residues known as the scissile
bond.40 Caspases have an absolute requirement for aspartic acid to be P1 in the S1 subsite
which is believed to be caused by hydrogen-bonding interactions between aspartic acid
and three residues of the caspase (Arg179, Gln283, and Arg341).40 Substitution of
aspartic acid-P1 with a different amino acid from the S1 subsite results in >100-fold
reduction in catalytic efficiency.40 Caspases have an equally stringent specificity for at
least four amino acids P4-P3-P2-P1 to the left of the cleavage site and this primary
sequence recognition is a necessary requirement for catalysis.40 Thornberry established
that caspases catalyze the hydrolysis of amide bonds through nucleophilic attack by the
activated cysteine thiol from the enzyme onto the amide carbonyl bond of the P1 amino
acid to form a tetrahedral intermediate which causes the cleavage of the peptide bond
when the double bound is reformed.40
Peptide Based Cell Death Inhibitors
14
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The first class of caspase inhibitors studied was peptide based. A typical peptide
based caspase inhibitor is comprised of a tetrapeptide sequence with an electrophilic
functionality known as a “warhead”. The “warhead” is typically located at the Cterminus of the peptide which may act as a reversible or irreversible moiety. Reversible
warheads are groups that can bind to the caspase temporarily through an intermediate and
then released, such as aldehydes, ketones or nitriles. Irreversible warheads possess good
leaving groups that are nontoxic, such as α-substituted ketones, so as to allow the leaving
group to be released once the nucleophilic caspase attacks and becomes attached to the
inhibitor.40 Also, the P4 amino acid is often capped with a neutral group like a acyl
moiety. Numerous peptide based caspase inhibitors have been synthesized and studied for
the inhibition of apoptosis. A potent peptide inhibitor that was one of the first to be
studied was acetyl-aspartyl-glutamyl-N-(2-carboxy-1-formylethyl)-valinamide (AcDEVD-CHO, 21) because DEVD is the cleavage sequence of poly(ADP-ribose)
polymerase (PARP) which is the DNA repair enzyme cleaved at the onset of apoptosis.42

Ac-DEVD-CHO is a potent and effective caspase inhibitor for in vitro studies
however it was less effective or useful for in vivo studies due to the three CO2H groups
that reduced the inhibitor’s ability to penetrate cells. Since the effectiveness of AcDEVD-CHO as a caspase inhibitor was limited due to the three CO2H groups, N-

15
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benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD-fmk, 22) was designed as a
peptide inhibitor likely to be more effective for in vivo studies. 43

Whereas the caspase inhibitor zVAD-fmk was shown to prevent apoptosis,
however it required high doses leading to toxicity because of the conversion of
fluoromethylketone into toxic fluoroacetate.44,45 Also, zVAD-fmk showed poor tissue
penetration indicating it too would not be suitable for diseases of the central nervous
system due the inability to penetrate the blood brain barrier.45,46 Brown et al. discovered
that the caspase inhibitor quinolyl-valyl-O-methylaspartyl-[2,6-difluorophenoxy]-methyl
ketone (Q-VD-OPh, 23) was significantly more effective in preventing apoptosis than
any other peptide-based caspase inhibitor.47

Q-VD-OPh exhibited increased potency, stability, and cell permeability compared
to other peptide caspase inhibitors and was non-toxic at high concentrations.47 Although
Q-VD-OPh exhibited significantly more attractive features than previous peptide based
caspase inhibitors, it has the disadvantage of being extremely difficult to produce in large
quantities.

16
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Haberkorn et al. introduced the concept that peptide based caspase inhibitors,
more specifically z-VAD-fmk, could be useful as an imaging agent of caspases.48 An
electrophilic aromatic substitution reaction was utilized to incorporate a radioactive
iodide at the benzyloxycarbonyl protecting group of the z-VAD-fmk creating [131I]zVAD-fmk (24). This compound was screened for its ability to measure apoptosis in
induced Morris hepatoma cells in which [131I]z-VAD-fmk was shown to have low
cellular uptake and high lipophilicity which caused unspecific binding.48 This poor cell
permeability hindered the intracellular targeting of activated caspases thus preventing in
vivo application.48

More recently, Bohn et al. aimed to label a peptide recognized by active caspase3 with a phenylalanine-glycine-cysteine (FGC) moiety that could complex technetium.49
The DEVD moiety was chosen as the peptide to target caspase-3. Stability and in vitro
studies were conducted to evaluate the usefulness of the peptide for monitoring the
effectiveness of cancer treatment.49 To perform such a procedure, the
(Me)FGC(Bz)DEVD peptide was purchased and effectively labeled using a phosphate
buffer, sodium tartrate and tin(II) chloride to yield 99mTc-(Me)FGCDEVD 26.49 Tin(II)
reduces the pertechnetate to technetium while the tartrate and the phosphate buffer
stabilize the technetium core prior to trans-chelating to the FGC motif. The benzoyl
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group in the precursor 25 has to be removed by heating (100 ᵒC, 30 min). During the
labeling process, the pH must remain neutral to enable the detection of the labeled
compound.
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The 99mTc-(Me)FGCDEVD was tested in tumor bearing mice treated with
cisplatin which induces apoptosis in tumors. Test subjects were re-evaluated three days
after initial treatment in which it was observed that uptake of 99mTc-(Me)FGCDEVD
was greater in subjects treated with cisplatin compared to control tumors.49 Therefore, it
is believed 99mTc-(Me)FGCDEVD has the potential to be a new apoptotic tracer for in
vivo studies in Single Photon Emission Computed Tomography (SPECT) but further
studies like toxicity and cell permeability need to be conducted.
It is unrealistic to pursue the use of peptides as effective caspase inhibitors or
imaging agents because of the numerous disadvantages they present such as the fact that
they can be metabolized in vivo. Also peptides have difficulties crossing the Blood Brain
Barrier (BBB) because of their size and the fact that they are mostly polar molecules
which is unfortunate since the treatment of neurological disorders require the ability to
cross the BBB. Due to the disadvantages presented by peptide based caspase inhibitors,
the use of small molecule caspase inhibitors was explored to greater success.
Small Molecule Approach
18
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Due to the limitations presented by peptide-based caspase inhibitors, researchers
looked for alternative small molecule inhibitors. SmithKline Beecham used a highthroughput screen of their compound library for inhibitors of caspase-3, which resulted in
the identification of 5-nitro-isatins 27, 28, and 29 which possessed IC50 values of 3 μM, 1
μM, and 0.25 μM, respectively.50

The role of C-5 substituents was then examined to assess the importance of the 5nitro functionality. A relationship was observed between the electron-withdrawing ability
of the 5-substituent (σm) and the potency of inhibition of caspase-3. The nitro (28), cyano
(31), methoxycarbonyl (32), and iodo (33) derivatives led to low micromolar inhibition
potencies but the protio (30) and carboxylate (34) compounds exhibited no activity at 50
μM.50
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As can be inferred from the values shown above, the electrophilicy of the isatin
C-3 carbonyl was deemed critical for activity and this indicated that the mechanism of
action involved addition of the catalytic cysteine residue of the enzyme to this
functionality.50 Binding models were developed based on X-ray structures which
allowed for the identification of the formation of a tetrahedral intermediate between the
catalytic cysteine thiol of caspase-3 and the isatin carbonyl group.51,52 It was deemed
necessary to find a replacement for the 5-nitro group since nitro groups can be subject to
metabolic reduction, and also in the interests of identifying a replacement functionality
that would allow for the facile incorportaion of molecular diversity.50 To this end, the
class of 5-N,N-dialkylisatin sulfonamides was developed and the new para 5-N,Ndialkylisatin sulfonamides were ultimately prepared by condensing secondary amines
with 5-chlorosulfonylisatin. However, in contrast to the original report in which isatin 2
was heated at 70oC in chlorosulfonic acid,53 the Glaxo team only obtained the gemdichloro derivative 35. To then attain the desired 5-isatin sulfonamide, the gem-dichloro
derivative 35 was reacted with an amine to give 36, and subsequent hydrolysis of the
gem-dichloro species with 3 N HCl afforded the 5-isatin sulfonamides 37.50

20

[Type text]
An alternative synthesis was later developed by Martinez et al. in which 5chlorosulfonylisatin was prepared by treating sodium 5-isatin sulfonate (38) with
phosphorus oxychloride in sulfolane at 80 oC. The resulting 5-chlorosulfonylisatin 39
was then reacted with 1 equiv. of amine in the presence of 1 equiv. diisopropylethylamine
in tetrahydrofuran to yield the 5-isatin sulfonamide 37.54

A series of isatin sulfonamides were then synthesized and evaluated for inhibition
of caspases which resulted in the identification of isatin sulfonamide 40 which exhibited
substantial activity against caspase-3 (Ki = 1.4 μM) and much more selectivity for
caspases-1, -3, and -7 relative to the active 5-nitro group of 28. This led to the
preparation of an extensive series of compounds with variation of groups about the
sulfonamide functionality and isatin nitrogen ultimately leading to the development of
isatin sulfonamides 41 and 42 which exhibited Ki(app) values of 60 and 15 nm inhibition
respectively against caspase-3.50

Lee et al. examined SAR utilizing pyrrolidine derivatives in which compound 40
was modified by extending groups from the C-2 position of the pyrrolidine ring. This led
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to the finding that chirality of the extended functionalities was significant. For example,
both R and S configurations of the methoxymethyl groups for 41 and 43 were examined,
wherein it was found that the (S)-configuration was found to be significantly more active
than that of the R-stereochemistry.50

These isatin sulfonamides inhibitors exhibited high selectivity towards caspases-3
and -7 which was possibly caused by the three hydrophobic residues, Tyr204, Trp206, and
Phe256 that are located in the S2 pocket which are unique to caspase-3 and -7.50 The xray co-crystal structure also revealed that a tetrahedral intermediate formed between the
catalytic cysteine thiolate and the isatin ketone carbonyl group indicating that the S2
pocket was involved in extensive hydrophobic contacts with the pyrrolidine ring of the
inhibitor. This supported the Lee et al. theory that the hydrophobic pocket allows for the
observed specificity of the isatin sulfonamides, which may be the reason 28 (e.g., N-CH3)
only exhibited moderate selectivity.55 Previously, it was believed that the S1 subsite of
caspases required a P1 aspartic acid residue in peptide-based inhibitors for recognition,
however, the co-crystal structure revealed that the S1 subsite in the case of isatins is
occupied only by a water molecule.50 This sulfonamide co-crystal structure model
revealed that caspase-3 exhibits minimal interactions with the S3 and S4 subsites and
selectivity is obtained by way of hydrophobic contacts between the pyrrolidine ring of the
inhibitor and residues of the S2 hydrophobic pocket.50
22

[Type text]
The SmithKline Beecham group had previously evaluated the importance of ring
size of the isatin sulfonamides by assessing compounds 40, 44, 45 and 46. From this
study it was discovered that there was no great effect on activity based on the ring size
from five to seven carbons, however the azetidine ring of 44 caused a significant increase
in potency compared to that of the analogous pyrrolidine moiety 40.50
N

O
S

O

O

N

O
S

N

O

O

IC50 2,800 nM
40

O

O

O
N
H

O
S

N
H

IC50 170 nM

O

O

IC50 2,200 nM

44

O
S

O
N
H

O

N

45

N
H

O

IC50 1,900 nM
46

However, the four member ring was an impractical choice for a lead since the
chiral five membered rings could be derived from either isomer of proline which would
allow for the facile incorporation of methyl or benzyl ether substituents with optimal
chirality (vide infra).50 For example, the potency of the SmithKline Beecham compounds
was further increased by adding a hydrophobic moiety such as a phenoxy group (e.g., 42)
or a methoxymethyl group attached to the pyrrolidine ring of 41 compared to those
compounds without a substituent such as 40 and 44. The potency was further increased
by N-alkylating the isatin sulfonamide compounds wherein it was observed that Nalkylation caused an increased activity for 47 over the N-H version 42.50
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Isatin Sulfonamides: Developments of the Washington University Group
Upon the initial discovery of the casapase inhibitory properties of isatin
sulfonamides by SmithKline Beecham, the Mach group from Washington University
School of Medicine further expanded the SAR of this scaffold 47.56 Salient structural
changes included substituting the para-position of the N-benzyl group, replacing the
pyrrolidine ring with a chiral C-2 substituted azetidine ring, and replacing the benzene
ring of the pendant phenoxymethyl moiety with a pyridine ring. As previously
discovered by SmithKline Beecham, N-alkylation of the isatin nitrogen of 42 with a
benzyl group 47 resulted in a 10 to 20 fold increase in potency for inhibiting caspase-3,
which led Mach to look at various N-alkylated derivatives.50 It was found that
incorporation of the azetidine ring on the isatin sulfonamide 44 caused an increase in
activity over the corresponding 5-membered congener. Mach found also that
replacement of pyrrolidine analogue with an analogous C-2 substituted azetidine
analogue (e.g., 48) unexpectedly resulted in little difference in potency for caspase-3, a
finding which was later explained by molecular modeling studies which revealed a high
degree of overlap in binding of the azetidine and pyrrolidine analogues to activated
caspase-3.56
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However, N-alkylation of the azetidine compounds possessing an O-benzyl/
substituted benzyl, or a pyridylmethyl group (e.g., 49-51, respectively) resulted in a 10 to
50 fold increase in potency against caspase-3.

Optimal caspase-3 inhibition (IC50 value of 3.9 nM) was achieved by replacement
of the benzene ring of the 2-(phenoxymethyl)pyrrolidine moiety with a pyridine ring
along with introducing a para-methoxy substituent on the N-benzyl substituent as in 52.56

The increase in potency of the pyridine analogues seems to be associated with a
possible hydrophilic interaction between the pyridinylmethyl moiety and the S3 binding
domain of caspase-3. All isatin sulfonamide caspase-3 inhibitors were found to be
involved in a

interaction with Phe381, however, the pyridines appeared to be

perfectly oriented to involve a hydrogen bond between the pyridine nitrogen and the
hydroxyl group of Ser381.56 Overall, the substitution of the pyridine ring for the benzene
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ring in the phenoxymethyl moiety resulted in a dramatic reduction in the overall
lipophilicity of the isatin analogues further increasing the effectiveness.56
Mach et al. also developed an alternate series of isatin sulfonamide substrates
called “isatin Michael acceptors” (IMA)57 that incorporate a Michael acceptor group at
the C-3 position of this scaffold. Such Michael acceptor inhibitors would allow for an
alternate mechanistic mode of attack by the cysteine thiol nucleophile upon the α,βunsaturated carbonyl compound in an irreversible manner. One such representative of this
alternate class of inhibitor was prepared by reaction of the isatin sulfonamide 47 with
malononitrile in methanol to give 53.

This IMA analog 53 showed an increased potency of roughly 10-fold for caspase6 when compared to similar isatin precursors but still retained high selectivity for both
caspases-3 and -7 as well.57,58 Replacement of the phenoxymethylpyrrolidine ring in 47
with a thiomorpholine ring followed by reaction of isatin sulfonamide 54 with
malononitrile led to the creation of the IMA analogue 55 which exhibited significantly
increased caspase-6 selectivity and reduced selectivity for caspase-3.58 Although such
isatin-based IMA derivatives represent the most potent (high nano) nonpeptidic caspase-6
inhibitors, such molecules also display only moderate selectivity for this caspase.
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Small Molecule Imaging Agents for Cancer
To date, imaging of cancer by Positron Emission Tomography (PET) has been
mainly limited to the use of [18F]-fluorodeoxyglucose (FDG)59-61or 99mTc-annexin-V,62-64
although both methods are beset with significant limitations (vide infra). Since 2006,
several groups have been developing radiotracers based on the isatin sulfonamide class of
caspase inhibitors and designed to assess the induction of apoptosis in tumors as a
response to chemotherapy.
The mainstay of PET imaging of cancer remains [18F]-FDG 56 which is based on
a change in the uptake of glucose in many tumor types.59

[18F]-FDG has many limitations including: an inability to detect small tumor
volumes; the fact that it is not useful with less glycolytic tumors, and; the need to perform
baseline scans. Moreover, glycolysis is also associated with inflammation and tissue
repair in response to damage which could lead to misinterpreted diagnosis. Recent
strategies have begun to move away from monitoring the differences in metabolism
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between cancerous and normal cells and have begun to look for specific biomarkers
associated with cell death or the lack thereof.65 Cell death exhibits two types of
biomarkers, intracellular and extracellular. Intracellular biomarkers include effector
caspase activation, mitochondrial membrane potential, cytosolic proteins, and exposed
DNA, while extracellular biomarkers are associated with plasma membrane
phospholipids, histones, and plasma membrane depolarization.65 Since the ability to
evade apoptosis is recognized as one of the hallmarks of cancer, the presence of caspases
in tumor cells after treatment can be indicative of a positive response to therapy.66 The
capability to noninvasively monitor the ability of a drug to induce or halt apoptosis
immediately after treatment would be of tremendous value to the research and clinical
community.
Initial strategies for the PET imaging of biomarkers associated with apoptosis
focused on 99mTc-Annexin-V, a 36-kDa protein which binds selectively and with high
affinity to externalized phosphatidylserine (PS) residues. Phosphatidylserine is normally
situated at the interior of the cell membrane but translocates to the exterior in the early
stages of apoptosis after activation of caspase-3.66 As opposed to FDG which takes days
to weeks for confirmation of an effective treatment, 99mTc-Annexin-V bound to
externalized PS gives immediate confirmation. However, since the externalization of PS
also occurs in necrosis, this method is incapable of distinguishing between these two
modes of cell death. Additionally, the slow clearance of radiolabeled Annexin-V from
non-targeted tissues requires imaging studies be conducted 4-6 h after administration
which is not compatible with the short-lived lifetimes of the radionuclides used in PET.66
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Recently, Wang et al. were able to develop a 18F- labeled Annexin B1 specifically
designed for in vivo PET imaging. Like 99mTc-Annexin-V, [18F]-Annexin B1 is a 38 kDa
peptide which also binds selectively and with high affinity to externalized PS.67
Interestingly, 18F-AnxB1 had great stability in vitro and in vivo without significant
degradation which prompted in vivo biodistribution and apoptosis-targeting studies with
PET/CT imaging. To study biodistribution, normal rats were injected with 18F-AnxB1
and imaged by PET/CT at different time points after probe administration to visualize the
whole-body biodistribution, organ uptake and tissue clearance.67 A series of PET/CT
images demonstrated that 18F-AnxB1 concentration was the highest in the liver and
kidney, cleared through renal excretion system, and accumulated finally into the bladder.
As opposed to 99mTc-Annexin-V which required 4-6 h to clear main organs, 18F-AnxB1
exhibited sufficiently rapid clearance from main organs so that only modest activity
remained after 2 h. Finally, 18F-AnxB1 was then used to detect cyclophosphamide
(CTX) induced-apoptosis in tumor bearing rats using PET/CT. It was discovered that
tumors treated with CTX could be observed by PET imaging with the best contrast at 2 h
after treatment with 18F-AnxB1 and tumors without CTX treatment presented low
contrast due to lack of apoptotic regions indicating a noninvasive apoptosis detection
imaging agent was created.67
The recognition that isatin sulfonamides are capable of acting as potent and
selective inhibitors of caspase-3 has led to the development of radiolabeled analogs based
upon this scaffold for imaging cancer. Mach et al. from Washington University Medical
School developed the isatin sulfonamide analog WC-II-89 (57) which was suitable for
radiolabeling with fluorine-18.68 WC-II-89 was synthesized from 5-chloro
29

[Type text]
isatinsulfonamide through a procedure in which methyl 4-hydroxybenzoate underwent
O-alkylation with sodium hydride in THF at 0oC followed by the addition of 1-bromo-2fluoroethane to produce (4-(2-fluoro-ethoxy)benzoic acid methyl ester.68 This ester was
then reduced with LiAlH4 in ether to create the alcohol [4-(2-fluoro-ethoxy)-phenyl]methanol, which was then converted to a bromo analog 59 through treatment with
tetrabromomethane and triphenylphosphine. 1-(2-Bromoethoxy)-4(bromomethyl)benzene (60) was obtained by benzylic bromination of 1-bromoethoxy-4methyl-benzene with NBS in CCl4. With these benzylic bromides in hand, the N-Boc
pyrrolidine 61 was with TFA and the resulting secondary amine was coupled with 5chlorosulfonylisatin (39) in THF using triethylamine as an acid scavenger to produce 5(2-phenoxymethyl-pyrrolidine-sulfonyl)-1H-2,3-dione, 42. Compound 42 was then Nalkylated at the isatin nitrogen through treatment with sodium hydride in DMF at 0 oC
followed by addition of 59 or 60 to give compound WC-II-89 or 62 which is the
precursor utilized to generate the [18F]-radiolabeled compound 58.68

To afford the radiolabeled version of WC-II-89, compound 62 was heated to
reflux with silver methanesulfonate in acetonitrile to generate the precursor 63.
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[18F]WC-II-89 was then generated starting from 63 using a nucleophilic displacement of
the mesylate group with [18F]-fluoride ion using the radiochemical method developed by
Yoo et al.69

[18F]WC-II-89 was evaluated as a radiotracer for imaging caspase-3 activation
through the use of an animal model that utilizes the protein synthesis inhibitor
cycloheximide (CHX) which induces apoptosis in rat liver in both a dose- and timedependent manner.68 Biodistribution studies of [18F]WC-II-89 were conducted in normal
and CHX treated male rats wherein it was discovered that initial uptake of [18F]WC-II89 was higher for CHX-treated rats than control rats. However, this difference between
control and treated rats was reduced with time except for in the liver and spleen.68 Isatin
sulfonamides are competitive inhibitors of caspase-3, meaning [18F]WC-II-89 binds to
the activated form of caspase-3 in tissues undergoing apoptosis, which is why the liver
and spleen of CHX treated rats exhibited slower washout of radioactivity. Another
promising observation from the biodistribution studies was that there was a very low
uptake of radioactivity in the bones, indicating that defluorination was not a concern.68
Researchers then performed Western Blot testing to correlate caspase-3 activity to the
biodistribution results. This revealed that the level of cleaved caspase-3 in the spleen and
liver of the treated rats was much higher than in the control animals indicating the
imaging agent could indeed be used for imaging caspase-cleaved apoptosis. Following
the promising results from the biodistribution studies and Western blot testing, Mach et al
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performed microPET images of a rat liver at 10-60 min post-iv injection of [18F]WC-II89. The microPET images revealed that a rat receiving 3 h pre-treatment of CHX
displayed a higher uptake of [18F]WC-II-89 in the liver versus the control rat. The
increased accumulation of [18F]WC-II-89 in the treated rat liver versus the control rat is
consistent with drug-induced caspase-3 activation. A two-fold increase in uptake of
[18F]WC-II-89 was observed in the treated rats compared to control rats and the normal
rat liver displayed a faster washout of radioactivity. Through these results, Mach et al
were able to demonstrate that apoptosis could be measured and imaged by PET using 18Flabeled caspase-3 inhibitors in the form of [18F]WC-II-89.
Given the success of [18F]WC-II-89 as an 18F-labeled caspase-3 targeting agent
for PET imaging, the Washington University group set out to compare the effectiveness
of two additional radiolabeled isatin analogs. An azetidine analog ([18F]WC-IV-3, 65)
and a pyrrolidine analog ([11C]WC-98, 67) were synthesized and compared to the
successful [18F]WC-II-89 analog. The [18F]WC-IV-3 was synthesized from a mesylate
precursor 64 through a nucleophilic substitution using [18F]fluoride/Kryptofix 2.2.2
complex. Alternatively, the [11C]WC-98 was synthesized through an O-methylation of a
precursor 66 using [11C] CH3I.70
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After completing the synthesis of both [11C]WC-98 and [18F]WC-IV-3,
biodistribution studies were conducted to determine the similarity to the successful
[18F]WC-II-89 analog. These studies revealed that in the control animals both [11C]WC98 and [18F]WC-IV-3 analogs behaved similarly to the [18F]WC-II-89 analog, with rapid
clearance from blood and normal excretion. Both [11C]WC-98 and [18F]WC-IV-3 uptake
levels in the spleen of CHX treated rats versus control was not as high as those seen in
the [18F]WC-II-89 analog indicating that [11C]WC-98 and [18F]WC-IV-3 may not
discriminate between varying caspase-3 levels in vivo as well as [18F]WC-II-89.70
Concurrent with these studies, Aboagye et al. from Imperial College further
expanded on the idea of employing isatin sulfonamides as 18F-labeled caspase-3 targeting
agents for PET imaging of apoptosis by developing a [18F]-labeled isatin with improved
metabolic profile, reduced lipophilicity, and subnanomolar affinity for caspase-3.71 In
this case, the previously synthesized 1-(4-fluoro-benzyl)-5-(2-phenoxymethylpyrrolidine-1-sulfonyl)-1H-indole-2,3-dione (68) was chosen as the lead compound and
modifications were made to the left side ether moiety and at the N-1 position.
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The goal was to improve the biological stability of 68 while retaining selectivity
and affinity for caspase-3.71 This was achieved by incorporating fluorine groups into the
left side phenyl ether group which was thought important because it was believed that the
major metabolic pathway for degradation of the isatins in the body involves aromatic
hydroxylation. Since the introduction of fluorine to aromatic groups is known to block
P450-catalyzed ring hydroxylation of the substituted carbon and also reduces metabolic
attack on neighboring nonsubstituted carbons by exerting a strong electron withdrawing
effect, it was believed that the 2,4-difluorophenyl ether would be significantly more
stable in vivo compared to unsubstituted phenyl ethers.71 Furthermore, the tolerance of
different heterocycles on the left side ether moiety was investigated in which the main
focus was the tolerance to 1,2,3-triazoles since these groups are inert to metabolic
degradation72 and can be easily labeled with fluorine-18.73 The target compounds were
synthesized by condensation of functionalized pyrrolidines with 5-chlorosulfonylisatin
and subsequent alkylation of the isatin nitrogen using potassium carbonate and DMF.
Reaction of commercially available phenols as well as 4-hydroxytetrahydropyran with
tosylate 69 provided the pyrrolidines 70, while O-alkylation of 71 with propargyl
bromide afforded 1-methyl-2-prop-2-ynyloxymethyl-pyrrolidine (72).71
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Deprotection of the N-Boc protected pyrrolidines with trifluoroacetic acid
followed by conjugation with 5-chlorosulfonylisatin (39) provided the sulfonamides 73.
Further N-alkylation of 4-fluorobenzyl bromide or propargyl bromide with potassium
carbonate in DMF yielded the target compounds 74 and 75.71

The three desired triazoles (e.g., 77, 78, 79) were prepared by the copper
catalyzed cycloaddition of 2-fluoroethylazide with the alkyne precursors 75a-b and 76.
However, the isatin scaffold was found to decompose on heating at 90 oC in the presence
of the copper sulfate and ascorbic acid resulting in poor yields of the three target
triazoles. This problem was partially resolved by increasing the copper sulfate
concentration, utilizing ambient temperatures, and reducing the reaction time from 2 h to
1 h producing the triazoles in higher yields.71
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Likewise, the 18F version of the triazole 78 was prepared by copper catalyzed
cycloaddition of 2-[18F]fluoroethylazide (80) with the alkyne precursor 75a. In turn, 2[18F]fluoroethylazide (80) was prepared by reaction of [18F]fluoride with the
corresponding tosylate precursor 81.

This initial click chemistry strategy to synthesize [18F]ICMT-11 avoided the prior
protection of the reactive dicarbonyl function, however, this process gave rise to a stable
by-product which could not be removed from the 18F tracer. Due to the potential
complications with caspase-3 binding, an optimization of the radiochemistry protocol
was explored to remedy the issue. Aboagye et al. improved the existing protocol by
introducing bathophenanthroline disulfonic acid disodium ligand (BPDS) as an additive
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to stabilize the Cu(I) catalyst.74 It was discovered that BPDS reduced the amount of
required alkyne precursor and shortened the reaction time. In this new synthesis, an
acetal protected isatin alkyne precursor 82 was reacted with 2-[18F]fluoroethylazide,
CuSO4/Na-ascorbate, and BPDS for 30 min at room temperature. The resulting
intermediate 83 was then deprotected by microwave heating with HCl or conventional
heating with sulfuric acid to produce [18F]ICMT-11.74

In the automated radiosynthesis protocol, Aboagye et al. used a pre-formed
triazole ring containing tosylate precursor 84 which underwent nucleophilic displacement
with 18fluoride to yield 83. Ketal hydrolysis then afforded [18F]ICMT-11 that displayed
high yield in a shorter time with very high specific activity.75

To determine if the modifications made to the left side ether moiety were
effective against caspase inhibition, Aboagye et al. utilized fluorimetic in vitro caspase
inhibition assays which revealed that the fluorine substituents on the phenyl ether were
well tolerated and the affinity for caspase-3 increased 2-fold as compared to the
nonfluorinated phenyl ether. The high potency of the fluorinated analogs was
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hypothesized to be attributed to -stacking or hydrogen bonding with other groups in the
S3 domain such as Ser381. The most important observation collected from the enzyme
assays was the knowledge that a 2’-fluoroethyl-1,2,3-triazole on either side of the
molecule led to a sharp increase in potency towards caspase-3. Furthermore, the triazole
ICMT-11 was by far the most potent inhibitor of caspase-3 and -7 with affinities of 0.5
nM and 2.5 nM, respectively which was greatly improved compared to 68 which
possessed affinities for caspase-3 and -7 of 50.5 nM and 19.8 nM, respectively. Given
the high potency towards caspase-3 and -7 inhibition of the difluorinated phenyl ether
analogues, the next logical step was to perform biodistribution studies on the analogues to
ensure metabolic stability and toxicity The biodistribution studies were performed using
the radiotracer [18F]ICMT-11 which was shown to rapidly distribute to tissues and was
rapidly eliminated with high localization of radioactivity in the kidney, urine and liver
indicating the importance of the renal and hepatic routes for elimination. A key
observation obtained from the biodistribution study was the lack of uptake in the bones
which suggested an absence of in vivo defluorination and hence metabolic stability of the
2’-fluoroethyl-1,2,3-triazole moiety. Tumor uptake studies were conducted with
[18F]ICMT-11 in control and cisplatin (CDDP) treated RIF-1 tumor bearing mice in
which the CDDP treated tumor exhibited 2.9 fold increase in [18F] ICMT-11 derived
radioactivity compared to that of the control tumor.75,76
After enzyme and distribution studies demonstrated that [18F]ICMT-11 would
have potential utility for imaging caspase-dependent cell death, Aboagye et al. performed
a study to validate the ability of [18F]ICMT-11 to non-invasively image drug induced
tumor apoptotic processes in vivo and its potential for the early detection and monitoring
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of a response to anticancer therapy in an experimental apoptosis tumor model. The
[18F]ICMT-11 PET imaging was performed 24 h after the treatment of 38C13 xenograftbearing mice with cyclophosphamide (CPA) and the tumor was then excised for tracer
biodistribution. Overall, the distribution was consistent with the normal tissue
biodistribution of [18F]ICMT-11 in which there was rapid distribution of the radiotracer
to tissues together with rapid elimination through hepatic and renal routes. PET images of
the CPA-treated mice showed an increase tumor uptake of [18F]ICMT-11 in which a 1.5fold increase of tumor uptake was observed in CPA treated mice compared to control
mice. Thus, Aboagye et al. was able to develop the first caspase-3/7 specific PET tracer
for tumor apoptosis imaging. This [18F]-labeled isatin sulfonamide, has desirable
attributes for PET imaging of apoptosis which include high affinity for active caspase-3,
high metabolic stability, reduced lipophilicity and ease of radiosynthesis which is why it
has been selected for clinical development.75,76
During the time Mach et al. was developing WC-II-89, Kopka et al.77 from
Germany were developing a series of 5-pyrrolidinylsufonyl isatins as caspase binding
radioligands (CBRs) potentially capable of directly targeting apoptosis in vivo. The
caspase inhibitor (S)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin (41) was chosen
as the lead structure for the development of CBRs. A series of 2-methoxymethylpyrrolidinyl analogues were N-alkylated with NaH in DMF to yield N-1-substituted
isatins which were evaluated to determine caspase inhibition potency for caspase-3. A
radioiodinated CBR 86 was synthesized by N-alkylation of 5-(2-phenoxymethylpyrrolidine-1-sulfonyl) isatin with p-tributlylstannylbenzyl mesylate to obtain the
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tributylstannylated precursor 85 which was then placed through a iododemetalation
reaction using [125I]NaI in the presence of chloroamine-T hydrate used as an oxidant.77

Kopka et al. first evaluated the binding potencies of a nonradioactive reference
compound of 86 as well as various modified 5-pyrrolidinylsulfonyl isatin analogs for the
ability to inhibit caspase-3/7. In accordance with the Washington University group, it
was found that all N-alkylated analogs display similar or even better caspase-3 binding
potencies compared with 38, thus confirming that modification of the isatins at the Nposition increases binding potency. However, Kopka et al. discovered that attaching
bulky N-benzyl as well as p-substituted N-benzyl residues does not influence the binding
potency of the isatin analogs in vitro.77 Since the groups para on the N-benzyl moiety do
not affect binding, he chose to attach the radiolabel at that site. The 1-(4-iodo-benzyl)-5(2-phenoxymethyl-pyrrolidine-1-sulfonyl)isatin reference compound was found to be less
effective at inhibiting caspase-3, thus indicating that the radioactive version 86 would
also likely be less effective. The (S)-1-(4-(2-fluoroethoxy)benzyl)-5[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin (87) which was synthesized through the N-alkylation
of 5-pyrrolidinylsulfonyl isatin 42 with 1-bromomethyl-4-(2-fluoro-ethoxy)-benzene
using sodium hydride (NaH) and DMF, exhibited moderate lipophilicity and was selected
for kinetic studies to determine the mechanism of inhibition for caspase-3 activity. This
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study revealed 87 displays competitive inhibition which was consistent with previous
studies which demonstrated that the isatins bind to the cysteinyl active site of the
activated caspase.55

The modified 5-pyrrolidinylsulfonyl isatin analogs were then evaluated in cellular
apoptosis assays in which the potency of inhibiting apoptosis was measured. These
studies were performed on human umbilical vein endothelial cells (HUVEC) undergoing
apoptosis which were incubated with different concentrations of isatin analogs for 8 h.
Western blot analysis revealed that caspase processing was inhibited by the 2methoxymethyl-substituted 5-pyrrolidinylsulfonyl isatins at concentration of 10 μM
while the 2-phenoxyphenyl analogs were less effective in inhibiting caspase-3
processing. This indicated that future work with the 5-pyrrolidinylsulfonyl isatins should
focus on the use of the 2-methoxymethyl analogs.77
Kopka et al. then focused on the synthesis of new fluorinated and non-fluorinated
5-pyrrolidinylsulfonyl isatins as caspase inhibitors because it was believed that
introduction of a fluorine substituent would enhance the potency of 42.78 The fluorine
analogs were incorporated through N-alkyl chains on the isatin nitrogen of the 2methoxymethyl-5-pyrrolidinylsulfonyl isatins. These new pyrrolidinylsulfonyl isatin
analogs were evaluated for their ability to inhibit caspase-3 and -7. This study revealed
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that the fluoroethyl and fluoropropyl isatins exhibited very weak inhibitory activity
toward caspase-3/-7 while butyl derivatives were the most potent caspase -3 and -7
inhibitors. For example, the 4-fluorobut-1-yl derivative 88 was a very potent inhibitor and
3-fluorobut-1-yl derivative 89 was the most potent caspase inhibitor. The study also
showed that terminal difluroalkyl and trifluoralkyl derivatives exhibited moderate
activity.78

Given the promising results obtained from the inhibition studies of the fluorinated
5-pyrrolidinylsulfonyl isatins caspase inhibitors above, Podichetty et al. turned their
focus to other fluorinated derivatives that could be radiolabeled to monitor apoptosis by
PET. The focus was to develop a radiofluorination methodology that would introduce a
[18F]fluorine radionuclide which might lead to isatin variants based on fluorohydrins.79
The chemistry utilized to perform such reactions was halofluorination techniques like
bromofluorination which is a versatile method to introduce fluorine to unsaturated
compounds along with a second reactive function into organic compounds. One of the
most common procedures for bromofluorination uses N–bromosuccinimide (NBS) as the
source of the bromonium ion and different amine-HFcomplexes.80,81 Katzenellenbogen et
al. demonstrated that bromofluorination could serve as a radiochemical tool for
introducing fluorine-18 into medicinally relevant compounds and facilitate their use as
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imaging agents for PET.69 In this case, bromofluorination of olefins as precursors and
epoxide ring opening reactions were used to obtain vicinal fluorohydrins.82-84
A series of 5-pyrrolidinylsulfonyl isatins were created with varying carbon units
through the N-alkylation of the isatin nitrogen to create the olefin 89, 91, 92 and terminal
epoxide precursors 93.79 The fluorinated isatin analogues were then prepared from these
precursors by bromofluorination and epoxide ring-opening with different amine/HF
reagents.

The potencies for caspase inhibition of all the synthesized analogues were
measured using fluorogenic in vitro caspase inhibition assays.79 From these inhibition
assays, it was found that all fluorinated 5-pyrrolidinylsulfonyl isatin analogues with the
exception of the gem-difluoride derivative 90 exhibited moderate to high inhibition
potencies for caspase-3 and -7. The most active terminal olefin against caspase-3 was 91
which had an IC50 value of 9.3 nM while 92 was the most active toward caspase-7 with
an IC50 value of 0.6 nM while the most active terminal epoxide 93 against both caspase-3
and caspase-7 was the styrene oxide derivative which exhibited IC50 values 6.6 nM and
1.9 nM, respectively.79 Although the olefin and epoxides would not be present in the
desired products, it was important to examine their potencies against caspases-3 and -7 to
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determine the best potential radiolabeling precursors to facilitate quicker development of
an active compound.

The most potent bromofluoride obtained was the mixture of regioisomers (7:3)
94a-b which exhibited high inhibition potency towards caspase-3 (IC50: 26 nM) and
caspase-7 (IC50: 1.9 nM). To synthesize compound 94a-b, a bromofluorination occurred
in which 91 was reacted with (NBS), and Olah’s reagent which is a nucleophilic
fluorinating agent that consists of a mixture of 70% hydrogen fluoride and 30% pyridine
and convert alcohols to alkyl fluorides.79

Through the analysis of the fluorohydrins it was discovered that 96 was the most
active inhibitor of caspase-3 and the fluorohydrin 97 was the most potent against caspase7. Both compounds were synthesized through the reaction of an epoxide derivative (93,
95) with triethylamine trihydrofluoride.79
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A proof of concept synthesis of a fluorine-18 labeled model compound was
performed on compound 93 to produce the [18F]98. Through optimization of the
synthesis, the radiochemical yield of [18F]98 was optimized to 7% when [18F] triethylamine trihydrofluoride ([18F]Et3N .3HF) was utilized for radiofluorination. This was the
first time a nucleophilic fluorinating reagent generated from Et3N.3HF and [18F]F- via
isotopic exchange was successfully applied in the synthesis of the [18F]labeled target.79
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Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common neurodegenerative disorder of the
elderly. It is a progressive neurodegenerative disorder characterized by dementia,
cognitive impairment, and memory loss. The early symptoms of AD are often
overlooked since they are very similar to the signs of natural aging, however, the
symptoms gradually worsen until patients lose the ability to perform basic functions like
speak, recognize people, and memory becomes non-existent.85 AD is characterized by
significant losses of neurons and synapses and diagnosed by the appearance of
extracellular β-amyloid (Aβ) plaques and intracellular neurofibrillary lesions in the
brain.85,86 As AD progresses, the density and spatial distribution of lesions yield
information on the disease, however, total plaque density correlates poorly with cognitive
decline and neurodegeneration.86 The neurofibrillary lesion formation has been shown to
correlate more closely with disease progression of AD.86,87 These lesion formations
consist of neurofibrillary tangles (NFTs) which contain paired helical filaments (PHF)
resulting from the hyper-phosphorylation of the microtubule-binding protein tau, which
plays an essential role in maintaining microtubule stability similar to ties along railroad
tracks.85 In AD, neuronal tau is phosphorylated and proteolyzed resulting in an
impairment of the normal functions of tau and even more importantly, tau appears
decades before neocortical Aβ deposition and signs of dementia can be detected which
makes tau a possible diagnostic tool for AD.85,86 Both tau and Aβ filaments consist of
parallel β-sheets aligned perpendicular to the fibril axis, resulting in a cross-β-sheet
structure.88 This parallel orientation of the β-sheets generates channels extending along
the length of the filament to which aromatic molecules can bind via
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interactions.89,90 Presently, there are a few small molecules such as Pittsburgh Compound
B developed for use in various modalities of whole brain imaging to capture the spatial
distribution of amyloid lesions in situ.91 However, most of these ligands bind cross-βsheet structures common to both tau and β-amyloid bearing lesions which indicates that
the information associated with neuritic lesions will be contaminated by cross reactivity
with amyloid plaques making it non ideal AD diagnostic tool.86 A new diagnostic tool
was proposed in which a tau selective binding agent would interact with aggregates
composed of full-length tau protein which appear much earlier in lesion formation and
even come before the formation of insoluble proteolytic products.86,92 The use of full
length tau proteins incubated in the presence of anionic surfactant inducers yield products
that react with commonly used fluorescent probes for cross-β-sheet conformation such as
Thioflavin S (ThS) and T (ThT) which support aggregation at low micromolar bulk tau
concentrations, facilitating screening for high affinity ligands.85,93 Since the presence of
anionic surfactants speeds aggregation rate and lowers bulk protein levels required for
fibrillization, it is possible to compare ligand binding to all major AD disease associated
protein targets.85,94
Kuret et al. used this approach in the pursuit of selective binding molecules for
tau. In this work, a chemical library of over 72,000 compounds was attained and
screened in order to identify ligands capable of interfering with the ThS fluorescence
signal which was used to monitor tau conformation. The ThS-reactive tau was prepared
with octadecyl sulfate (ODS) which is an alkyl sulfate inducer of tau conformational
change and aggregation. A full length tau was used as substrate because it aggregates in
early stage AD therefore representing an early marker for AD progression.86 The ODS
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was utilized as an inducer because it efficiently drives conformational changes at low
concentrations of full-length tau over short time periods under reducing conditions.95
Following the assay of the 72,000 compounds, 45 compounds representing 35 active and
10 structurally related inactive analogs were chosen for additional studies. In this follow
up study, the inducer arachidonic acid replaced ODS to exclude nonspecific alkyl-sulfatemediated effects on ThS fluorescence. The 35 active compounds were screened once
again and all but eight showed similar dose response curves and half maximal activity
concentration (AC50) values in the presence of arachidonic acid. The eight inactives were
then eliminated from the study while Thiazine red 99 and 100 were added to the library
because of their ability to bind to protein aggregates.86 Thiazine red 99 is known to
selectively bind to neurofibrillary lesions in AD tissue while 100 binds Aβ aggregates in
vitro.96, 97

The compounds were grouped into six classes which included benzothiazoles,
phenylazenes, quinoxaline nitriles, anilines, anthraquinones, and indolinones. These
compounds were then measured for their relative affinity for tau, α-synuclein, and Aβ1-42.
Several of the compounds measured exhibited significant fold selectivity for tau relative
to at least one other substrate. For example, Evans blue 101 and aniline crystal violet 102
which were exclusively selective for tau against both α-synuclein, and Aβ1-42.
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As opposed to the benzothiazole 100, the aniline 103, the anthraquinone 104, and
the indolinone 99 were all selective for both tau and Aβ1-42 relative to the α-synuclein
with the benzothiazole being the most potent with a Ki of 7.8 nM.

Kuret et al. found that aggregates composed of tau, α-synuclein, and Aβ1-42
display an overlapping variety of small molecule binding affinities. Through the study of
six different scaffold classes it was discovered that tau aggregates were the most
discriminating substrate tested with the strongest binding affinities, while α-synuclein
fibrils were the least discriminating and exhibited weaker overall affinity for the test
compounds. A structural feature shared by the two most potent compounds towards tau
(e.g., 99 and 101) was the presence of at least three aromatic or rigid moieties connected
by two rotatable bonds. For efficient tau binding the requisite geometry has been
proposed to be completely planar. Also another common feature for tau binding is the
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utilization of a hydroxyl group ortho to an azo linker which is predicted to form a
hydrazone over the azo tautomer, thereby creating a six-membered ring through hydrogen
bonding which would result in a third ring possibly being important for selective
interaction with tau filaments. The indolinone 105 was an effective binder of all
filamentous substrates tested and other studies have shown hydroxyindoles as Aβ1-40 and
Aβ1-42 fibrillization inhibitors so they may have applications as tau binders.98
The indolinone, phenothiazine, and triarylmethines scaffolds, which were very
potent as ThS displacement agents, shared the commonality of having a planar, rigid
structure that could substitute highly delocalized aromatic pi-electrons when
appropriately substituted with electron donating and accepting groups.97 Due to this,
certain derivatives of these scaffolds were highly polarizable and capable of supporting
strong van der Waals interactions between the ligand and binding sites exposed on the
fibril surfaces therefore introducing the idea of compound polarizability as an important
determinant of tau fibril binding affinity.99,100 To test this theory, an SAR was conducted
on phenothiazine, triarylmethine, and indolinone scaffold derivatives while interacting
with both authentic and synthetic tau filaments. It was found that polarizability is an
important descriptor of tau filament binding affinity for these ligands. This was
accomplished by examining closely related analogs of phenothiazine, triarylmethine, and
indolinone in which net charge, surface area, sterics, charge, hydrophobicity and number
of rotatable bonds was held constant or controlled. However, the binding affinity within
scaffold families was lost when compounds from multiple classes were combined
indicating that additional factors beyond polarizability contributed to tau filament binding
affinity.99
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The eventual goal of Kuret’s work is to develop a tau imaging101 agent for the
diagnosis of AD. Currently, the methods for whole-brain imaging of dementia patients
utilize positron emission tomography (PET) to image the binding of radiolabeled
compounds to lesions containing filamentous amyloid-β (Aβ) peptide. The current
radiolabeled PET compounds consist of Aβ-directed agents that have high sensitivity for
detection of AD but have limited specificity. Another drawback to the Aβ-directed
agents lies in the fact that Aβ levels plateau as the disease progresses which limits the
utility of pre-mortem Aβ detection for longitudinal assessment.101 In addition, Aβdirected agents cannot distinguish different forms of frontotemporal lobar degeneration
which does not accumulate Aβ aggregates from AD.101 Thus, Kuret anticipates that
selective radiotracers for tau-bearing neurofibrillary lesions could complement the
established Aβ imaging in many ways. For example, neurofibrillary lesions appear in
large numbers at certain sites years before the onset of dementia in AD providing a
potential biomarker for the detection of the disease in early stages.101 Furthermore, due
to the relationship between disease progression and spatial distribution of neurofibrillary
pathology, tau-based imaging could help monitor the effectiveness of drug treatments
over time.101 A tau directed imaging agent must fulfill four principal criteria which
include: 1) the ability to cross the BBB after intravenous injection while simultaneously
having the capability of rapid elimination; 2) the tau imaging agent should be capable of
engaging their target within cells undergoing neurofibrillary degeneration and also must
bind to a target that varies in composition and post-translational modification, and; 3) tau
imaging agents must bind tau aggregates with sufficient selectivity so that neuritic lesion
spatial distribution is not disrupted by other lesions that appear in the disease.101 As
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mentioned earlier, the first tau aggregate binding agents were identified on the basis of
direct fluorescence in tissue and include Thioflavin T and its neutral benzothiazole
derivatives102, BF-168103, and X-34.104,105 The tau directed imaging agents have potential
for diagnosing and staging of AD. However, despite the numerous advantages which
they afford, there are still disadvantages which include the complexity of the target. The
target for tau directed imaging agents presents up to six tau isoforms in varying states of
post translational modification and its low concentration relative to Aβ aggregates which
provide a source of off target binding sites. Due to this, tau directed imaging agents must
deliver substantial binding selectivity if their diagnostic potential is to be realized.101
Aims and Background to Research
WSU Approach
Given the proven efficacy of benzylidene oxindoles as cell-death inhibitors
(Ketcha/Apoptrol) as well as the potential of this scaffold to serve as ligands for various
biological targets, the goals of this project were to design and synthesize a library of
benzylidene oxindoles (especially fluorinated analogues) as potential cell death inhibitors
by strategies which maximize the creation of sub-libraries, and if possible prepare
molecules capable of serving as PET targeting agents for cancer or AD. Since (as will be
detailed) the incorporation of a strongly Electron Withdrawing Group (EWG) such as
chlorine at the C-5 position was determined to be of importance for cell death inhibitors,
it was determined that the use of a fluorine atom at the C-5 position would be the next
logical step. Not only is fluorine a strong EWG but it is also serves critical functions in
many active drug leads.
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The incorporation of fluorine atoms into the core structures of pharmaceutical
agents has been a recurring and sometimes uncommented upon strategy in drug design.106
In terms of caspase inhibitors, Brown in 2003 made the ex post facto suggestion that the
effectiveness of Q-VD-OPh (23) to inhibit apoptosis was attributable to the ability of the
carboxy terminal 2,6-difluorophenoxy warhead to increase cell permeability, stability and
efficacy.47 Additionally, it has also been postulated that the mechanism of action of QVD-OPh involves the formation of an irreversible thioether bond between the aspartyl
warhead in the inhibitor and the active site cysteine of the caspase, with displacement of
the non-toxic 2,6-difluorophenol leaving group.107 Alternatively, in designing the isatin
sulfonamide PET imaging agent [18F]ICMT-11 (72), introduction of fluorine atoms onto
the left side ether moiety was originally intended to enhance metabolic activity by
retarding P450-catalyzed ring hydroxylation of the phenolic ring, and in the event, the
difluorinated isatin was found even more potent against caspase-3 than the nonfluorinated analog.71
Some of the design considerations for benzylidene oxindole cell-death inhibitors
in the Ketcha group were based on a consideration of the structural features of Q-VDOPh as well as the isatin sulfonamide class of inhibitors. In terms of the peptide inhibitor
Q-VD-OPh, it was deemed important to incorporate a quinoline or possibly a pyridine
ring into the core structure of the WSU scaffold, as well as some type of fluorinated
aromatic ring by analogy to the difluorophenoxy ring at the C-terminus. The main
structural features obtained from the isatin sulfonamides included the use of a strong
electron withdrawing group at the C-5 position and the incorporation of a group (such as
a substituted benzyl substituent) at the N-position on the isatin or oxindole ring.50 Such
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structural design considerations were therefore incorporated into the benzylidene
oxindole cell-death inhibitors with 3 potential points of variability. Figure 1

Another overarching stratagem of this design concept was to achieve these goals
through a ‘libraries from libraries’ approach, wherein sub-libraries of precursor
compounds could be prepared and screened for alternative applications before subjecting
these compounds to further elaboration for subsequent screens in terms of cell-death
inhibition or Alzheimer’s. Since both isatin and oxindoles are “privileged scaffolds”4
creating sub-libraries of each class would allow for the benefits of screening each subset
for biological targets (e.g., kinase inhibitors, tau binding agents) normally associated with
those scaffolds. Ultimately, this would lead to the goal of creating a benzylidene
oxindole library with 3 points of variability. The creation of each sub-library can be
demonstrated through the multistep reaction manifold in Scheme 1

Scheme 1
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In the upper manifold of this scheme, N-alkylation of isatins 100 with benzylic
halides 101 would initially give a sublibrary of N-alkylated (mainly benzylic) derivatives
104; Wolff-Kishner reduction of these would then afford an N-alkylated oxindole
sublibrary 105. Finally, along this top branch, aldolization with various aromatic
aldehydes 106 would then provide the desired N-alkylated benzylidene oxindoles with
three points of variability 108. Following the lower pathway, after reduction of the
isatins to the corresponding oxindoles 107, aldolization gives an N-H benzylidene
oxindole (potential kinase inhibitors) sub-library 8, wherein the ultimate target can be
achieved by final N-alkylation.
An overview of previous results from the Ketcha group regarding small-molecule
cell-death inhibitors is provided herewith. The first successful small-molecule cell-death
inhibitor created at WSU was synthesized by Abdullah in which the 2,6-difluorobenzylmoiety characteristic of the C-terminal warhead of Q-VD-OPh was utilized in the
creation of 5-nitro-3-(2,6-difluorobenzylidene)indolin-2-one (109). Compound 109
exhibited the same level of activity as the peptide inhibitor Q-VD-OPh matching the 5μM
inhibition against Jurkat T-cells (Ketcha/Apoptrol).47,107

However, since the nitro group of 109 was viewed as metabolically unstable, it
was deemed impracticable as a cell death inhibitor. Due to this issue, a subsequent study
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was performed in an attempt to find an alternative EWG at the C-5 position that would
allow for enhanced or equivalent activity. Originally, fluorine was thought of as a
suitable replacement for the nitro group but it was deemed more cost effective to use the
less electronegative chlorine because the cost of 5-fluoroisatin starting material
($12.84/g) was far greater than that of the 5-chloroisatin ($1.23/g). Additionally, it was
also found more difficult (less efficient) to reduce 5-fluoroisatin to 5-fluorooxindole
compared to converting 5-chloroisatin to 5-chlorooxindole. In light of those
considerations, Repasky then undertook the task of creating analogues possessing a 5chloro substituent and was able to synthesize the variant comparable to 109, namely 5chloro-3-(2,6-difluorobenzylidene)indolin-2-one (110).

Surprisingly, 110 showed no inhibition of Jurkat T-cell death at 100 μM, which
was quite unexpected given the fact that the 2,6-difluorophenyl- moiety was thought to be
partially responsible for the initially observed activity. It was therefore reasonable to
suspect that while the incorporation of a chlorine might not be as effective as the
metabolically unstable nitro group, the 5-chloro derivative might still have been thought
to show inhibition at the 20-50 M level.
Since the presence of a 2,6-difluorophenyl- group at the C-3 position was
apparently not an absolute requirement, it was then decided to incorporate the alternate
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structural feature of Q-VD-OPh, namely a quinoline type group (e.g., pyridyl) or at least
one that contained lone pair electrons at the C-3 site. For simplicity, mimics of the
quinoline type group examined were the pyridyl (2-, 3-, and 4-) moiety and also the pmethoxyphenyl group. To that end, Abdullah and Clay synthesized 3-(pyridine-4ylmethylene)indolin-2-one (111), 3-(pyridine-3-ylmethylene)indolin-2-one (112), 3(pyridine-2-ylmethylene)indoline-2-one (113), and 3-(4-methoxybenzylidene)indolin-2one (114).

It was determined that all pyridine derivatives exhibited some cell-death
inhibitory activity against Jurkat T-cells, wherein the 4-pyridyl-moiety was the most
active at 50 μM. It was also determined that the p-methoxyphenyl- moiety would be a
good candidate since it also showed inhibitory activity at 50 μM. From these findings
involving an oxindole lacking a C-5 substituent, it was deemed valuable to create a 4pyridyl- bearing compound with an electron withdrawing group (i.e., chlorine) at the C-5
position. This was accomplished by Repasky in synthesizing 5-chloro-3-(pyridine-4ylmethylene)indolin-2-one (115).
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Surprisingly, compound 115 showed the same inhibitory activity of 50 μM
against Jurkat T-cells as compound 111 which did not contain an EWG at the C-5
position. In contrast to the isatin sulfonamide inhibitors, it was now questionable if
incorporating an EWG at the C-5 position of a benzylidene oxindole was in fact crucial
for activity. Thus, while a strong EWG might be expected to increase the electrophilicity
of a C-3 ketone in the case of isatins, such a group may play little role in enhancing the
presumptive nucleophilic attack of the caspase thiol upon the beta-carbon of the α,βunsaturated amide moiety of the oxindole class. Moreover, it was beginning to appear
that hydrogen bond acceptor properties of a C-3 substituent might play an important role
as suggested by Loeser et al.107 who postulates that hydrogen binding between caspase
and inhibitor influences the effectiveness of the inhibitor. This led to the idea that
substituent groups with available lone pair electrons like hydroxyl, methoxy, and pyridyl
groups could be utilized as necessary structural features in the design of potential
inhibitors of caspases.
Although there is no established correlation of the ability of isatin sulfonamides to
inhibit caspases by nucleophilic attack of the thiol at the C-3 ketone carbonyl and the
presumed ability of benzylidene oxindoles to serve as Michael acceptors for this enzyme,
the value of incorporating an N-benzyl group seemed appealing as it typically enhanced
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activity by roughly an order of magnitude for the isatins.37 Inspection of the Q-VD-OPh
molecule suggested that the addition of a 2,6-difluorobenzyl moiety at the N-position
might be a good choice because of the EWG effects and the expected increased cell
permeability as a consequence of the fluorines. Therefore, the 2,6-difluorobenzyl moiety
was incorporated onto the already active lead compounds 111, 114, and 115 at the Nposition of the oxindole scaffold so as to afford the corresponding N-substituted
analogues, N-(2,6-difluorobenzyl)-3-(pyrid-4-yl-methylene)indolin-2-one (116), N-(2,6difluorobenzyl)-3-(4-methoxy-benzylidene)indolin-2-one (117), and N-(2,6difluorobenzyl)-5-chloro-3-(pyrid-4-yl-methylene)indolin-2-one (118).

In general, a trend towards increased activities against Jurkat T-cells was found to
be associated with introducing the 2,6-difluorobenzyl group versus the N-unsubstituted
counterparts. For instance, compound 116 exhibited activity at 15-20 μM (versus 50 μM
for 111), and the most active compound 118 showed activity at 10 μM compared to 50
μM for 115. Mysteriously, in the case of the 4-methoxy derivative 117, a decrease in celldeath activity was observed wherein the N-substituted derivative was found to be inactive
at 100 μM in contrast to the corresponding N-H derivative 114 which exhibited 50 μM
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activity. While at present the lack of a synergistic effect for a molecule possessing two
favorable fragments (e.g.,4-methoxy/N- 2,6-difluorobenzyl) is obscure, the main
conclusion developed through these SAR studies was that the 3 points of variability can
possibly work in a synergistic way to increase the inhibitory activity of these benzylidene
oxindole cell death inhibitors. With that overview of previous work relating to
benzylidene oxindoles as cell-death inhibitors in the Ketcha Group completed, a more
detailed examination of the relevant chemistry towards the target sub-libraries will ensue.
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Results and Discussion
N-Alkylation of Isatins
The preparation of N-alkylated isatins has been reported utilizing numerous alkyl, allyl-, benzyl-, and propargyl halides under a variety of basic conditions. In most
examples, the use of conventional heating methods under reflux were utilized, however
more recent efforts have focused upon conducting the N-alkylation of isatins utilizing
microwave irradiation. Regardless of the heating source, the N-alkylation of isatin occurs
through the reaction of isatin 2 with some base-solvent combination. Herein the base
abstracts a proton from the nitrogen forming the highly conjugated (and often highly
colored) isatin anion 119. The alkyl halide then undergoes nucleophilic attack by the
nitrogen anion forming the N-alkylated isatin 120.

The most popular base-solvent combination utilized in the N-alkylation of isatin
with alkyl halides is sodium hydride in N,N-dimethylformamide (DMF).37,50,109 For
example, Chen et al. alkylated numerous 4,5,7-substituted isatin derivatives 121 with
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sodium hydride and various alkyl bromides in DMF to provide the corresponding Nalkylisatin derivatives 122 in moderate yields depending on the substituent groups.

Due to the flammibility issues associated with the use of NaH, it is often replaced
with calcium hydride (CaH2). Garden et al. utilized calcium hydride in DMF to
synthesize a set of 7-substituted-N-alkylisatin derivatives, wherein a 7-substituted isatin
123 was reacted with an alkyl halide in DMF at temperatures ranging from 25-50oC to
produce the isatin derivatives 124. It was observed that isatin derivatives bearing an
electron-withdrawing substituent at the C-5 and C-7 position reacted more readily with
CaH2 at room temperature reflecting the increased acidity at the amide proton.110

Due to the advances in technology, the use of microwave irradiation as an
alternative heat source has gained popularity in recent years. The use of microwave
irradiation is particularly attractive because it allows for rapid and highly efficient
synthesis while minimizing the thermal decomposition of products that is sometimes
associated with conventional heating due to longer reaction times. The advantages of
utilizing microwave irradiation in organic synthesis have been reviewed on a number of
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topics including classic organic reactions,111 green organic synthesis,112 and multicomponent reactions.113
The most successful approach for the N-alkylation of isatins using microwave
irradiation is with K2CO3 and alkyl halides in a minimal amount of DMF.114 Additionally,
several groups have devised parallel methods minimizing purification and which are
amenable to automation under thermal or microwave conditions. Noteworthy examples
include a parallel microwave procedure by Lindsley which employed K2CO3/KI in
acetonitrile (160 oC, 10 min),34 or an analogous process in DMF (150 oC, 5-15 min)
developed by Wee et al.115 In Lindsley’s case, a variety of N-benzyl isatins 125 were
synthesized by reacting 5-substituted isatins 100 with a variety of benzylic halides (2.5
equiv) and K2CO3 (2.0 equiv) with KI (0.1 equiv) as the catalyst in acetonitrile (ACN).34

Alternatively, in regards to devising highly efficient and rapid solution-phase
methodologies for the parallel synthesis of diverse isatins, Shuttleworth utilized polymersupported 2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2diazaphosphorine (BEMP) on polystyrene for the preparation of a library of serine
protease inhibitors.116 Another fairly new approach to the N-alkylation of isatin is through
the use of potassium fluoride on alumina (KF/Al2O3), a solid-supported base introduced
by Ando et al.117 in 1979 for N-alkylation. The main advantage of the use of the solid
base KF/Al2O3 in solution phase chemistry involves avoiding difficult workups, because
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the base can be removed through vacuum filtration. Chibale employed this less
expensive solid-supported base to perform parallel solution phase synthesis of N-alkyl
isatins 114 in ACN starting from a substituted isatin 115.118 More recently, the Ketcha
group reported the use of KF/Al2O3 in ACN for the N-alkylation of isatins under thermal
conditions or microwave-irradiation (180 oC).115,116

The use of the solid base KF alumina by the Ketcha group was envisioned as an
expedient protocol since the catalyst might be removed by simple filtration and this
methodology might then be utilized in an automated synthesizer in multiparallel fashion
using an instrument such as the Quest 210. However, upon filtration, evaporation of the
ACN led to a product containing all organic impurities and purification by
recrystallization or chromatography was then necessary. Thus, the first objective of this
work entailed examining the use of a soluble organic base in a solvent capable of
executing a crystallization of the product upon cooling. Therefore, initial studies
involved a comparison of the N-alkylation of isatin derivatives with the solid base of
KF/alumina utilizing conventional heating to those obtained with the liquid base 1,8diazabicyclo[5.4.0]undec-7-ene (DBU) in ethanol (EtOH) utilizing microwave
irradiation. Although the N-alkylation of isatins with DBU as a base had yet to be
explored, if this base were sufficiently strong to effect the amide N-H abstraction, then
this approach would allow for the expedited synthesis of substrates wherein the products
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might precipitate from the reaction mixture in high yields and high purity and be isolable
by simple filtration without column chromatography.
N-Alkylation of Isatin Utilizing DBU
To explore the possibility of employing DBU as a potential base for the Nalkylation of isatins, a study was conducted employing isatin, 5-chloroisatin, and 5fluoroisatin and a series of alkylating agents including benzyl chloride, 2,6difluorobenzyl bromide, 2,6-dichlorobenzyl bromide, propargyl bromide, and ethyl
bromoacetate. The parameters set forth for the reaction involved the use of the isatin
(2.00 mmol), DBU (1.1 equiv), and the alkyl- or benzylic halide (1.1 equiv) in EtOH (3
mL) in a microwave vial (10 mL). Reactions were conducted at temperatures from 120°C
to 140°C and at time intervals of 10 to 25 min after which reactions were monitored by
TLC and GC/MS to ascertain completeness of reaction; the results are presented below in
Table 1. In the case of isatin itself, the N-alkylations required a time of 10 min at 140
°C, while effective alkylations of 5-chloroisatin and 5-fluoroisatin could be effected at a
temperature of 120 °C for 20 min and 25 min, respectively. The lower temperatures and
longer reaction times are attributed to the electron withdrawing effect of the chlorine and
fluorine atoms, which are thought to weaken the nucleophilicity of the isatin salt thus
making it easier to abstract the proton but reducing the attack on the alkyl halides.
Generally, it was also found that increasing the amount of DBU to 1.5 equiv did not
result in substantially enhanced conversion. In all cases, after heating for the appropriate
time, the reaction vessel was then allowed to stand in a freezer followed by a vacuum
filtration to afford the pure (TLC, GC/MS) products as light orange (or red) solids. The
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filtrate could then be evaporated under reduced pressure to afford an oil and subsequently
purified by silica gel chromatography (70:30 hexanes/EtOAc) to provide additional
product if desired. The only deviation from the above procedure involved the case of 1(prop-2-yn-1-yl)indoline-2,3-dione wherein a ramping technique was required to obtain
higher yields.

The percent yield and melting points for all cases are reported in Table 1 below
along with the structure of the product of interest.
Table 1. N-alkylation of 5-substituted isatin derivatives via DBU
Compound
Number

Compound

Melting Point Lit. Melting
Point

Percent Yield

128

129-134ᵒC

128-133ᵒC119

61%

129

105-110ᵒC

124-129ᵒC119

47%

130

147-149ᵒC

157-158ᵒC110

81%
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131

184-186ᵒC

184-189ᵒC119

93%

132

155-158ᵒC

154-156ᵒC119

84%

133

130-133ᵒC

134ᵒC119

71%

134

126-128ᵒC

130-135ᵒC119

68%

135

157-159ᵒC

N/R150

64%

136

232-235ᵒC

233-235ᵒC119

84%

137

171-174ᵒC

172-177ᵒC119

72%

138

130-132ᵒC

130-132ᵒC137

88%
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139

129-132ᵒC

N/R34

82%

The above success using the soluble base DBU and a solvent from which the
product might spontaneously crystallize, ensured that a substantial savings in timeconsuming steps would be achieved as opposed to previous methods in which a workup
or purification was required after filtration. The yields listed are a summation of the pure
solid obtained upon the first crystallization and that obtained by chromatographic
purification of the filtrate. In all instances, the material obtained by crystallization from
the reaction medium was pure as determined by GC/MS and in most cases provides
sufficient amounts of material to be carried on in subsequent steps if desired. In general,
electron-withdrawing substituents at the C-5 position of the isatin allowed for alkylations
at lower temperatures albeit with longer reaction times. Additionally, electron
withdrawing groups on the benzylic halides served to enhance observed reactivity in
comparison to those rings not so substituted or the propargyl halide. It is also worthy to
note that it was found that ethyl 2-(5-chloro-2,3-dioxoindolin-1-yl)acetate 124 reacted at
room temperature while waiting to be placed in the microwave reactor. Thus, the use of
the soluble base DBU in conjunction with a crystallizing solvent under microwave
conditions allows for the expedited construction of a small library of N-alkylated isatins
which could be isolated in a pure state and in good yields by simple filtration.
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N-Alkylation of Isatins utilizing KF/Al2O3
Concurrent with the investigations to develop an expedited microwave synthesis
of N-alkyl isatins amenable to automation, wherein product isolation could be achieved
by simple filtration, efforts were also devoted to extending the scope of the
KF/Al2O3115,116 protocol previously devised in our group. Despite the more extensive
workup required for this thermal process, it is in general a more scalable procedure
allowing for the larger quantities of N-alkyl isatins 131 required for our intended multistep sequences.

Following the procedure originally developed by Clay,119,120 the isatin starting
materials 130 (R1 = H, F, Cl) were refluxed in ACN for approximately 24 h utilizing 6
equiv of KF/Al2O3 and a slight excess of the appropriate alkyl halide (X = Cl, Br, 1.5
equiv). The crude products were separated from the solid base by vacuum filtration and
the solid catalyst was washed with additional cold solvent. The resulting filtrate was then
evaporated under reduced pressure to afford an orange (or red) solid. The solids could
then be recrystallized from dichloromethane and hexanes to afford the pure (TLC,
GC/MS) products as bright orange or red crystals. The percent yield results and melting
points for these reactions are reported in Table 2 below along with the structure of the
product of interest.
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Table 2: Alkylation of 5-substituted isatin derivatives via KF/Al2O3
Compound
Number

Compound

Melting Point

Lit. Melting
Point

Percent Yield

130

153-156 ᵒC

157-158 ᵒC110

69%

140

150-153 ᵒC

N/R146

55%

141

161-164˚C

N/R

50%

135

164-168ᵒC

N/R150

52%

142

148-150ᵒC

152-153ᵒC145

75%

143

173-175ᵒC

N/R

95%

144

124-126ᵒC

N/R

36%
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138

128-129ᵒC

130-133˚C137

82%

145

132-135ᵒC

138-139 ˚C146

71%

139

143-145ᵒC

N/R34

85%

146

160-161ᵒC

N/R

96%

Reduction of Isatin
Having in hand new or expanded protocols for the effective N-alkylation of isatins
(thereby creating a new sub-library of diversified isatins), it was then deemed valuable to
conduct the reductive-deoxygenation of such derivatives to produce a library of Nalkylated oxindoles in anticipation of final conversion to benzylidene oxindoles. The
reduction of isatins to oxindoles is a well-established procedure first reported by Baeyer
in 1866,6 wherein isatin 2 was reduced with sodium amalgam in alkaline medium to
create 3-hydroxyoxindole 147. Further reduction of the dioxindole with tin and mineral
acids or by sodium amalgam in acid medium gave oxindole 3.6
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One well-known method for the reduction of a carbonyl group in an aldehyde or
ketone to a methyl or methylene group is the Wolff-Kishner reduction in which the
corresponding hydrazones of aldehydes and ketones are converted to the respective
hydrocarbons in the presence of the sodium ethoxide at 180-200oC for 6-8 h.121 A review
of this reaction covers the literature prior to 1948,122 however more recent studies have
described techniques in which milder conditions were utilized to synthesize oxindole.
Soriano described a Wolff-Kishner reduction of isatin under mild conditions for 3-4 h. In
this procedure, isatin (2) was treated with 55% hydrazine hydrate and heated for 1 h to
form the isatin-3-hydrazone 148 which was then treated with sodium ethoxide and
acidified with 10% HCl before being recrystallized in water to form the desired oxindole
product 3.123 However, the drawback to this procedure was that it still required 3-4 h for
completion, so Parquet et al. utilized microwave technology to make the procedure more
efficient. In this modification, isatin was treated with 55% hydrazine hydrate, ethylene
glycol and placed in the microwave for 30 s to yield the isatin-3-hydrazone. A mixture of
ethylene glycol and potassium hydroxide was then combined with the hydrazone and
irradiated in the microwave for 10 s, then acidified with 6 M HCl and extracted with
diethyl ether to yield oxindole.124
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All previous Wolff-Kishner methods for the reduction of isatin required the
isolation of the isatin-3-hydrazone 148 until Crestini and Saladino discovered a one-pot
synthesis method in 1994.125 In this one-pot synthesis, it was discovered that Nsubstituted-isatin 124 derivatives reacted readily with hydrazine hydrate to directly
produce the corresponding N-substituted-oxindole derivative 149 without isolating the
intermediate hydrazine and without an additional base.125 In this reaction synthesis, isatin
or N-substituted-isatins were added to 98% hydrazine hydrate and refluxed for 15-30
min. The reaction was then poured into cold water and extracted into ethyl acetate. It
was believed that the direct decomposition of the isatin hydrazone was due to the ability
of the α-ketoamine to give anchimeric assistance in the stage of decomposition of
hydrazone.121

WSU Wolff-Kishner Reduction of Isatins to Oxindoles
The second step required in the creation of the desired trisubstituted oxindole
derivatives (and sub-libraries thereof) involves a Wolff-Kishner type reduction of the C-3
ketone carbonyl on the isatin scaffold. The compounds prepared in this study involved a
slight modification of the Crestini and Saladino one-pot protocol,125 involving heating in
hydrazine hydrate (80 wt%), but refluxing for 3 h instead of the reported 15-30 min.
Additionally, instead of isolating indoles by extraction, the reaction mixture was acidified
and the product was obtained as it precipitated slowly from the aquous solution.
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Furthermore, it was found advantageous to wrap aluminum foil around the reaction
vessel to facilitate faster/higher heating temperatures of the vessel which allowed for the
precipitated hydrazone to ‘dissolve’ back into solution and for the reaction to continue
with loss of nitrogen to afford the desired oxindole.126 The only exception occurred in the
case of 5-fluoroindoline-2-one (154), wherein which it was required that the solution be
left undisturbed for a week before dark brown crystals would precipitate out of solution.
Since the reduction of N-substituted isatin derivatives is a relatively neglected area, most
of the derivatives created were unknown compounds. The percent yields and melting
points for these Wolff-Kishner reactions are reported in Table 3 below along with the
structure of the product of interest.

Table 3: Wolff Kishner Reduction of N-alkylated isatin derivatives
Compound
Number
151

Compound

Melting Point

Lit. Melting
Point

Percent Yield

84-85ᵒC

77-78147

86%

199-202˚C

195˚C126

86%

152
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153

90-91˚C

88-89126

90%

154

145-147ᵒC

N/R

95%

125-129˚C

120-125˚C126

88%

156

169-170ᵒC

N/R

91%

157

140-143ᵒC

143-147ᵒC138

58%

158

76-78ᵒC

N/R148

84%

159

124-127ᵒC

N/R

91%

160

96-98ᵒC

N/R

77%

155
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161

170-173ᵒC

N/R

84%

Aldol Condensation
The most common method in C-3 functionalization of oxindoles is through the
use of an aldol (or perhaps more appropriately a Knoevenagel) type reaction. In an aldol
condensation, aldehydes or ketones with an α-hydrogen atom undergo a base catalyzed
condensation with another carbonyl compound. The aldol reaction occurs by
nucleophilic addition of the enolate ion of the donor molecule to the carbonyl group of
the acceptor molecule. The resulting tetrahedral intermediate is then protonated to give an
alcohol product which can then be followed by dehydration yielding a conjugated enone.
A Knoevenagel reaction is a modified version of the aldol condensation that involves a
nucleophilic addition of a stabilized enolate anion to a carbonyl group of another
molecule followed by spontaneous elimination of water creating an -conjugated
enone. The typical method for attaining alkylidene or benzylidene-2-oxindoles 8 involves
the use of an oxindole 7 with an aldehyde in refluxing ethanol in the presence of catalytic
amounts of piperidine.10
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An alternative method for the condensation of aldehydes and ketones with
oxindole is the dry synthesis method developed by Villemin and Martin.127 This method
utilizes the solid support base of KF/alumina to create arylidene/benzylidene-indolin-2ones 8 under microwave irradiation. In this condensation, 5-substituted oxindoles 7 and
aldehydes were mixed in acetonitrile at room temperature for 5 min, after which the
solvent was evaporated by vacuum. The solid was then irradiated and extracted with
acetonitrile yielding the desired arylidene/benzylidene-indolin-2-ones 8.127
Such aldol or Knoevenagel type condensations upon oxindoles are the standard
means of producing the α,β-unsaturated products characteristic of the “nitrogen-linked
Michael acceptor” motif likely responsible for the biological activity of such
heterocycles. Considering the previous demonstration of 3-benzylidene-indolin-2-ones as
cell death inhibitors it was deemed important to investigate the effects of a 5-fluoro
substituent on this inhibition. Initial work focused on implementing an aldol type
condensation to attain 3-substituted-5-fluoroindolin-2-ones with a variety of aryl
aldehydes. As described earlier, design considerations focused on incorporating some of
the structural features of Q-VD-OPh or the SAR of compounds previously prepared and
found active from this laboratory. From these previous studies, it was concluded that a
an electron-withdrawing substituent at the C-5 position was necessary (or at least
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optimal), and that fluorine atoms on the benzylidene aryl substituent were well tolerated
but perhaps not necessary. Knowing this information, it was deemed important that a 5fluoro-indolin-2-one bearing a 2,6-difluoro-benzylidene moiety at the C-3 position be
created. Moreover, since Repasky had found that the 5-chloro-indolin-2-one bearing a
2,6-difluoro-benzylidene moiety at the C-3 position was inactive against Jurkat T-cells, it
was desireable to ascertain whether the analogous 5-fluoro derivative might retain the
activity noticed in the case of the analogous 5-nitro derivative. Additionally, since the
N-H derivatives containing 4-pyridyl (e.g., 111) and p-methoxy (e.g., 114), synthesized
by Abdullah and the 5-chloro N-H derivative containing 4-pyridyl (e.g., 115)
synthesized by Repasky showed 50 μM inhibition, it was decided that making analogs
exhibiting hydrogen bond donating motifs would be important since such hydrogen
binding between caspase and inhibitor might influence the effectiveness of the inhibitor.
Thus, the aldol type condensations of 5-fluoro-indolin-2-one (157) were
conducted with the requisite aryl aldehydes (1.2 equiv) in refluxing ethanol (3-6 h) in the
presence a catalytic amount of piperidine (0.147 equiv). After that time the reactions
were allowed to cool and the products isolated in pure form by crystallization. The
percent yield and melting points for these reactions are reported in Table 4 below along
with the structure of the product of interest.
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Table 4: 3-Substituted-Indolin-2-ones from Knoevenagel Condensations
Compound

Percent

Melting

Literature

Configuration

Yield

Point

Melting

(Z:E)

Point

163

61%

248-253˚C

N/R

(100:0)

164

63%

210-212˚C

N/R

(60:40)

165

81%

229-231˚C

N/R

(90:10)

166

98%

205-208˚C

N/R

(0:100)

167

70%

305-308ᵒC

N/R

(0:100)
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168

58%

192-195ᵒC

N/R144

(40:60)

169

81%

218-219˚C

N/R

(0:100)

170

58%

250-255˚C

N/R

(100:0)

171

81%

218-221˚C

N/R

(60:40)

172

43%

220-223˚C

N/R149

(60:40)

Since it is known from the work of Mach et al.37 that introduction of an alkyl or
benzylic group on the isatin nitrogen results in dramatic improvement in potency for
inhibiting caspase-3 activity, it was determined that a library of N-substituted oxindole
compounds would be synthesized containing a fluorine at the C-5 position of the
oxindole scaffold and with an appropriately substituted benzylidene group at the C-3
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position.5 The fluorine was utilized for its high electron withdrawing effect. The first
library of compounds was synthesized utilizing the N-(2,6-difluorobenzyl)-5-fluoroindolin-2-one scaffold. This allowed for the incorporation of the 2,6-difluorobenzyl
moiety characteristic of Q-VD-OPh and also present in the most active compounds
created in the Ketcha lab. The increased inhibition of 118 (possessing a 3-pyridyl group
and N-2,6-difluorobenzyl substituent) indicated that it might be important to synthesize
more molecules that incorporate the available 3 points of variability. This was
accomplished in the case of the 5-fluoro and 5-chloro-N-2,6-difluorobenzylindolin-2ones (173) in the aldol type condensation reaction with associated aryl-aldehyde (1.2
equiv.) at 90ᵒC for 3-6 h in the presence of catalytic amounts of piperidine (0.147 equiv.)
yielding the corresponding arylidene oxindoles 174. In those cases where the products
would not precipitate out of solution, the reaction mixtures were evaporated under
reduced pressure and purified by passing through a silica gel column (70:30 hexanes:
EtOAc). If necessary, the products could be recrystallized from dichloromethane and
hexanes to afford the pure (TLC/GC-MS) product. Moreover, since these compounds had
not previously been reported, no literature melting point values could be attained for
comparison. The percent yield results and melting points for these reactions are reported
in Table 5 below along with the structure of the product of interest.
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Table 5: N-(2,6-Difluorobenzyl)-5-fluoro-3-Substituted-Benzylidene-Indolin-2-ones
Compound

Percent Yield

Melting Point

Configuration
(Z:E)

175

38%

129-131˚C

(0:100)

176

72%

253-255˚C

(0:100)

177

62%

207-211˚C

(0:100)

178

68%

141-144˚C

(40:60)
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179

63%

136-140˚C

(30:70)

180

38%

205-208˚C

(0:100)

181

38%

158-161˚C

(40:60)

182

25%

142-144 ºC

(100:0)

183

59%

175-176˚C

(0:100)

83

[Type text]

184

45%

135-138 ˚C

(0:100)

185

45%

174-176 ˚C

(100:0)

186

69%

250-255 ˚C

(0:100)

187

65%

149-151 ˚C

(0:100)

Although it is hypothesized that the addition of a 2,6-difluorobenzyl substituent
at the N-position of benzylidene oxindoles is partly responsible for enhanced cell-death
inhibition, it is unknown whether the 2,6-difluorobenzyl ring is necessarily required or if
the addition of a simple benzyl or alternately substituted benzyl group would suffice. To
examine this query, the 5-hydrogen, 5-fluoro and 5-chloro-N-benzylindolin-2-ones (188)
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were reacted in the aldol type condensation reaction with associated aryl-aldehyde (1.2
equiv.) at 90ᵒC for 3-6 h in the presence of catalytic amounts of piperidine (0.147 equiv.)
yielding the corresponding arylidene oxindoles 189. After the appropriate time, the
mixture was cooled and the precipitate was collected by vacuum filtration. In some
cases, the mixture was cooled but the product would not precipitate out of solution. In
these situations, the mixture was evaporated under reduced pressure and silica gel column
(70:30 hexanes: EtOAc) was utilized to purify the product. The product was then
evaporated under reduced pressure to a solid or oil and recrystallized from
dichloromethane and hexanes to afford the pure (TLC/GC-MS) product. The percent
yield results and melting points for these reactions are reported in Table 6 below along
with the structure of the product of interest.

Table 6: N-(Benzyl)-5-fluoro-3-Substituted-Benzylidene-Indolin-2-ones
Compound

Percent Yield

Melting Point

Configuration
(Z:E)
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190

70%

185-187˚C

(0:100)

191

81 %

236-238 ºC

(0:100)

192

25%

140-142 ºC

(30:70)

193

74%

126-127˚C

(0:100)

194

51%

157-158˚C

(40:60)
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195

49%

161-164˚C

(30:70)

196

49%

162-164˚C

(0:100)

197

48%

145-149 ºC

(40:60)

198

76%

139-140˚C

(100:0)

199

82%

255-257 ˚C

(0:100)
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200

76%

139-140 ˚C

(70:30)

The orientation of the fluorines on the benzyl ring was also investigated to
determine if the substitution pattern had any impact on biological activity. This was
accomplished by the incorporation of a 3,5-difluorobenzyl ring at the N-position of the
isatin scaffold. In this work, 5-fluoro and 5-chloro-N-3,5-difluorobenzylindolin-2-ones
(201) were utilized as substrates in the aldol type condensation reactions with associated
aryl-aldehydes (1.2 equiv.) at 90ᵒC for 3-6 h along with catalytic amounts of piperidine
(0.147 equiv.) yielding the corresponding arylidene oxindoles (202). In some cases, the
mixture was cooled but the product would not precipitate out of solution. In these
situations, the mixture was evaporated under reduced pressure and a silica gel column
(70:30 hexanes: EtOAc) was utilized to purify the product. The product was then
evaporated under reduced pressure to a solid or oil and recrystallized from
dichloromethane and hexanes to afford the pure (TLC/GC-MS) product. The percent
yield results and melting points for these reactions are reported in Table 7 below along
with the structure of the product of interest.
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Table 7: N-(3,5-Difluorobenzyl)-5-fluoro-3-Substituted-Benzylidene-Indolin-2-ones
Compound

Percent Yield

Melting Point

Configuration
(Z:E)

203

37.1%

204-206˚C

(0:100)

204

59%

138-141 ºC

(40:60)

205

98.9 %

125-126˚C

(40:60)
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206

29%

162-164˚C

(100:0)

207

69%

157-159˚C

(0:100)

208

55%

130-133˚C

(40:60)

209

68%

165-167˚C

(0:100)

Additionally, in previous results from the Ketcha Group it had been observed that
the incorporation of a moiety with a lone pair of electrons attached to the C-3
benzylidene group (e.g., -OCH3 or pyridyl-) seemingly enhanced cell-death inhibition
presumably through hydrogen bonding to the active site of the caspase. Coincidentally, in
the case of isatin sulfonamides, Mach found that 5-(3-pyridin-3-yl-
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oxymethyl)pyrrolidine-1-sulfonyl)isatin bearing a 4-methoxy-benzyl ring at the Nposition (e.g., 210) was the most potent inhibitor of caspase-3, with IC50 of 3.9 μM.37

Due to these observations, it was hypothesized that incorporating an N-substituent
with available electrons (e.g., 4-methoxybenzyl-) could potentially increase biological
activity in the case of benzylidene oxindoles. This was accomplished by utilizing 5-fluoro
or 5-chloro-N-(4-methoxybenzyl)-5-fluoro-indolin-2-one (211) in the aldol type
condensation with associated aryl-aldehyde (1.2 equiv.) at 90ᵒC for 3-6 h in the presence
of catalytic amounts of piperidine (0.147 equiv.) yielding the corresponding arylidene
oxindoles (212). In some cases, the mixture was cooled but the product would not
precipitate out of solution. In these situations, the mixture was evaporated under reduced
pressure and silica gel column (70:30 hexanes: EtOAc) was utilized to purify the product.
The product was then evaporated under reduced pressure to a solid or oil and
recrystallized from dichloromethane and hexanes to afford the pure (TLC/GC-MS)
product. The percent yield results and melting points for these reactions are reported in
Table 8 below along with the structure of the product of interest.
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Table 8: N-(4-Methoxybenzyl)-3-Substituted-Benzylidene-Indolin-2-ones
Compound

Percent Yield

Melting Point

Configuration
(Z:E)

213

75%

139-140˚C

(0:100)

214

66%

135-139˚C

(40:60)

215

72%

140-143˚C

(70:30)
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216

99%

152-155 ˚C

(0:100)

217

75%

159-162 ˚C

(100:0)

N-Alkylation of Benzylidene Oxindoles
The N-alkylation of an arylidene- or benzylidene oxindole is a reaction that has
seen only limited usage and sometimes as the first step in a multi-step sequence (without
isolation or characterization of the initial alkylated product). In terms of preparing Nalkylated beznylidene oxindoles, the standard strategy involves initial N-alkylation of the
isatin followed by Wolff-Kishner, and ultimately the aldol condensation. However, in
order to take full advantage of the libraries from libraries concept, we visualized an
alternate strategy commencing with the aldol reaction of an oxindole so as to afford a
library of N-H benzylidene oxindoles (i.e., kinase inhibitors), followed by the Nalkylation of this sublibrary. As stated before, this reaction upon benzylidene oxindoles
is not well known and just recently Overman et al. reported this alkylation as a protocol
to N-alkylated 3-substituted oxindoles in a sequence involving an initial aldol upon an
oxindole to afford a benzylidene oxindole followed by an N-alkylation using sodium
hydride in DMF immediately followed by reduction of the alkene double bond by zinc
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under acidic conditions to yield the C-3 alkylated products(e.g., 219).128 A similar
approach was employed by Trost and Zhang for the introduction of a MOM protecting
group on the nitrogen of benzylidene oxindoles.129

In what represents the most extensive study to date, Zhou et al. developed an
alternative synthesis for the N-alkylation of a benzylidene oxindole 220 in the attempt to
develop 3-substituted-N-(5-formylfurfuryl)-indolin-2-ones 221.23 In this synthesis, the
benzylidene oxindoles were attained through an aldol condensation with an aldehyde and
piperidine in refluxing ethanol for 3-5 h. The resulting benzylidene oxindoles were then
alkylated with 5-chloromethylfurfuraldehyde in the presence of K2CO3 as well as a
catalytic amount of KI in DMF to produce the desired 3-substituted-N-(5-formylfurfuryl)indolin-2-one 221 in varying yields between 5-70%.23

As can be seen from the examples provided above, the N-alkylation of
benzylidene oxindoles is a fairly new reaction that has not been thoroughly studied. The
existing synthetic methods for this reaction sometimes involve working with hazardous
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solid bases (e.g., NaH) and/or long drawn out workups due to the use of very polar
aprotic solvents like DMF. These workups require multiple extractions with ethyl acetate
(EtOAc) or dichloromethane (DCM) and column chromatography. Thus, discovering
new methods to N-alkylate benzylidene oxindoles appears to be important because of the
encouraging medicinal properties of such compounds. The possibility of readily adding
variability to N-H benzylidene oxindoles can only serve to increase the chances of
discovering biologically active compounds based upon this scaffold.

Alternative Route of Synthesis
It was originally expected that the synthetic sequence involving initial Nalkylation of isatins followed by Wolff-Kishner reduction and final aldol condensation of
the N-alkylated oxindole could be utilized to create molecules bearing an N-propargyl
moiety which could be utilized in cycloaddition reactions with azides as a means of
preparing PET imaging agents by click chemistry (vide infra). To accomplish this task,
isatin and 5-substituted isatins (5-chloro-, 5-fluoro-) were N-alkylated with KF/alumina
in acetonitrile (or DBU in ethanol) with propargyl bromide to yield the corresponding Npropargyl derivatives 130, 135, and 141, respectively.

The next step in the proposed sequence involved Wolff-Kishner reduction of the
N-propargyl-indolin-2,3-dione compounds prior to aldol condensation. However,
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attempted Wolff-Kishner reduction of N-propargyl-indolin-2,3-one (130) (with or
without subsequent acidification of the reaction mixture) resulted in degradation of the
substrate. In this Wolff-Kishner reaction, N-propargyl-indolin-2,3-dione (130) and the
hydrazine hydrate were placed in a reaction vessel that was wrapped with aluminum foil
and the mixture was refluxed for 3 h. After heating, the mixture was poured in to a
beaker submerged into an ice bath and acidified with dilute hydrochloric acid and left
undisturbed overnight. However, the precipitate that formed from this reaction was black
and intractable. A second Wolff-Kishner reaction was performed on N-propargylindolin-2,3-dione (130), wherein after heating for 3 h, the mixture was poured into a
beaker submerged into an ice bath and left undisturbed overnight. In this case, the
mixture was not acidified with dilute hydrochloric acid and the precipitate obtained
consisted of a small amount of orange, gummy oil. GC-MS analysis of this oil indicated
starting material. Upon determining that the C-3 carbonyl of N-propargyl-indolin-2,3dione could not be effectively reduced utilizing the Wolff-Kishner reaction, it was
envisioned that an alternate synthesis would be required to create the desired 3 points of
variability on the isatin or oxindole scaffold.

An alternative synthesis was therefore envisioned involving an initial WolffKishner of an isatin substrate followed by an aldol condensation and finally ending with
an N-alkylation of the resultant benzylidene oxindole. To that end, a variety of N-H
oxindoles were subjected to aldolization with a variety of aromatic aldehydes to create
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series of sublibraries with various C-5 substituents. For the 5-H series, oxindole was
reacted with aryl aldehydes (1.2 equiv.) under standard conditions leading to the
compounds shown below in Table 9.

Table 9: 3-substituted-benzylidene-indolin-2-ones
Compound

Percent

Melting

Literature

Configuration

Yield

Point

Melting

(Z:E)

Point

226

81%

169-172˚C

175-176˚C139

(0:100)

227

83%

186-188˚C

188-190˚C140

(0:100)

228

84%

205-207˚C

N/R

(60:40)
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229

89%

174-176˚C

N/R

(100:0)

230

29%

181-182˚C

188-189˚C141

(0:100)

231

91%

154-157˚C

158-159˚C142

(40:60)

232

79%

217-220˚C

213-218˚C143

(100:0)

233

54%

197-199˚C

202-205˚C143

(100:0)

234

86%

218-220˚C

N/R

(0:100)

Similarly, a library of benzylidene oxindoles containing an electron-withdrawing
group at the 5-position of the oxindole scaffold was constructed. 5-Chloro-oxindole was
chosen because it was much easier and efficient to synthesize in large quantities
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compared to the 5-fluoro analogue. In this aldol reaction, 5-chloro oxindole (152) and
associated aryl-aldehydes (1.2 equiv.) were mixed at 90ᵒC for 3-6 h in the present
catalytic amounts of piperidine (0.147 equiv) yielding 235. The percent yield results and
melting points for these reactions are reported in Table 10 below along with the structure
of the product of interest

Table 10: 5-chloro-3-substituted benzylidene-indolin-2-ones
Compound

Percent

Melting

Literature

Configuration

Yield

Point

Melting

(Z:E)

Point

236

97%

204-205˚C

210˚C126

(0:100)

237

90%

249-250˚C

N/R

(100:0)
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238

78%

247-248˚C

252-254˚C126

(40:60)

239

85%

273-276˚C

N/R

(80:20)

240

51%

218-220

220-223150

(60:40)

241

88%

218-220˚C

219-220˚C126

(20:80)

242

64%

215-218˚C

197-199˚C151

(0:100)

243

80%

245-246˚C

242-244˚C126

(100:0)
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244

59%

158-162˚C

N/R

(0:100)

245

83%

227-231˚C

N/R

(80:20)

246

65%

288-290˚C

N/R

(0:100)

247

65%

250-253 ˚C 257-260˚C151

(0:100)

The final step of the alternative synthesis, involved an investigation into the Nalkylation of the aforementioned benzylidene oxindoles utilizing two different bases; the
solid supported base KF/alumina or the soluble liquid base DBU. The N-alkylation
utilizing KF/alumina as base involved the reaction of various benzylidene oxindoles (1
mmol) along with KF/alumina (6 equiv.) in acetonitrile. The mixture was placed on a
heating mantle and allowed to stir at room temperature for 10-15 min, after which time
various alkyl halides (3 equiv.) were added to the reaction mixture and the mixture was
placed under reflux for 24-36 h. The solid base was then removed via vacuum filtration
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and the filtrate was evaporated under reduced pressure and purified with silica gel
column (hexanes: ethyl acetate, 70:30). The product was then evaporated under reduced
pressure to a solid or oil and recrystallized from dichloromethane and hexanes to afford
the pure (TLC/GC-MS) product.

Benzylidene oxindoles were also N-alkylated utilizing the soluble liquid base
DBU. This was accomplished through the reaction of various benzylidene oxindoles (1
mmol) and DBU (2 equiv.) in ethanol. The mixtures were placed on a heating mantle and
allowed to stir at room temperature for 10-15 min before the addition of an alkyl halide (3
equiv.), after which time the reaction was refluxed for 24 h and the crude reaction
mixture was evaporated under reduced pressure and purified with silica gel column
(hexanes: ethyl acetate, 70:30). The product was then evaporated under reduced pressure
to a solid or oil and recrystallized from dichloromethane and hexanes. The N-alkylation
of benzylidene oxindoles with DBU was also performed in the CEM microwave. This
was performed by placing benzylidene oxindole (1 mmol), DBU (2 equiv.), and alkyl
halide (3 equiv.) into a 10 mL microwave vial with ethanol (3 mL) and heating the
reaction for 20 min at 180 oC. The reaction mixture was then evaporated under reduced
pressure and purified with silica gel column (hexanes: ethyl acetate, 70:30). The product
was then evaporated under reduced pressure to a solid or oil and recrystallized from
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dichloromethane and hexanes. The optimal parameters for this process were determined
by varying time and temperature in temperature ranges from 120 oC to 180 oC, and time
ranges from 10 to 20 min. Temperature ranges were increased in 20 oC increments and
time was increased in 5 minute increments. Upon attempting to N-alkylate these
benzylidene oxindoles, it was discovered that benzylidene oxindoles substituted at the 3position with a pyridine could not be effectively alkylated. It was hypothesized that
when N-alkylating the benzylidene oxindole, the nitrogen on the pyridine would compete
with the nitrogen in the isatin ring causing the creation of a salt thus preventing the
reaction from moving to completion. Therefore, the desirable, biologically active
pyridine benzylidene oxindole derivatives could not be N-alkylated. The results of the
reaction between various benzylidene oxindoles and alkyl halides in the presence of
DBU or KF/alumina and utilizing either traditional reflux (R) and microwave heating
techniques (M) are presented in Table 11. Likewise, results from the the reaction
between benzylidene oxindoles and propargyl bromide are shown in Table 12..
Table 11: Arylidene Oxindoles via N-Alkylation of Benzylidene Oxindole
Compound

248

Percent Yield

Melting

Literatur

Configurat

Point

e Melting

ion

Point

(Z:E)

N/R

(40:60)

DBU (R): 45%

139-141˚C

DBU (M): 41%

135-138˚C

KF/Alumina (R):

139-141˚C

51%
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249

DBU (R): 28%

135-138˚C

DBU (M): 68%

140-142˚C

KF/Alumina (R):

147-149˚C

N/R

(40:60)

N/R

(100:0)

N/R

(100:0)

N/R

(40:60)

N/R

(100:0)

25%

250

DBU (R): 59%

137-139˚C

DBU (M): 62%

135-138˚C

KF/Alumina (R):

139-141˚C

51%

251

DBU (R): 77%

167-170˚C

DBU (M): 48%

163-165˚C

KF/Alumina (R):

160-165˚C

73%

252

253

DBU (R): 73%

214-216˚C

DBU (M): 51%

215-217˚C

DBU (R): 41%

163-166˚C

DBU (M): 41%

169-171˚C

KF/Alumina (R):

167-169˚C

65%
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Table 12: N-Propargyl-3-substituted benzylidene-indolin-2-ones
Compound

Base

Percent

Melting

Configuration

Yield

Point

(Z:E)

254

DBU (M)

45%

121-124˚C

(10:90)

255

DBU (M)

51%

174-177˚C

(80:20)

256

DBU (M)

33%

151-155˚C

(80:20)

257

DBU (M)

34%

125-128˚C

(30:70)

258

DBU (M)

51%

95-98˚C

(40:60)
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259

DBU (M)

26%

167-169˚C

(0:100)

260

KF/Alumina

17%

123-125˚C

(100:0)

(R)

261

DBU (M)

57%

132-134˚C

(60:40)

262

DBU (M)

49%

106-109˚C

(70:30)

263

KF/Alumina

66%

127-129˚C

(40:60)

74.0%

107-110 ˚C

(100:0)

(R)

264

DBU (M)
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265

DBU (M)

23%

119-121˚C

(100:0)

266

DBU (M)

62%

177-179˚C

(0:100)

53%

171-175˚C

(100:0)

KF/Alumina
(R)

KF/Alumina

267

(R)

“Click Chemistry”
The term “click chemistry” was coined by Sharpless et al. on the basis of
developing an expanding set of powerful, selective, and modular building blocks that add
together reliably in both small and large scale applications.130,131 A set of criteria was
developed for a reaction to be considered “click chemistry” which include: the reaction
must be modular, wide in scope, give high yields, generate only inoffensive byproducts
that can be removed by non-chromatographic methods, and be stereospecific. A “click
reaction” should involve simple reaction conditions; have readily available starting
materials and reagents, and simple product isolation.130 Sharpless thought of these
reactions as being “spring loaded” for a single trajectory because of the speed at which
they should proceed. The main focus here will be towards “click chemistry” reactions
such as 1,3-dipolar cycloadditions involving two unsaturated reactants which provides
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fast access to an enormous variety of five and six-membered heterocycles.132 Of these
1,3-dipolar cycloaddition reactions, the Huisgen dipolar cycloaddition of azides and
alkynes resulting in 1,2,3-triazoles is considered important because of the favorable
biological properties they have exhibited.133 Although azides are rarely utilized in
organic synthesis, they are believed to be the most reliable way to introduce a nitrogen
substituent through the 1,3-dipolar cycloaddition reaction.133 The main downside of the
original azide/alkyne reaction was that the triazole forming reaction would usually result
in a mixture between the 1,4- and 1,5-regioisomers.132 However, Rostovtsev et al.
developed a synthesis in which copper (I) was utilized to combine a terminal acetylene
268 and an azide 269 to produce only the 1,4-disubstituted 1,2,3-triazole 270.133 It was
discovered that making the copper catalyst in situ by reduction of copper (II) salts in the
form of CuSO4 . 5 H2O worked the best for the reaction and the use of sodium ascorbate
allowed for a variety of substituents with high yields. It was also discovered that a variety
of solvents like ethanol, tert-butyl alcohol, and water could be utilized at ambient
temperatures for anywhere between 6-36 h.133

Appukkuttan et al. expanded on the click chemistry of 1,2,3-triazoles by
developing a more efficient method that shortened reaction times from 6 h to just 10-15
min through the use of microwave irradiation. To optimize this reaction, benzyl bromide
and phenylacetylene (268) were chosen as the starting materials.134 These starting
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materials along with sodium azide were suspended in a 1:1 mixture of t-BuOH and water
with the copper (I) catalyst which was prepared in situ through the combination of Cu(0)
and Cu(II).134 The mixture was irradiated for 10 min at 100 Watt and 125oC producing
the desired product 1-benzyl-4-phenyl-1H-1,2,3-triazole (271) in 93% yield with no trace
of the 1,5-regioisomer.134 This microwave-enhanced, regioselective reaction allows for an
efficient means of synthesizing 1,4-disubstituted-1,2,3-triazoles in a timely manner.

Recently, Jiang et al. developed a route towards isatin 1,2,3-triazoles as potential
caspase inhibitors.135 In this synthesis, 5-(S)-2-(methoxymethyl)pyrrolidinylsulfonyl
isatin (272) was alkylated in acetonitrile using 3-bromopropyne in the presence of
Cs2CO3 to produce 5-(S)-2-(methoxymethyl)-pyrrolidinylsulfonyl-N-prop-2-ynyl isatin
(273).135

The desired 1,2,3-triazoles were then obtained through 2 different methods
involving either a thermal cycloaddition reaction or copper (I) catalyzed cycloaddition
reaction. In the thermal cycloaddition reaction, 273 was combined with the benzyl azide
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in methanol and heated, yielding both the 1,4- and 1,5-disubstituted triazole isomers (274,
275) which were then separated by chromatography. In the copper catalyzed
cycloaddition reaction, 273 was placed in a mixture with phenyl azide, CuSO4, and
sodium ascorbate in methanol at room temperature yielding only the 1,4-disubstituted–
phenyl-triazole 274.135

It was determined that the 1,4-disubstituted 1,2,3-triazole 274 was more potent
against caspase-3 the the 1,5-regioisomer 275. Interestingly, in the case of triazoles
derived from phenyl azide, the 1,5-disubstituted isomer (e.g., 276) exhibited 2-fold higher
potency than the 1,4-regioisomer derived from benzyl azide (274). Jiang et al. was able
to conclude that the substitution pattern in the 1,2,3 triazole ring affected the binding
affinity towards caspase-3 which explains why the potency of 1,4-disubstituted 1,2,3triazoles was higher in the case of tyriazoles produced from phenyl azide but 1,5-
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disubstituted 1,2,3-triazoles prepared from benzyl azide exhibited higher potency than
that of the 1,4-isomer.135

WSU Approach to “Click” chemistry
The main advantage in synthesizing the N-alkylated propargyl compounds was
their capability to take part in a “click” reaction to create the isatin 1,2,3-triazole which
could theoretically be utilized to perform radiochemistry with a [18F]-radiolabel. The
goal was to identify a caspase inhibitor in which an 18F radioisotope may be attached
through the “click” reaction and utilize this inhibitor as a possible PET imaging agent for
apoptosis. To accomplish this task, the N-alkynyl derivatives in Table 12 would be
reacted with 2-fluoroethyltosylate in the presence of CuSO4, ascorbic acid and sodium
azide in DMF to attain the cold version of the desired triazole targeting agent.

If effective, the radiolabeled [18F]-fluoroethylazide could then be prepared by
nucleophilic fluorination of 2-azidoethyl-4-toluenesulfonate with Kryptofix 2.2.2 [18F]
KF to create the [18F]-radiolabeled triazole.
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The table below shows three proof of concept compounds which were synthesized
as cold versions of potential cell death imaging agents for PET imaging. Since the most
active C-3 pyridyl-derivatives could not be utilized because of the presumed creation of a
salt during the N-alkylation step, it was decided to utilize the next most potent compound
which was 3-(2,6-difluorobenzyl)indolin-2-one. Thus, 3-(2,6-difluorobenzyl)indolin-2one (170) was N-alkylated with propargyl bromide and KF/alumina in acetonitrile to
produce N-propargyl-5-fluoro-3-(2,6-difluorobenzyl)indolin-2-one (267). A click
reaction was then performed on the N-propargyl-5-fluoro-3-(2,6-difluorbenzyl)indolin-2one (267) in a vial with 2-fluoro-ethyl-4-toluenesulfonate (1 equiv), copper (II) sulfate (5
mol%), ascorbic acid (10 mol %) and sodium azide (1.1 equiv) in DMF to create 5fluoro-1-[1-(2-fluoro-ethyl)-1H-[1,2,3]triazol-4-ylmethyl]-3-(2,6-difluorobenzyl)indolin2-one (281).
Table 13: Isatin Triazole
Compound

Percent
Yield
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76%

170-174oC

281

NMR Analysis
NMR Analysis of N-Substituted Isatins
All of the N-substituted compounds made by microwave heating using DBU
listed in Table 1 were achieved in moderate to high yields. These N-alkylated isatins
molecules were further characterized by 13C NMR spectroscopy using the Bruker Avance
300 MHz NMR. These samples were compared to previously made derivatives prepared
using conventional heating and KF/Alumina. However, since the 5-fluoroisatin
molecules had not previously been synthesized in the WSU library, the 1H NMR and 13C
NMR spectra were utilized to fully characterize these compounds. Prior to the analysis of
the substituted molecules, a thorough analysis of the chemical shifts of 5-fluoroisatin
(Figure 2) itself was completed and compared to shifts reported in the literature and were
found to agree accordingly. All of the following spectra generated were analyzed and
expanded using SpinWorks 3.1. The 1H NMR spectrum of 5-fluoroisatin (SigmaAldrich) is presented below in Figure 3 There are clearly four signals which represent the
four protons found on the 5-fluoroisatin molecule.

Figure 2.
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Figure 3.
The signal furthest downfield is a singlet at 11.03 ppm and its downfield shift is
due to a strong deshielding caused by the effect of the nitrogen atom bonded to this
proton. There is a doublet of doublets at 7.48 ppm (J = 2.7 Hz, J = 17.9 Hz), a doublet of
doublets at 7.50 ppm (J = 3.9 Hz, J = 8.5 Hz), and a doublet at 7.40 ppm (J = 7.2 Hz)
which are assigned to the protons labeled 4, 6, and 7 respectively. The signals from
proton 4 appear further downfield due to the proximity to the carbonyl group. The 13C
NMR spectrum (Figure 4) of 5-fluoroisatin is presented below and shows eight signals
which correspond to the eight carbons in the 5-fluoroisatin molecule. The peak furthest
downfield at 183.8 ppm (d, J = 2.3 Hz) correlates to the C-3 ketone carbonyl group of the
5-fluoroisatin molecule, while the amide carbonyl appears at 159.4 ppm (d, J = 1.3 Hz).
The C-5 fluoro-carbon exhibits a fairly large splitting pattern appearing at 159.6-156.4 (d,
J = 240 Hz) ppm. Carbon 3a appearing at 118.5-118.4 (d, J = 7.1 Hz) ppm and 7a
appearing at 146.9 (d, J = 1.6 Hz) ppm like carbons 2 and 3 are quaternary carbons and
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consequently do not appear in the 13C DEPT spectrum. The remaining signals for
carbons 4, 6, and 7 fall within the aromatic region of the spectrum and appear at 124.6124.3 (d, J = 24.0 Hz), 111.5-111.1 (d, J = 24.0 Hz), and 113.4-113.3 (d, J = 7.3 Hz)
respectively. For reference, the solvent signal appears at 39.6 ppm for DMSO-d6.

Figure 2.

Figure 4.
The NMR spectra for the N-alkylated products were similarly analyzed as well,
and as expected there are several shifts of the original carbon peaks due the addition of a
group at the nitrogen atom, along with of course the appearance of new proton and
carbon signals. The addition of either a benzyl group or a 2,6-difluorobenzyl group at the
N-position of the 5-fluoroisatin resulted in a shift of the original carbon peaks (vide
infra).
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The 13C NMR spectrum of 138a is shown below which gives 13 signals.

Figure 5
In Figure 5 above the DMSO-d6 signal appears at 40.35 ppm. There are two
carbonyl peaks which are located at 182.4 ppm for carbon 3 and 158.3 ppm (d, J = 1.4
Hz) for carbon 2. In addition the remaining aromatic peaks for carbons 3a-7a are
consistent with those of the 5-fluoroisatin molecule carbon shifts and only change
slightly, appearing at 118.7-118.6 (d, J = 7.2 Hz), 123.9-123.6 (d, J = 24.0 Hz), 160.09156.86 (d, J = 241 Hz), 111.6-111.3 (d, J = 24.3 Hz), 112.4-112.3 (d, J = 7.4 Hz), and
146.5-146.4 (d, J = 1.6 Hz) ppm, respectively. In addition the spectrum includes an
aliphatic peak due to carbon 8, which appears at 42.9 ppm. Likewise there are an
additional four signals which correspond to the benzyl phenyl ring. The signal for the
quaternary carbon 9 appears at 135.3 ppm and does not appear in the 13C DEPT
spectrum. The carbons 10’ and 10’ are symmetric and are shown as a large intense peak
at 127.3 ppm, as does the signal for carbons 11’ and 11’ which appears at 128.6 ppm.
Carbon 12 appears at 127.5 ppm in the spectrum. The 13C NMR spectrum of 139 is
shown below in Figure 6 which gives 13 signals.
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Figure 6
The main difference in the spectrum of compound 139 compared to that of 138
could be seen in carbons C-8, C-9, C-10’, C-11’, and C-12 in which carbon shifts could
be observed at 32.2 (t, J = 3.9 Hz), 110.9-110.4 (t, J = 18.7 Hz), 162.6-159.2 (dd, J = 7.7
Hz), 112.0-111.7 (dd, J = 7.3 Hz), and 130.9-130.6 (t, J = 10.5 Hz) respectively. The
splitting in compounds 138 and 139 could be attributed to the fluorine atom at the C-5
position of the isatin scaffold. Other N-substituted 5-fluoroisatins were synthesized in
Table 2 through the use of KF/Alumina and ACN under conventional heating conditions.
These compounds produced spectra that only slightly deviated from the spectra produced
by compound 138 and 139.
NMR Analysis of 5-fluorooxindoles and N-Substituted 5-fluorooxindoles
The compounds synthesized in Table 2 were prepared through the use of a WolffKishner reaction in which hydrazine hydrate was used to reduce the C-3 carbonyl to a
methylene. The chemical shifts and splitting patterns in the 13C NMR spectrum for these
types of compounds were very similar to that of the 5-fluoroisatin and the N-substituted
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5-fluoroisatins except for slight chemical shifts. For example the 13C NMR spectrum of
158 is shown below, which gives 8 signals.

Figure 7
Figure 7 above displays one carbonyl peak which is located at 176.1 ppm for
carbon 2. In addition the remaining aromatic peaks for carbons 3a-7a are consistent with
those of the 5-fluoroisatin molecule carbon shifts and only change slightly, appearing at
127.6-127.5 (d, J = 9.1 Hz), 113.6-113.5 (d, J = 23.2 Hz), 159.2-156.1(d, J = 235 Hz),
112.3-111.9 (d, J = 24.6 Hz), 109.5-109.4 (d, J = 8.2 Hz), and 139.8 (d, J = 1.6 Hz) ppm
respectively.
A variety of oxindole compounds were produced with different substituents at the
N-position producing numerous spectral results. For example, the 13C NMR spectrum of
159 is shown below which gives 13 signals.

118

[Type text]

Figure 8
In Figure 8 above there is one carbonyl peak which is located at 174.2 ppm for
carbon 2. In addition the remaining aromatic peaks for carbons 3a-7a are consistent with
those of the N-benzyl-5-fluoroisatin molecule carbon shifts, appearing at 126.8-126.7 (d,
J = 9.2 Hz), 113.5-113.2 (d, J = 23.4 Hz), 159.7-156.6 (d, J = 236 Hz), 112.4-112.1 (d, J
= 25.0 Hz), 109.4-109.3 (d, J = 8.3 Hz), and 140.1 (d, J = 1.6 Hz) ppm, respectively. In
addition, the spectrum includes an aliphatic peak due to carbon 8, which appears at 42.6
ppm. Likewise there are an additional four signals which correspond to the benzyl phenyl
ring. The signal for the quaternary carbon 9 appears at 136 ppm and does not appear in
the 13C DEPT spectrum. The carbons 10’ are symmetric and are shown as a large intense
peak at 127.2 ppm, as does the signal for carbons 11’ which appears at 128.5 ppm.
Carbon 12 appears at 127.3 ppm in the spectrum. The 13C NMR spectrum of 160 is very
similar to that of 139 as shown below.
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13

13

C NMR spectrum of 160

C NMR spectrum of 139

Figure 9 Comparison of 13C NMR spectrum of 160 to 13C NMR spectrum of 139
Figure 9 shows that there is one carbonyl peak which is located at 173.6 ppm for
carbon 2. In addition the remaining aromatic peaks for carbons 3a-7a are consistent with
those of the 139a carbon shifts, appearing at 126.6-126.5 (d, J = 9.2 Hz), 113.7-113.3 (d,
J = 23.2 Hz), 159.6-156.5 (d, J = 237 Hz), 112.5-112.2 (d, J = 24.8 Hz), 108.6-108.5 (d, J
= 8.3 Hz), and 139.9 (d, J = 1.4 Hz), ppm respectively. In addition the spectrum includes
an aliphatic peak due to carbon 8, which appears at 31.9-31.8 (t, J = 3.6 Hz) ppm.
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Likewise there are an additional four signals which correspond to the 2,6-difluorobenzyl
phenyl ring. The signal for the quaternary carbon 9 appears at 111.2 ppm and does not
appear in the 13C DEPT spectrum. The carbons 10’ contain fluorines which exhibit as
doublet of doublets at 162.6-159.2 (dd, J = 8.0 Hz) ppm. The signal for 11’ appear at
111.9-111.5 (dd, J = 7.4 Hz) ppm and carbon 12 appears as a triplet at 130.3 (t, J = 10.4
Hz) ppm in the spectrum.
NMR Analysis of 5-Fluoro-3-substituted indolin-2-ones
Compound 158 from Table 3 was reacted with a variety of aryl aldehydes through
an aldol condensation. In this reaction, compound 158 was reacted with a selected aryl
aldehyde and piperidine in the presence of ethanol to produce 5-fluoro-3-substituted
indolin-2-ones. These 5-fluoro-3-substituted indolin-2-ones existed as either the E or Z
isomer or mixture of the two about the exocyclic double bond. The E or Z isomer is
dependent on the characteristics of the substituents placed at the C-3 position. Through
the use of 1H NMR analysis, the E or Z isomers could be determined due to the chemical
shifts of the aromatic protons on the benzylidene ring (H-2’ and H-6’) and the vinylic
proton being significantly influenced by configuration. In the E-isomer, the vinylic
proton (Hvin) is more deshielded due to the influence of the C-2 carbonyl just as the
ortho-benzylidene protons (Ho) are shifted downfield due to the C-2 carbonyl.
Therefore, in the Z isomer, the H-2‟ or H-6‟ protons occur in the range of 7.85-8.53 ppm
compared to 7.45-7.84 ppm for the same protons in the E isomers.24 In cases where the
H- 2’ and H-6’ positions were substituted, only the influence of the vinylic proton was
used to determine configuration, where the vinylic proton occurs about 7.55 ppm in the Z
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isomer and 7.84 ppm in the E isomer.136 For example, the 1H NMR spectrum for 170 is
presented below in Figure 10 with the vinylic proton occurring at 7.43 as a singlet
resulting in assignment as a Z isomer.

Figure 10
In most cases, the 3-substituted benzylidene compounds favored either 100% E or
Z configuration. The compounds exhibiting the Z isomer could be attributed to the
attraction of the lone pair of electrons at the C-2 carbonyl for partial positive charges
created at the carbons attached to electron withdrawing atoms such as –F, and -Cl, upon
the benzylidene ring. In addition compounds such as (164, 165, 168, 179, 181) showed a
mixture of both E and Z isomers which has also been observed in previous investigations
in which polar solvents such as DMSO or methanol has been utilized, or in the presence
of light.10
Summary and Conclusions
A library of fluorinated derivatives of both oxindoles and isatins were synthesized
as potential pharmaceuticals or targeting agents for imaging purposes related to cancer or
Alzheimer’s disease. These novel compounds have an advantage over other current
small molecule inhibitors because of the ability to prepared in a three step synthesis that
included the N-alkylation of 5 substituted isatin with either solid base of DBU or solid
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base support of KF/Al2O3 followed by Wolff-Kishner reduction to the corresponding
oxindoles and finally Knoevenagel condensation with aryl aldehydes. This allowed for
the incorporation of 3 points of variability which was previously shown to increase the
potency of oxindoles as caspase inhibitors when the electron-withdrawing chlorine was
utilized at C-5 position of the isatin and oxindole scaffold. Additionally, a novel
alternative route of synthesis was created to allow for the synthesis of N-propargyl
benzylidene oxindoles. This novel alternative synthesis involved the Wolff-Kishner
reduction of the isatins followed by condensation and finishing with the N-alkylation of
the aldol products. Finally, the capability to synthesize the N-propargyl benzylidene
oxindoles allowed for the synthesis of the isatin 1,2,3-triazoles which could be utilized as
potential imaging agents for cancer.
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Experimental
Chemical Analysis
Melting points were determined via the use of open capillaries with an Electrothermal
melting point apparatus and are reported uncorrected. Elemental analyses were
performed by Midwest Microlab, Indianapolis, IN. Elemental analysis results are within
+0.4% of the theoretical values. The 1H and 13C NMR data were obtained on a Bruker
Avance 300 MHz NMR in CDCl3 or DMSO-d6 solution unless otherwise indicated. The
chemical shifts are reported in δ (ppm) downfield from tetramethylsilane as an internal
standard; coupling constants (J) are in Hz. The following abbreviations are used to
describe peak patterns where appropriate: s, singlet; d, doublet, dd, double doublet; t,
triplet; q, quartet; dt, double triplet; m, multiplet. GC/MS measurements were performed
using Hewlett-Packard 6890 Series GC with auto injection and mass fragments are
reported as mass per charge, m/z. The GC was coupled with a mass spectrometer with a
Hewlett-Packard 5973 mass selective detector/quadrupole system. Flash column (Silica
Gel, Premium Rf, 200-400 mesh, Sorbent Technologies) and thin layer chromatography
(TLC) were performed on silica gel with indicated solvent systems. All microwave
reactions were performed in a monomode Biotage Emery’s Creator 300 Watt system and
the MARS Glasschem 300 Watt system by CEM. It should be noted that all reactions
were run with sample absorption set to “normal”. Multiple reactions were carried out
using the FIRSTMATE system by Argonaut Technologies.

1-Benzylindolin-2,3-dione (128)
To a 10 mL microwave vial charged with ethanol (3 mL) and a magnetic stir bar was
added isatin (0.2943 g, 2.00 mmol), DBU (329 μL, 1.1 eq) and benzyl chloride (257μL,
1.1 eq). The reaction vessel was sealed and heated under microwave irradiation in
standard mode for 10 min at 140 oC with a pre-stirring 30 sec. After cooling to rt, the
reaction vessel was allowed to stand overnight in a freezer and then vacuum filtered to
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afford the pure (TLC, GC/MS) product as a light orange solid (0.0536 g, 11.3%): mp
129-134 ᵒC (lit.119mp 128-133oC); Rf = 0.41 (hexanes/EtOAc, 1:1). The filtrate was then
evaporated under reduced pressure to afford an oil which was purified by silica gel
chromatography (hexanes/EtOAc, 70:30) to provide additional product (0. 2895 g) for a
combined overall yield of 60.7 %; 13C NMR (300 MHz DMSO-d6) δ 183.1, 158.3, 150.3,
137.9, 135.5, 128.6, 127.5, 127.3, 124.4, 123.3, 117.7, 111.0, 42.9; MS (m/z) 237 (M+),
146 (100%).
Ethyl 2-(2,3-dioxoindolin-1-yl)acetate (129)
To a 10 mL microwave vial charged with ethanol (3 mL) and a magnetic stir bar was
added isatin (0.3111 g, 2.11 mmol), DBU (325 μL, 1.1 eq) and ethyl bromoacetate (257
μL, 1.1 eq). The reaction vessel was sealed and heated under microwave irradiation in
standard mode for 10 min at 140 oC with a pre-stirring 30 sec. After cooling to rt, the
reaction vessel was allowed to stand overnight in a freezer and then vacuum filtered to
afford the pure (TLC, GC/MS) product as a light orange solid (0.1049 g, 21.2 %): mp
105-110 ºC (lit.119mp 124-129 ˚C); Rf = 0.21 (hexanes/EtOAc, 1:1). The filtrate was
then evaporated under reduced pressure to afford an oil which was purified by silica gel
chromatography (hexanes/EtOAc, 70:30) to provide additional product (0.1130 g) for a
combined overall yield of 46.7%;

13

C NMR δ 182.3, 167.1, 158.2, 150.1, 138.5, 124.5,

123.7, 117.3, 111.3, 61.3, 41.1, 14.0 ppm; MS (m/z) 233 (M+), 132 (100%).
1-(Prop-2-yn-1-yl)indolin-2,3-dione (130)
To a 10 mL microwave vial charged with ethanol (3 mL) and a magnetic stir bar was
added isatin (0.3064 g, 2.08 mmol), DBU (342 μL, 1.1 eq) and propargyl bromide (210
μL, 1.1 eq). The reaction vessel was sealed and heated under microwave irradiation in
dynamic mode where the mixture was heated in 5 stages with pressure and high power
being held constant throughout the run time at 130 psi and 200 watts, respectively. The
first stage of heating was set at 110 oC for 3 min, the second stage of heating was set at
120 oC for 2 min, the third stage of heating was set at 100 oC for 1 min, the fourth stage of
heating was set at 120 oC for 2 min, and the final stage of heating was set at 95 oC for 6
min. The first stage had high stirring while the final 4 stages had a low stir setting. The
pre-stirring for this setup was high for 1 min. After cooling to rt, the reaction vessel was
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placed in the freezer overnight and vacuum filtered to afford the pure product
(GCMS/TLC) as an orange solid (0.1277 g, 33.1%): mp 147–149 oC (lit.110mp 157-159
o

C); Rf = 0.46 (hexanes/EtOAc, 1:1). The filtrate was then evaporated under reduced

pressure and purified by silica gel chromatography (hexanes/EtOAc, 70:30) to give
additional product (0.1844 g) for a combined overall yield of 81%; 1H NMR (300 MHz
DMSO-d6) δ 7.75 (td, J = 1.3 Hz, J = 7.8 Hz, 1H), 7.61 (dd, J = 0.5 Hz, J = 1.2 Hz,
1H), 7.58 (dd, J = 0.5 Hz, J = 1.2 Hz, 1H ), 7.24 (d, J =7.9 Hz, 1H), 7.21 (dd, J = 0.8
Hz, J = 15.0 Hz, 1H), 7.19 (d, J = 0.7 Hz, 1H), 4.55 (d, J = 2.5 Hz, 2H); 13C NMR (300
MHz DMSO-d6) δ 182.5, 157.3, 149.4, 138.1, 124.5, 123.6, 117.6, 111.1, 77.2, 74.8,
28.9; MS (m/z) 185 (M+), 129 (100%).
1-(Prop-2-yn-1-yl)indolin-2,3-dione (130)
To a solution of isatin (1.0302 g, 7.00 mmol) in acetonitrile (45 mL), was added 6 equiv.
of KF/alumina (6.4234 g, 42.0 mmol) and the resulting mixture was stirred at rt for 5 min
until the initial orange solution turned to a dark brownish color. To the mixture, propargyl
bromide (1.5 equiv, 0.961 mL, 10.5 mmol,) was then added to the stirred solution after
which time the mixture was refluxed for 9 h. The mixture was then allowed to cool to rt
and the suspended KF/alumina was removed by vacuum filtration. The filtrate was then
evaporated under reduced pressure to afford an orange solid which was then
recrystallized from EtOH to afford the pure (TLC, GC/MS) product as bright orange
crystals (0.9291 g, 69.1%): mp 153-155 ºC (lit.110mp 157-159 ºC); Rf = 0.61
(EtOAc/hexanes, 1:1); MS 185 (m/z) (M+), 129 (100%).
1-(2,6-Dichlorobenzyl)indoline-2,3-dione (131)
To a 10 mL microwave vial charged with ethanol (3 mL) and a magnetic stir bar was
added isatin (0.3062 g, 2.08 mmol), DBU (342 μL, 1.1 eq) and 2,6-dichlorobenzyl
bromide (0.5711 g, 1.1 eq). The reaction vessel was sealed and heated under microwave
irradiation in standard mode for 10 min at 140 oC with a pre-stirring 30 sec. After cooling
to rt, the reaction vessel was allowed to stand overnight in a freezer and then vacuum
filtered to afford the pure (TLC, GC/MS) product as an orange solid (0.4151 g, 65.3%):
mp 181-186 ºC (lit.116mp 175-180˚C); Rf = 0.57 (hexanes/EtOAc, 1:1). The filtrate was
then evaporated under reduced pressure and purified by silica gel chromatography
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(hexanes/EtOAc, 70:30) to provide additional product (0.1787 g) for a combined overall
yield of 93.2%; 13C NMR (300 MHz DMSO-d6) δ 182.7, 157.7, 150.6, 138.4, 135.4,
130.8, 129.7, 129.1, 124.7, 123.4, 117.9, 110.8, 40.4; MS (m/z) 305 (M+), 270 (100%).
1-(2,6-Difluorobenzyl)indoline-2,3-dione (132)
To a 10 mL microwave vial charged with ethanol (3 mL) and a magnetic stir bar was
added isatin (0.2962 g, 2.01 mmol), DBU (329 μL, 1.1 eq) and 2,6-difluorobenzyl
bromide (0.5278 g, 1.1 eq). The reaction vessel was sealed and heated under microwave
irradiation in standard mode for 10 min at 140 oC with a pre-stirring 30 sec. After cooling
to rt, the reaction vessel was allowed to stand overnight in a freezer and then vacuum
filtered to afford the pure (TLC, GC/MS) product as yellow-orange solid (0.2469 g, 44.9
%): mp 155-158 ºC (lit.119mp 154-156 ˚C); Rf = 0.32 (hexanes/EtOAc, 1:1). The filtrate
was then evaporated under reduced pressure to afford an oil which was purified by silica
gel chromatography (hexanes/EtOAc, 70:30) to provide additional product (0.2100 g) for
a combined overall yield of 83.6%; 13C NMR (300 MHz DMSO-d6) δ: 182.8, 162.7159.3 (dd, J = 7.8 Hz), 157.6, 150.3, 138.3, 130.8-130.6 (t, J = 10.4 Hz), 124.6, 123.4,
117.6, 111.9-111.65 (d, J = 7.4 Hz), 110.8, 110.40-110.36 (t, J = 7.8 Hz), 32.1; MS (m/z):
273 (M+), 146 (100%).

1-Benzyl-5-chloroindoline-2,3-dione (133)
To a 10 mL microwave vial charged with ethanol (3 mL) and a magnetic stir bar was
added 5-chloroisatin (0.3785 g, 2.08 mmol), DBU (329 μL, 1.1 eq) and benzyl chloride
(257 μL, 1.1 eq). The reaction vessel was sealed and heated under microwave irradiation
in standard mode for 20 min at 120 oC with a pre-stirring 30 sec. After cooling to rt, the
reaction vessel was placed in the freezer overnight but did not afford a solid. The
resulting orange-red liquid was then evaporated under reduced pressure to afford an
orange oil which was purified by silica gel chromatography (hexanes/EtOAc, 70:30) to
afford a pure (GC-MS/TLC) orange red solid (0.3875 g, 71%): mp 130-133 ºC (lit.119mp
134 ˚C); Rf = 0.65 (hexanes:EtOAc, 1:1). 13C NMR δ 181.9, 158.1, 148.8, 136.7, 135.1,
129.7, 128.6, 127.5, 127.2, 123.9, 119.1, 112.6, 42.9; MS (m/z) 271 (M+), 180 (100%).

Ethyl-2-(5-chloro-2,3-dioxoindolin-1-yl)acetate (134)
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To a 10 mL microwave vial charged with ethanol (3 mL) and a magnetic stir bar was
added 5-chloroisatin (0.3689 g, 2.00 mmol), DBU (329 μL, 1.1 eq) and ethyl
bromoacetate (243 μL, 1.1 eq). The reaction vessel was sealed and heated under
microwave irradiation in standard mode for 20 min at 120 oC with a pre-stirring 30 sec.
After cooling to rt, the reaction vessel was allowed to stand overnight in a freezer and
then vacuum filtered to afford the pure (TLC, GC/MS) product as a light orange solid
(0.1662 g, 31.0%): mp 126-128 ºC (lit.119mp 130-135 ˚C); Rf = 0.63 (hexanes/EtOAc,
1:1). The filtrate was then evaporated under reduced pressure to afford an oil which was
purified by silica gel chromatography (hexanes/EtOAc, 70:30) to provide additional
product (0.1965 g) for a combined overall yield of 67.8%; 13C NMR δ 181.5, 167.3,
157.8, 148.9, 137.3, 127.9, 124.1, 118.6, 112.9, 61.4, 41.3, 13.9; MS (m/z) 267 (M+), 28
(100%).
5-Chloro-1-(prop-2-yn-1-yl)indoline-2,3-dione150 (135)
To a 10 mL microwave vial charged with ethanol (3mL) and a magnetic stir bar was
added isatin (0.3632 g, 2.00 mmol), DBU (329 μL, 1.1 eq) and propargyl bromide (201
μL, 1.1 eq). The reaction vessel was sealed and heated under microwave irradiation in
standard mode for 20 min at 110 oC with pre-stirring 30 sec. After cooling to rt, the
reaction vessel was placed in the freezer overnight and then vacuum filtered to afford a
pure (GCMS/TLC) orange solid (0.0521 g, 11.9%): mp 157-159 ºC; Rf = 0.51
(hexanes/EtOAc, 1:1). The filtrate was then evaporated under reduced pressure to afford
an orange oil which was purified by silica gel chromatography (hexanes/EtOAc, 70:30)
to give additional product (0.3145 g) for a combined overall yield of 64.3%: 1H NMR
(300 MHz DMSO-d6) δ 7.79 (dd, J = 2.2 Hz, J = 8.4 Hz, 1H), 7.65 (d, J = 2.116 Hz, 1H),
7.27 (d, J = 8.4 Hz, 1H), 4.56 (d, J = 2.5 Hz, 2H), 4.35 (t, J = 5.0, 1H) 13C NMR (300
MHz DMSO-d6) δ 181.4, 157.1, 147.9, 136.9, 127.8, 124.0, 119.1, 112.8, 77.0, 75.1,
29.1; MS (m/z) 219 (M+), 28 (100 %).
5-Chloro-1-(prop-2-yn-1-yl)indoline-2,3-dione150 (135)
To a solution of 5-chloro-isatin (1.0302 g, 5.67 mmol) in acetonitrile (45 mL), was added
6 equiv of KF/alumina (6.2751 g, 41.0 mmol) and the resulting mixture was stirred at rt
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for 5 min until the initial orange solution turned to a dark brownish color. To the mixture
1.5 equiv. of propargyl bromide (937µL, 7.87 mmol,) was then added dropwise to the
stirred solution after which time the mixture was refluxed for 7 h. The mixture was then
allowed to cool to rt and the suspended KF/alumina was removed by vacuum filtration.
The filtrate was then evaporated under reduced pressure to afford a dark orange solid
which was then recrystallized from EtOH to afford the pure (TLC, GC/MS) product as
dark orange crystals (0.6503 g, 52.3%): mp 164-168 ºC; Rf = 0.52 (EtOAc/hexanes, 1:1);
1

H NMR (300 MHz, DMSO-d6): 7.79 (dd, J=2.261 Hz, J=8.455 Hz, 1H), 7.65 (d,

J=2.116 Hz, 1H), 7.27 (d, J=8.458 Hz, 1H), 4.56 (d, J=2.511 Hz, 2H), 4.35 (t, J=5.090,
1H) 13C (300 MHz, DMSO-d6): δ 181.4, 157.1, 147.9, 136.9, 127.8, 124.0, 119.1, 112.8,
77.0, 75.1, 29.1 ; MS (m/z): 219 (M+), 163 (100 %).
1-(2,6-Dichlorobenzyl)-5-chloroindoline-2,3-dione (136)
To a 10 mL microwave vial charged with ethanol (3 mL) a magnetic stir bar was added
5-chloroisatin (0.3658 g, 2.01 mmol), DBU (329 μL, 1.1 eq) and 2,6-dichlorobenzyl
bromide (0.5310 g, 1.1 eq). The reaction vessel was sealed and heated under microwave
irradiation in standard mode for 20 min at 120 oC with a pre-stirring 30 sec. After cooling
to rt, the reaction vessel was placed in the freezer for 2 h and then vacuum filtered to
afford the pure (GC-MS/TLC) product as an orange-red solid (0.5772 g, 84.1 %): mp
232-235 ºC (lit.119mp 233-235 ˚C); Rf = 0.60 (hexanes/EtOAc, 1:1). 13C NMR δ 181.6,
157.5, 149.2, 137.3, 135.4, 130.8, 129.5, 129.1, 127.6, 124.2, 118.9, 112.6, 40.4; MS
(m/z) 339 (M+), 180 (100%).

1-(2,6-Difluorobenzyl)-5-chloroindoline-2,3-dione (137)
To a 10 mL microwave vial charged with ethanol (3 mL) and a magnetic stir bar was
added 5-chloroisatin (0.3650 g, 2.00 mmol), DBU (329 μL, 1.1 eq) and 2,6difluorobenzyl bromide (0.4554 g, 1.1 eq). The reaction vessel was sealed and heated
under microwave irradiation in standard mode for 20 min at 120 oC with a pre-stirring 30
sec. After cooling to rt, the reaction vessel was placed in the freezer overnight and then
vacuum filtered to afford the pure (TLC, GC/MS) product as a red solid (0.4091 g,
66.3%): mp 171-174 ºC (lit.119mp 172-177 ˚C); Rf = 0.56 (hexanes:EtOAc, 1:1). A
second crop afforded additional product (0.0339 g) for a combined overall yield of 71.7
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%. 13C NMR δ 181.7, 162.7-159.4 (dd, J = 8.2 Hz), 157.5, 148.8, 137.1, 130.9-130.6 (t, J
= 10.5 Hz), 127.6, 124.0, 119.0, 112.2-112.1 (t, J = 2.6 Hz), 111.9-111.6 (d, J = 17.8 Hz),
110.6, 32.2; MS (m/z) 307 (M+), 127 (100%).

1-Benzyl-5-fluoroindoline-2,3-dione (138)
To a 10 mL microwave vial charged with ethanol (3 mL) and a magnetic stir bar was
added 5-fluoroisatin (0.3310 g, 2.00 mmol), DBU (330 μL, 1.1 eq) and benzyl chloride
(254 μL, 1.1 eq). The reaction vessel was sealed and heated under microwave irradiation
in standard mode for 25 min at 120 oC with a pre-stirring of 30 sec. After cooling to
room temperature, the reaction vessel was placed in the freezer overnight and then
vacuum filtered to afford a pure (GCMS/TLC) dark red solid (0.1408 g, 27.5%): mp 128131ºC (lit137mp 130-133 ˚C); Rf = 0.64 (hexanes:EtOAc, 1:1). The filtrate was then
evaporated under reduced pressure to afford a red oil which was purified by silica gel
chromatography (hexanes/EtOAc, 70:30) to give a dark red solid (0.3073 g) for a
combined overall yield of 87.6%: 1H NMR (300 MHz DMSO-d6)  7.57 ppm (d, J = 2.0
Hz, 1H), 7.50 (dd, J = 8.2 Hz, 2.2 Hz, 1H), 7.39-7.28 (m, 1H), 6.96 (t, J = 8.1 Hz, 1H),
6.75 (d, J = 8.5 Hz, 1H), 4.94 (s, 2H); 13C NMR (300 MHz DMSO-d6) δ 182.4, 160.09156.86 (d, J = 241 Hz), 158.35-158.33 (d, J = 1.4 Hz), 146.5-146.4 (d, J = 1.6 Hz), 135.3,
128.6, 127.5, 127.3, 123.9-123.6 (d, J = 24.0 Hz), 118.7-118.6 (d, J = 7.2 Hz), 112.4112.3 (d, J = 7.4 Hz), 111.6-111.3 (d, J = 24.3 Hz), 42.9; MS (m/z) 255 (M+), 164
(100%).

1-Benzyl-5-fluoro-indolin-2,3-dione (138)
To a solution of 5-fluoro-isatin (0.7394 g, 4.48 mmol) in acetonitrile (45 mL), was added
6 equiv. of KF/alumina (4.0994 g, 26.8 mmol) and the resulting mixture was stirred at rt
for 5 min until the initial red solution turned to a dark brownish color. To the mixture
benzyl chloride (1.5 equiv, 934 µL, 8.12 mmol,) was then added to the stirred solution
after which time the mixture was refluxed for 8 h. The mixture was then allowed to cool
to rt and the suspended KF/alumina was removed by vacuum filtration. The filtrate was
then evaporated under reduced pressure to afford a red solid which was then
recrystallized from EtOH to afford the pure (TLC, GC/MS) product as a bright red
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powder (0.9336 g, 81.8%): mp (128-129 ºC) (lit137mp. 130-133 ˚C); Rf = 0.73
(EtOAc/hexanes, 1:1); MS (m/z) 255 (M+), 164 (100 %).

1-(2,6-Difluorobenzyl)-5-fluoroindoline-2,3-dione (139)
To a 10 mL microwave vial charged with ethanol (3mL) and a magnetic stir bar was
added 5-fluoroisatin (0.3294 g, 1.99 mmol), DBU (329 μL, 1.1 eq) and 2,6difluorobenzyl bromide (0.4594 g, 1.1 eq). The reaction vessel was sealed and heated
under microwave irradiation in standard mode for 25 min at 120 oC with a pre-stirring of
30 sec. After cooling to rt, the reaction vessel was placed in the freezer overnight and
then vacuum filtered to afford a dark red solid (0.2133 g, 36.7%): mp 129-132 oC. The
filtrate was then evaporated under reduced pressure to afford a red oil which was purified
by silica gel chromatography (hexanes/EtOAc,70:30) to give additional product (0.2612
g) for a combined overall yield of 81.7%; 1H NMR (300 MHz, DMSO): δ .7.60 (ddd, J =
2.8 Hz, J = 8.7 Hz, 1H ), 7.49 (dd, J = 2.7 Hz, J = 7.0 Hz, 1H), 7.44 (dd, J = 1.7 Hz, J =
6.8 Hz, 1H) 7.15 (t, 3H), 7.25 (dd, J = 2.7 Hz, J = 8.6 Hz, 1H), 6.98 (t, J = 8.1 Hz, 1H),
6.91 (dd, J = 3.5 Hz, J = 8.6 Hz, 1H), 4.96 (s, 2H); 13C NMR (300 MHz DMSO-d6) δ
182.19-182.16 (d, J = 2.1 Hz), 167.7, 162.6-159.2 (dd, J = 7.7 Hz), 160.0-156.8 (d, J =
241 Hz), 157.73-157.71 (d, J = 1.7 Hz), 146.56-146.54 (d, J = 1.6 Hz), 130.9-130.6 (t, J
= 10.5 Hz), 124.41-124.0 (d, J = 24.1 Hz), 118.5-118.4 (d, J = 7.1 Hz), 111.9-111.7 (d, J
= 7.3 Hz), 111.6-111.4 (d, J = 17.7 Hz), 110.9-110.4 (t, J = 18.7 Hz), 32.2 (t, J = 3.9 Hz);
MS (m/z) 291 (M+), 164 (100%).
1-(2,6-Difluorobenzyl)-5-fluoro-indoline-2,3-dione (139)
To a solution of 5-fluoroisatin (1.0984 g, 6.65 mmol) in acetonitrile (45 mL), was added
6 equiv. of KF/alumina (6.1030 g, 39.9 mmol) and the resulting mixture was stirred at rt
for 5 min until the initial red solution turned to a dark brownish color. To the mixture,
2,6-difluorobenzyl bromide (1.5 equiv, 2.1002 g, 10.1 mmol,) was then added to the
stirred solution after which time the mixture was refluxed for 15 h. The mixture was then
allowed to cool to rt and the suspended KF/alumina was removed by vacuum filtration.
The filtrate was then evaporated under reduced pressure to afford a red solid which was
then recrystallized from EtOH to afford the pure (TLC, GC/MS) product as bright red
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crystals (1.6521 g, 85.3%): mp 143-145 ºC; Rf = 0.61 (EtOAc/hexanes, 1:1); ); MS (m/z)
291 (M+), 164 (100%).
1-(4-Methoxy-benzyl)-indoline-2,3-dione146 (140)
To a solution of isatin (0.5099 g, 2.95 mmol) in acetonitrile (45 mL), was added 6 equiv.
of KF/alumina (3.1820 g, 12.1 mmol) and the resulting mixture was stirred at rt for 5 min
until the initial orange solution turned to a dark brownish color. To the mixture 4methoxybenzyl chloride (1.5 equiv, 705 µL, 5.20 mmol) was then added to the stirred
solution after which time the mixture was refluxed for 22 h. The mixture was then
allowed to cool to rt and the suspended KF/alumina was removed by vacuum filtration.
The filtrate was then evaporated under reduced pressure and purified with silica gel
(hexanes/EtOAc, 70/30) which was then recrystallized from DCM/hexanes to afford the
pure (TLC, GC/MS) product as an orange powder (0.5746 g, 55.1%): mp 150-153 ºC; Rf
= 0.64(EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6) : 7.60 (d, J = 1.3 Hz, 1H),
7.58-7.54 (m, 2H), 7.37 (d, J = 8.6 Hz, 2H), 7.13 (t, J = 7.5 Hz, 1H), 7.01 (d, J = 7.8 Hz,
1H), 6.91 (d, J = 8.7 Hz, 2H), 4.83 (s, 2H), 3.71 (s, 3H); 13C NMR : 183.1, 158.6, 158.1,
150.3, 137.9, 128.8, 127.2, 124.4, 123.2, 117.6, 114.0, 111.1, 55.0, 42.3 ppm: MS (m/z)
267 (M+), 146 (100 %).

1-(3,5-Difluorobenzyl)-indoline-2,3-dione (141)
To a solution of isatin (0.6128 g, 4.17 mmol) in acetonitrile (45 mL), was added 6 equiv.
of KF/alumina (3.4532 g, 22.6 mmol) and the resulting mixture was stirred at rt for 5 min
until the initial orange solution turned to a dark brownish color. To the mixture 1.5 equiv.
of 3,5-difluorobenzyl bromide (0.808 mL, 5.85 mmol,) was then added to the stirred
solution after which time the mixture was refluxed for 3 h. The mixture was then
allowed to cool to rt and the suspended K2CO3 was removed by vacuum filtration. The
filtrate was then evaporated under reduced pressure and purified with silica gel
(hexanes/EtOAc, 70:30) afford an orange solid (0.5634 g, 49.5%): mp 157-159 ºC. The
solid was recrystallized from DCM/Hexanes to afford the pure (TLC, GC/MS) product as
orange-red crystals (0.1866 g, 16.4%): mp. 161-164 ºC; Rf = 0.55 (EtOAc/hexanes, 1:1);
1

H (300 MHz, CDCl3): δ 7.68 (d, J = 8.2 Hz, 1H), 7.58 (dd, J = 1.3 Hz, J = 15.6 Hz, 1H),
132

[Type text]
7.55 (d, J = 1.3 Hz,1H), 7.28 (s, 1H), 7.19 (dd, J = 0.6 Hz, J = 15.0 Hz, 1H), 7.16 (d, J
=0.4 Hz, 1H), 6.89 (d, J = 7.8 Hz, 2H), 6.81 (t, J = 2.283 Hz, 1H), 6.77 (d, J = 8.1 Hz,
2H), 4.92 (s, 2H); 13C (300 MHz, CDCl3): δ 182.5, 165.1-161.5 (dd, J = 12.6 Hz), 158.1,
150.1, 138.4, 125.7, 124.2, 117.7, 110.5, 110.4-110.0 (dd, J = 8.3 Hz), 104.1-103.4 (t, J
= 25.3 Hz, 43.3-43.2 (t, J = 1.9 Hz) ppm; MS (m/z) 273 (M+), 28 (100 %).

1-(4-Methoxy-benzyl)-5-chloro-indoline-2,3-dione (142)
To a solution of 5-chloro-isatin (0.8655 g, 4.76 mmol) in acetonitrile (45 mL) was added
6 equiv. of KF/alumina (4.4752 g, 29.2 mmol) and the resulting mixture was stirred at rt
for 5 min until the initial orange solution turned to a dark brownish color. To the mixture
4-methoxybenzyl chloride (1.5 equiv, 969 µL, 7.14 mmol,) was then added to the stirred
solution after which time the mixture was refluxed for 22 h. The mixture was then
allowed to cool to rt and the suspended KF/alumina was removed by vacuum filtration.
The filtrate was then evaporated under reduced pressure to afford a red solid which was
then recrystallized from DCM/hexanes to afford the pure (TLC, GC/MS) product as a
bright red powder (1.0726 g, 74.5%): mp 148-150 ºC (lit.145 mp. 152-153ᵒC); Rf = 0.60
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6) 7.64 (d, J = 8.1 Hz, 2H), 7.38
(d, J = 8.7 Hz, 2H), 7.00 (d, J = 7.4z, 1H), 6.91 (d, J = 6.6 Hz, 2H), 5.75 (s, 1H), 4.83
(s, 2H), 3.72 (s, 3H); 13C NMR : 182.0, 158.7, 158.0, 148.7, 136.7, 128.8, 127.4, 126.9,
123.9, 119.0, 114.0, 112.7, 55.0, 42.4 ppm: MS (m/z) 301 (M+), 121 (100 %) ; Anal.
Calcd for C16H12ClNO3: C, 63.69; H, 4.01; N, 4.64; Found: C, 63.34; H, 4.10; N, 4.67.

1-(3,5-Difluorobenzyl)-5-chloro-indoline-2,3-dione (143)
To a solution of 5-fluoroisatin (0.8604 g, 4.73 mmol) in acetonitrile (45 mL) was added 6
equiv. of KF/alumina (4.3469 g, 28.4 mmol) and the resulting mixture was stirred at rt for
5 min until the initial orange solution turned to a dark brownish color. To the mixture 1.5
equiv. of 3,5-difluorobenzyl bromide (0.919 mL, 6.69 mmol,) was then added to the
stirred solution after which time the mixture was refluxed for 24 h. The mixture was then
allowed to cool to rt and the suspended KF/alumina was removed by vacuum filtration.
The filtrate was then evaporated under reduced pressure and purified with silica gel
(hexanes/EtOAc, 70:30) to afford an orange solid (0.8110 g, 55.8%): mp 165-167 ºC.
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The orange solid was recrystallized from DCM/hexanes to afford the pure (TLC,
GC/MS) product as orange-red crystals (0.7477 g, 51.4%): mp 174-177 ºC; Rf = 0.68
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz, CDCl3) 7.65 (d, J= 4.9 Hz, 1H), 7.61(d,
J=2.2 Hz, 1H), 7.25 (dd, J=2.2 Hz, J=8.6 Hz, 1H), 7.17 (tt, J=2.3 Hz, J=9.3 Hz), 6.93 (d,
J=8.8 Hz, 1H), 5.75 (s,1H), 4.93 (s, 2H) ; 13C NMR : 181.5, 164.2-160.7 (dd, J = 13.2
Hz), 158.2, 148.3, 140.1-139.9 (t, J = 9.5 Hz), 136.5, 127.5, 123.8, 119.5, 112.4, 110.5110.2 (dd, J = 8.0 Hz), 103.2-102.5 (t, J = 25.7 Hz), 42.2 (t, J = 1.6 Hz) ppm; MS (m/z)
307 (M+), 127 (100%). Anal. Calcd for C15H8ClF2NO2: C, 58.55; H, 2.62; N, 4.55 Found:
C, 58.51; H, 2.74; N, 4.48
1-(3,5-Difluorobenzyl)-5-chloro-indoline-2,3-dione (143)
To a solution of 5-fluoroisatin (0.6076 g, 3.35 mmol) in acetonitrile (45 mL) was added 6
equiv. of KF/alumina (3.0696 g, 20.1 mmol) and the resulting mixture was stirred at rt
for 5 min until the initial orange solution turned to a dark brownish color. To the mixture
1.5 equiv. of 3,5-difluorobenzyl bromide (0.650 mL, 5.02mmol,) was then added to the
stirred solution after which time the mixture was refluxed for 24 h. The mixture was then
allowed to cool to rt and the suspended KF/alumina was removed by vacuum filtration.
The filtrate was then evaporated under reduced pressure to afford a red solid. The red
solid was recrystallized from DCM/hexanes to afford the pure (TLC, GC/MS) product as
orange-red crystals (0.9320 g, 95.4%): mp 173-175 ºC; Rf = 0.68 (EtOAc/hexanes, 1:1);
MS (m/z) 307 (M+), 127 (100%).
5-Fluoro-1-(prop-2-yn-1-yl)indoline-2,3-dione (144)
To a solution of 5-fluoro-isatin (0.5975 g, 3.62 mmol) in acetonitrile (45 mL) was added
6 equiv. of KF/alumina (3.3214 g, 21.7 mmol) and the resulting mixture was stirred at rt
for 5 min until the initial red solution turned to a dark brownish color. To the mixture 1.5
equiv. of propargyl bromide (500 µL, 5.46 mmol,) was then added dropwise to the stirred
solution after which time the mixture was refluxed for 48 h. The mixture was then
allowed to cool to rt and the suspended KF/alumina was removed by vacuum filtration.
The filtrate was then evaporated under reduced pressure and recrystallized from
DCM/hexanes to afford the pure (TLC, GC/MS) product as red crystals (0.2665 g,
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36.3%): mp 124-126 ºC; Rf = 0.59 (EtOAc/hexanes, 1:1); 1H NMR: (DMSO-d6) : 7.63
(ddd, J= 2.7 Hz, J = 8.6 Hz, 1H), 7.52 (dd, J = 2.6 Hz, J = 7.1 Hz, 1H), 7.28 (dd, J = 3.8
Hz, J = 8.6 Hz, 1H), 4.56 (d, J = 2.5, 2H), 3.77 (t, J = 2.4 Hz,1H); 13CNMR (DMSO-d6)
: 181.8 (d, J = 2.2 Hz), 160.2-157.0 (d, J = 241 Hz), 157.3 (d, J = 1.5 Hz), 145.6 (d, J =
1.6 Hz), 124.2-123.8 (d, J = 24.1 Hz), 118.6-118.5 (d, J = 7.4 Hz), 112.6-112.5 (d, J =
7.4 Hz), 111.6-111.5 (d, J = 24.5 Hz), 77.1, 75.0, 29.1 ppm; MS (m/z) 203 (M+), 147
(100%). Anal. Calcd for CnHnClNOn: C, 65.03; H, 2.98; N, 6.89; Found: C, 64.63; H,
3.04 ; N, 6.80.

1-(4-Methoxy-benzyl)-5-fluoro-indoline-2,3-dione (145)
To a solution of 5-fluoro-isatin (0.4896 g, 2.95 mmol) in acetonitrile (45 mL) was added
6 equiv. of KF/alumina (2.7466 g, 17.9 mmol) and the resulting mixture was stirred at rt
for 5 min until the initial red solution turned to a dark brownish color. To the mixture 4methoxybenzyl chloride (1.5 equiv, 603 µL, 4.44 mmol,) was then added to the stirred
solution after which time the mixture was refluxed for 19 h. The mixture was then
allowed to cool to rt and the suspended KF/alumina was removed by vacuum filtration.
The filtrate was then evaporated under reduced pressure and purified with silica gel
(hexanes/EtOAc, 70/30) which was then recrystallized from DCM/hexanes to afford the
pure (TLC, GC/MS) product as a orange powder (0.3174 g, 41.9%): mp 132-135 ºC
(lit.146 mp. 138-139˚C); Rf = 0.54 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6)
: 7.47 (d, J = 8.5 Hz, 2H), 7.42 (d, J = 2.7 Hz, 2H), 7.37 (d, J = 6.8 Hz, 1H), 7.00 (d, J
= 7.4 Hz, 1H), 6.99 (d, J = 8.1 Hz, 1H), 6.90 (dd, J = 2.0 Hz, J = 6.6 Hz, 1H), 5.75 (s,
1H), 4.83 (s, 2H), 3.72 (s, 3H); 13C NMR : 182.5, 160.0, 158.2, 157.7, 146.5, 128.8,
127.0, 123.7, 118.5, 114.0, 112.4, 111.4, 55.0, 42.4 ppm: MS (m/z) 285 (M+), 121 (100
%). Anal. Calcd for C16H12FNO3: C, 67.36; H, 4.24; N, 4.91; Found: C, 67.44; H, 4.30 ;
N, 4.91

1-(3,5-Difluorobenzyl)-5-fluoro-indoline-2,3-dione (146)
To a solution of 5-fluoroisatin (1.1089 g, 6.72 mmol) in acetonitrile (45 mL) was added 6
equiv. of KF/alumina (6.1608 g, 40.3 mmol) and the resulting mixture was stirred at rt for
5 min until the initial red solution turned to a dark brownish color. To the mixture 1.5
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equiv. of 3,5-difluorobenzyl bromide (1.302 mL, 10.1 mmol,) was then added to the
stirred solution after which time the mixture was refluxed for 31 h. The mixture was then
allowed to cool to rt and the suspended KF/alumina was removed by vacuum filtration.
The filtrate was then evaporated under reduced pressure and purified with silica gel
(hexanes/EtOAc, 70:30) to afford a red solid (1.889 g, 96.6%): mp 149-152ºC. The red
solid was recrystallized from DCM/hexanes to afford the pure (TLC, GC/MS) product as
bright red crystals (1.697 g, 86.8 %): mp 160-161 ºC; Rf = 0.88 (EtOAc/hexanes, 1:1);
1

H NMR (300 MHz, DMSO-d6): δ 7.51 (dd, J=2.5, J =7.1 Hz, 1H), 7.48 (ddd, J = 2.7 Hz,

J =8.6 Hz, 1H), 7.26 (dd, J =2.2 Hz , J =8.6 Hz, 2H), 7.17 (dt, J =2.3 Hz, J =9.3 Hz,
1H), 6.93 (dd, J =3.7 Hz, J = 8.6 Hz, 1H), 5.75 (s, 1H), 4.93 (s, 2H): 13C (300 MHz,
DMSO-d6): δ 182.0 (d, J = 2.2 Hz), 164.2-160.7 (dd, J = 13.2 Hz), 160.1-156.9 (d, J =
241 Hz), 158.5 (d, J = 1.4 Hz), 146.0 (d, J = 1.7 Hz), 140.2-140.0 (t, J = 8.9 Hz), 123.7123.3 (d, J = 24.0 Hz), 119.0-118.9 (d, J = 7.2 Hz), 112.1-112.0 (d, J = 7.5 Hz), 111.5111.2 (d, J = 24.3 Hz), 110.5-110.2 (dd, J = 8.0 Hz), 103.2-102.5 (t, J = 25.8 Hz), 42.2 (t,
J = 2.0 Hz) ppm; MS (m/z) 291 (M+), 28 (100%). Anal. Calcd for C15H8F3NO2: C,
61.86; H, 2.77; N, 4.81; Found: C, 61.84; H, 2.80; N, 4.75.

1-Benzyl-indolin-2-one (151)
1-Benzyl-indoline-2,3-dione (0.5585 g, 2.35 mmol) was added to a 250 mL rbf with
hydrazine hydrate 80% (20 mL). The flask was wrapped in aluminum foil and heated
under reflux for 3 h. The reaction mixture was transferred to a beaker submerged in an
ice bath and acidified to a pH of 4 with dilute HCl (3M, 125 mL), placed in a hood
uncovered and allowed to sit overnight. A white solid formed and was vacuum filtered to
yield a pure product (0.4516 g, 85.9 %); mp 84-85°C (lit.147 mp. 77-78ᵒC); Rf = 0.62
(EtOAc/hexanes, 1:1);

1

H NMR (300 MHz, DMSO-d6) d, J = 4.4 Hz, 4H), 7.28

(m, 2H), 7.20 (t, J = 7.7 Hz, 1H), 7.00 (m, 1H), 6.87 (d, J = 7.7 Hz, 1H), 4.88 (s, 2H),
3.66 (s, 2H) ; 13C NMR : 174.5, 143.9, 136.5, 128.5, 127.3, 127.2, 127.2, 124.7, 124.3,
121.8, 108.8, 42.5, 35.1 ppm: MS (m/z): 223 (M+), 28 (100%).
5-Chloro-indolin-2-one (152)
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5-Chloro-isatin (1.6720 g, 9.21 mmol) was added to a 250 mL rbf with hydrazine hydrate
80% (20 mL). The flask was wrapped in aluminum foil and heat under reflux for 3 h.
The reaction mixture was transferred to a beaker submerged in an ice bath and acidified
to a pH of 4 with dilute HCl (3M, 150 mL), placed in a hood uncovered and allowed to
sit overnight. Brown crystals formed and were vacuum filtered with water to yield a pure
product (1.3195 g, 85.5%); mp 199-202°C (lit.126 mp 195°C); Rf = 0.17 (EtOAc/hexanes,
1:1); MS (m/z) 167 (M+), (100%)

1-(Benzyl)-5-chloro-indolin-2-one (153)
1-(Benzyl)-5-chloro-indoline-2,3-dione (0.5028 g, 1.86 mmol) was added to a 250 mL
rbf with hydrazine hydrate 80% (27 mL). The flask was wrapped in aluminum foil and
heat under reflux for 3 h. The reaction mixture was transferred to a beaker submerged in
an ice bath and acidified to a pH of 4 with dilute HCl (3M, 167 mL), placed in a hood
uncovered and allowed to sit overnight. A white solid formed and was vacuum filtered
to yield a pure product (0.4291 g, 90.0%); mp 90-91°C (lit.126 mp. 88-89°C); Rf = 0.69
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6) m, 5H), 7.31 (s, 1H), 7.25
(d, J =8.5 Hz, 2H), 6.87 (d, J =8.3 Hz, 1H), 4.88 (s, 2H), 3.71 (s, 2H) 13C NMR : 174.1,
142.8, 136.2, 128.5, 127.3, 127.1, 127.1, 127.0, 125.9, 124.5, 110.0, 42.5, 35.1 ppm; MS
(m/z) 257 (M+), 121 (100%);
1-(4-methoxy-benzyl)-5-chloro-indolin-2-one (154)
1-(4-Methoxy-benzyl)-5-chloro-indoline-2,3-dione (0.4549 g, 1.51 mmol) was added to a
250 mL rbf with hydrazine hydrate 80% (15 mL). The flask was wrapped in aluminum
foil and heat under reflux for 3 h. The reaction mixture was transferred to a beaker
submerged in an ice bath and acidified to a pH of 4 with dilute HCl (3M, 150 mL) was
placed in a hood uncovered and allowed to sit overnight. A white solid formed and was
vacuum filtered to yield a pure product (0.4135 g, 95.3%); mp 145-147°C; Rf = 0.55
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6)  7.33 (d, J =2.0 Hz, 1H), 7.277.24 (m, 3H), 7.22 (d, J = 2.2 Hz, 1H), 6.89 (d, J = 8.7 Hz, 1H), 4.80 (s, 2H), 3.70 (s,
3H), 3.68 (s, 2H); 13C NMR : 174.1, 158.5, 142.8, 128.6, 128.0, 127.0, 125.9, 124.4,
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113.9, 110.0, 55.0, 42.0, 35.1 ppm ; MS (m/z) 287 (M+), 121 (100 %). C, 66.79; H, 4.90;
N, 4.87; Found C, 66.90; H, 4.80; N, 4.99.
1-(2,6-Difluorobenzyl)-5-chloro-indolin-2-one (155)
1-(2,6-Difluorobenzyl)-5-chloro-indoline-2,3-dione (0.4395 g, 1.43 mmol) was added to
a 250 mL rbf with hydrazine hydrate 80% (15 mL). The flask was wrapped in aluminum
foil and heat under reflux for 3 h. The reaction mixture was transferred to a beaker
submerged in an ice bath and acidified to a pH of 4 with dilute HCl (3M, 155 mL), placed
in a hood uncovered and allowed to sit overnight. A brown solid formed and was
vacuum filtered to yield a pure product (0.3682 g, 87.8%); mp 125-129°C (lit. 126 mp.
120-125˚C); Rf = 0.60 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6)
m, 1H), 7.32 (d, J = 1.6 Hz, 1H), 7.30-7.27 (dd, J = 2.2 Hz, J = 8.2 Hz,
1H), 7.10 (t, J = 8.2 Hz, 2H), 6.88 (d, J = 8.2 Hz, 1H), 4.94 (s, 2H), 3.62 (s, 2H);

13

C

NMR : 173.4, 162.5-159.2 (dd, J = 7.9 Hz), 142.6, 130.6-130.3 (t, J = 10.4 Hz), 127.2,
126.8, 125.9, 124.5, 111.8-111.6 (dd, J = 7.5 Hz), 111.2, 34.8, 31.8 ppm; MS (m/z) 293
(M+,100 %).

1-(3,5-Difluorobenzyl)-5-chloroindolin-2-one (156)
1-(3,5-Difluorobenzyl)-5-chloro-indoline-2,3-dione (0.4992 g, 1.63 mmol) was added to
a 250 mL rbf with hydrazine hydrate 80% (20 mL). The flask was wrapped in aluminum
foil and heat under reflux for 3 hr. The reaction mixture was transferred to a beaker
submerged in an ice bath and acidified to a pH of 4 with dilute HCl (3M, 90 mL), placed
in a hood uncovered and allowed to sit overnight. A white solid formed and was vacuum
filtered to yield a pure product (0.4321 g, 90.7%): mp 169-170°C; Rf = 0.48
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz, CDCl3): δ 7.28 (s, 1H), 7.20 (d, J=8.349,
1H), 6.82 (d, J=6.886 Hz, 1H), 6.76 (d, J=17.797 Hz, 1H), 6.73 (s, 1H), 6.61 (d, J=8.349
Hz, 1H), 4.88 (s, 2H), 4.31 (s, 1H) ppm

13

C (300 MHz, DMSO-d6): 174.3, 165.0-161.5

(dd, J = 12.7 Hz), 142.2, 139.6-139.3 (t, J = 8.8 Hz), 128.2, 127.9, 125.9, 125.1, 110.2109.9 (dd, J = 8.2 Hz), 109.5, 103.7-103.0 (t, J = 25.4 Hz), 43.1 (t, J = 2.0 Hz), 35.5 ppm;
MS (m/z) 293 (M+), 28 (100%). Anal. Calcd for C15H10ClF2NO: C, 61.34; H, 3.43; N,
4.77. Found: C, 61.30; H, 3.53; N, 4.97.
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5-Fluoro-indolin-2-one (157)
5-Fluoro-isatin (0.3279 g, 1.98 mmol) was added to a 250 mL rbf with hydrazine hydrate
80% (30 mL). The flask was wrapped in aluminum foil and heat under reflux for 3 h.
The reaction mixture was transferred to a beaker submerged in an ice bath and acidified
to a pH of 4 with dilute HCl (3M, 150 mL), placed in a hood uncovered and allowed to
sit for 8 days. Brown crystals formed and were vacuum filtered to yield a pure product
(0.1749 g, 58.3%); mp 140-143°C (lit.138 mp 143-147°C); Rf = 0.51 (EtOAc/hexanes,
1:1); 1H NMR (300 MHz, DMSO-d6) 10.35 (s, 1H, N-H), 7.11 (dd, J = 2.6 Hz (H,F), J
= 8.5 Hz (H,H), 1H, 4-H), 6.99 (ddd, J = 8.5 Hz (H,F), J = 2.5 Hz (H,H), 1H, 6-H), 6.79
(dd, J = 4.5 Hz (H,F), J = 8.4 Hz (H,H), 1H, 7-H), 3.49 (s, 2H, 3-H); 13C NMR : 176.1,
159.2-156.1 (d, J = 24.6 Hz), 109.5-109.4 (d, J = 8.2 Hz), 36.1 (d, J = 1.6 Hz) ppm; MS
(m/z) 151 (M+), 122 (100%).
1-Benzyl-5-fluoro-indolin-2-one148 (158)
1-Benzyl-5-fluoro-indoline-2,3-dione (0.6933 g, 2.72 mmol) was added to a 250 mL rbf
with hydrazine hydrate 80% (41 mL). The flask was wrapped in aluminum foil and heat
under reflux for 3 hr. The reaction mixture was transferred to a beaker submerged in an
ice bath and acidified to a pH of 4 with dilute HCl (3M, 225 mL), placed in a hood
uncovered and allowed to sit overnight. A white powdery solid formed overnight and
was vacuum filtered to yield a pure product (0.5468 g, 83.5%): mp 76-78°C; Rf = 0.65
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz DMSO-d6)  : 7.33 (d, J = 4.4 Hz, 4H), 7.297.22 (m, 1H), 7.20 (dd, J = 2.4 Hz, J = 8.4 Hz, 1H), 7.05 (ddd, J = 2.6 Hz, J = 9.5Hz,
1H), 6.86 (dd, J = 4.4 Hz, J =8.5 Hz, 1H), 4.88 (s, 2H), 3.70 (s, 2H);

13

C NMR δ: 174.2,

159.7-156.6 (dd, J = 236 Hz), 140.1(d, J = 1.6 Hz), 136.3, 128.5, 127.3, 127.2, 126.8126.7 (d, J = 9.2 Hz), 113.5-113.2 (d, J = 23.4 Hz), 112.4-112.1 (d, d, J = 25.0 Hz),
109.4-109.3 (d, J = 8.3 Hz), 42.6, 35.5-35.4 (d, J = 1.5 Hz) ppm; MS (m/z) 241 (M+),
127 (100%) .

1-(4-Methoxy-benzyl)-5-fluoro-indolin-2-one (159)
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1-(4-Methoxy-benzyl)-5-fluoro-indoline-2,3-dione (0.4163 g, 1.46 mmol) was added to a
250 mL rbf with hydrazine hydrate 80% (15 mL). The flask was wrapped in aluminum
foil and heat under reflux for 3 h. The reaction mixture was transferred to a beaker
submerged in an ice bath and acidified to a pH of 4 with dilute HCl (3M, 65 mL), placed
in a hood uncovered and allowed to sit overnight. A white solid formed overnight and
was vacuum filtered to yield a pure product (0.3596 g, 90.8%); mp 124-127°C; Rf = 0.52
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6) 7.28 (dd, J = 2.0 Hz , J = 6.8
Hz, 1H), 7.19 (dd, J = 2.5 Hz, J = 8.4 Hz, 1H), 7.05 (ddd, J = 2.6 Hz, J = 8.6 Hz, 1H),
6.90 (dd, J = 2.0 Hz, J = 6.7 Hz, 1H), 6.85 (d, J = 4.5 Hz), 4.80 (s, 2H), 3.70 (s, 3H),
3.67 (s, 2H); 13C NMR : 174.1, 159.7-156.5 (dd, J = 236 Hz), 158.5, 140.1 (d, , J =
1.5Hz), 128.6, 128.2, 126.8-126.7 (d, , J = 9.1Hz), 113.9, 113.5-113.2 (d, , J = 23.2 Hz),
112.4-112.1 (d, , J =24.8Hz), 109.4-109.3 (d, , J = 8.3 Hz), 54.9, 42.0, 35.5-35.4 (d, , J =
1.5Hz) ppm: MS (m/z) 271 (M+), 121 (100 %). Anal. Calcd for C16H14FNO2: C, 70.84;
H, 5.20; N, 5.16; Found C, 70.59; H, 5.33; N, 5.23.
1-(2,6-Difluorobenzyl)-5-fluoroindolin-2-one (160)
1-(2,6-Difluorobenzyl)-5-fluoro-indoline-2,3-dione (0.3726 g, 1.28 mmol) was added to a
250 mL rbf with hydrazine hydrate 80% (15 mL). The flask was wrapped in aluminum
foil and heat under reflux for 3 h. The reaction mixture was transferred to a beaker
submerged in an ice bath and acidified to a pH of 4 with dilute HCl (3M, 90 mL), placed
in a hood uncovered and allowed to sit overnight. A tan clay-like solid formed overnight
and was vacuum filtered to yield a pure product (0.2727 g, 76.9%); mp 100-103°C; Rf =
0.81 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6): δ 7.48-7.38 (m, 1H), 7.18
(ddd, J = 2.6 Hz , J = 8.3 Hz, 1H), 7.12 (t, J = 8.3 Hz, 1H), 6.86 (d, J = 4.3Hz , J = 8.5
Hz, 1H), 4.95 (s, 2H), 3.62 (s, 2H);
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C (300 MHz, DMSO-d6): δ 173.5, 162.6-159.2 (dd,

J = 8.0 Hz), 159.6-156.5 (d, J = 237 Hz), 140.0 (d, J = 1.4 Hz), 130.5-130.3 (t, J = 10.4
Hz), 126.6-126.5 (d, J = 9.1 Hz), 113.7-113.3 (d, J = 23.2 Hz), 112.4-112.1 (d, J = 24.6
Hz), 111.9-111.5 (dd, J = 7.4 Hz), 111.2, 108.6-108.5 (d, J = 8.4 Hz), 35.2-35.1 (d, J =
1.5 Hz), 31.9-31.8 (t, J = 3.7 Hz) ppm; MS (m/z) 277 (M+), 127 (100 %). Anal. Calcd for
C15H10F3NO: C, 64.98; H, 3.64; N, 5.05; Found: C, 65.02; H, 3.77; N, 5.25.
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1-(3,5-Difluorobenzyl)-5-fluoroindolin-2-one (161)
1-(3,5-Difluorobenzyl)-5-fluoro-indoline-2,3-dione (0.5345 g, 1.84 mmol) was added to a
250 mL rbf with hydrazine hydrate 80% (30 mL). The flask was wrapped in aluminum
foil and heat under reflux for 3 hr. The reaction mixture was transferred to a beaker
submerged in an ice bath and acidified to a pH of 4 with dilute HCl (3M, 148 mL), placed
in a hood uncovered and allowed to sit overnight. A white solid formed overnight and
was vacuum filtered to yield a pure product (0.4284 g, 84.2%): mp 170-173°C, Rf = 0.63
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6): δ 7.22 (dd, J = 2.5 Hz, J = 8.4
Hz, 1H), 7.17 (dt, J = 2.3 Hz, J =9.3 Hz, 1H), 7.08 (dd, J = 1.6 Hz, J = 8.4 Hz, 1H), 6.88
(dd, J = 4.3 Hz, J = 8.5 Hz, 1H), 4.91 (s, 2H), 3.72 (s, 2H): 13C (300 MHz, DMSO-d6): δ
174.4, 164.1-160.7 (dd, J = 13.2 Hz), 159.8-156.7 (d, J = 236 Hz), 141.1 (t, J = 9.1 Hz),
139.8 (d, J = 1.6 Hz), 127.0-126.8 (d, J = 9.2 Hz), 113.6-113.3 (d, J = 23.2 Hz), 112.5112.2 (d, J = 25.0 Hz), 110.4-110.2 (dd, J = 8.0 Hz), 109.2-109.1 (d, J = 8.3 Hz), 103.2102.5 (t, J = 25.9 Hz), 41.9, 35.5 (d, J = 1.4 Hz) ppm; MS (m/z) 277 (M+), 28 (100 %).
Anal. Calcd for C15H10F3NO: C, 64.98; H, 3.64; N, 5.05; Found: C, 64.99; H, 3.50; N,
5.07.

5-Fluoro-3-(pyridin-2-ylmethylene)indolin-2-one (163)
To a vial was added 5-fluoro-indolin-2-one (0.1051 g, 0.696 mmol) with 2pyridincarboxaldehyde (1.2 equiv, 0.846 mmol, 0.0805 mL), piperidine (0.1 equiv,
0.0708 mmol, 0.007 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C
for 3 h while stirring. A light-green precipitate (0.1031 g, 60.9%) was collected by
vacuum filtration and washed with cold EtOH: mp 248-253˚C; Rf = 0.33
(EtOAc/hexanes, 1:1): 1H NMR (300 MHz, DMSO) 10.64 (s, 1H), 8.97 (dd, J =
2.7Hz, J = 10.3 Hz, 1H), 8.91 (dt, J = 1.2Hz, J = 8.1 Hz, 1H), 8.00 (ddd, J = 1.8 Hz , J =
7.6 Hz ), 7.92 (d, J = 7.7 Hz, 1H), 7.62 (s, 1H), 7.52 (qd, J = 1.4 Hz, 4.7 Hz, 1H),
7.17(ddd, J = 2.5 Hz, J = 8.7, 1H), 6.87 (dd, J = 4.6 Hz, J = 8.7 Hz, 1H); 13C NMR (300
MHz, DMSO-d6) : 169.2, 158.8-155.7 (d, J = 234 Hz), 152.8, 149.6, 139.9 (d, J = 1.5
Hz), 137.4, 135.0, 129.0, 128.9 (d, J = 2.8Hz), 124.4, 122.6-122.4 (d, J = 10.2 Hz) ,
117.1-116.8 (d, J = 23.9 Hz), 115.1-114.7 (d, J = 27.2 Hz), 110.1-110.0 (d, J = 8.3 Hz)
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ppm; MS (m/z) 240 (M+), 212 (100%). Anal. Calcd for C14H9FN2O: C, 69.99; H, 3.78;
N, 11.66; Found: C, 69.84; H, 3.73; N, 11.63.

5-Fluoro-3-(pyridin-3-ylmethylene)indolin-2-one (164)
To a vial was added 5-fluoro-indolin-2-one (0.1051 g, 0.696 mmol) with 3pyridincarboxaldehyde (1.2 equiv, 0.831 mmol, 0.0780 mL), piperidine (0.1 equiv,
0.0506 mmol, 0.005 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C
for 3 h while stirring. The vial was placed in the freezer overnight to afford an orange
solid. The orange precipitate (0.0864 g, 62.9%) was collected by vacuum filtration and
washed with cold EtOH: mp 210-212˚C; Rf = 0.36 (EtOAc/hexanes, 1:1); 1H NMR (300
MHz, CDCl3) 10.69 (s, 1H), 9.19 (d, J = 2.0 Hz, 1H), 8.91 (dd, J = 1.7 Hz, J = 8.0
Hz, 1H), 8.90 (d, J = 8.3 Hz), 8.61 (dd, J = 1.6, J = 4.7 Hz, 1H), 7.90 (s, 1H), 7.70 (s,
1H), 7.66 (dd, J = 2.5 Hz, J =8.9 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.10 (dd, J = 2.5 Hz,
J = 18.0 Hz, 1H), 7.07 (d, J = 2.5 Hz, 1H), 6.83 (d, J = 8.5 Hz, 1H), 4.12 (q, J = 5.2 Hz,
1H) ; 13C NMR (300 MHz, DMSO-d6) : 167.0, 159.5-156.3 (d, J = 235 Hz), 152.4,
150.3, 137.9, 137.3 (d, J = 1.3 Hz), 134.4, 129.6, 128.4 (d, J = 3.1 Hz), 125.8-125.7 (d, J
= 9.0 Hz), 123.7, 115.8-115.5 (d, J = 23.8Hz), 110.3-110.2 (d, J = 8.1 Hz), 107.8 -107.4
(d, J = 25.4 Hz) ppm; MS (m/z) 240 (M+), 212 (100%). Anal. Calcd for C14H9FN2O: C,
69.99; H, 3.78; N, 11.66; Found: C, 69.72; H, 3.78; N, 11.58.

5-Fluoro-3-(pyridin-4-ylmethylene)indolin-2-one (165)
To a vial was added 5-fluoro-indolin-2-one (0.2190 g, 1.460 mmol) with 4pyridincarboxaldehyde (1.2 equiv, 1.762 mmol, 0.166 mL), piperidine (0.1 equiv, 0.2123
mmol, 0.021 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 5 h
while stirring. The vial was placed in the freezer overnight to afford a golden yellow
solid. The golden yellow precipitate (0.2835 g, 80.6%) was collected by vacuum
filtration and washed with cold EtOH: mp 229-231˚C; Rf = 0.34 (EtOAc/hexanes, 1:1); );
1

H NMR (300 MHz, DMSO-d6) 10.73 (s, N-H), 8.74 (dd, J = 1.6 Hz , J = 4.6 Hz, 1H),

7.62 (s, 1H), 7.15 (ddd, J = 2.6 Hz, J = 8.8 Hz, 1H), 7.04 (dd, J = 2.4 Hz, J = 9.1 Hz,1H),
6.90 (dd, J = 4.6 Hz, J = 8.5 Hz,1H), 6.84 (d, J= 8.543 Hz, 1H); 13C NMR :168.0, 158.7
(d, J = 236 Hz), 150.2, 141.9, 139.6 (d, J = 1.6 Hz), 133.9, 129.9 (d, J = 3.0 Hz), 124.6,
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121.1-121.0 (d, J = 8.7Hz), 117.4-117.1 (d, J = 23.8 Hz), 111.2-111.1 (d, J = 8.5 Hz ),
110.0-109.7 (d, J = 25.7 Hz) ppm; MS (m/z) 240 (M+), 212 (100%). Anal. Calcd for
C14H9FN2O: C, 69.99; H, 3.78; N, 11.66; Found: C, 69.71; H, 3.72; N, 11.52.

5-Fluoro-3-(2-hydroxybenzylidene)indolin-2-one (166)
To a vial was added 5-fluoro-indolin-2-one (0.1051 g, 0.696 mmol) with salicyclaldehyde
(1.2 equiv, 0.847 mmol, 0.090 mL), piperidine (0.147 equiv, 0.1011 mmol, 0.010 mL)
and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 6 h while stirring. The
vial was cooled in an ice bath and placed in the freezer overnight but no product was
formed. The mixture was then evaporated under reduced pressure to afford a brown oil.
The oil was recrystallized with DCM/Hexanes to afford an orange precipitate (0.1745 g,
98.4%) was collected by vacuum filtration: mp 205-208˚C; 1H NMR (300 MHz, DMSOd6) δ; 10.58 (s, NH), 10.33 (s, OH), 7.75 (s, 1H), 7.61 (dd, J = 1.1 Hz, J = 7.6 Hz, 1H),
7.37 (ddd, J = 1.5 Hz, J = 7.7 Hz, 1H), 7.19 (dd, J = 2.5 Hz, J = 9.3 Hz, 1H), 7.09 (ddd,
J = 2.5 Hz , J = 9.3 Hz, 1H), 7.01 (d, J = 8.2 Hz, 1H), 6.97 (t, J = 7.5 Hz, 1H), 6.87 (dd, J
= 4.6 Hz, J = 8.5 Hz, 1H);
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C NMR δ: 168.7, 158.6-155.5 (d, J = 234 Hz), 156.4,

138.8, 134.0, 131.9, 129.5, 126.3-126.2 (d, J = 2.9 Hz), 122.3-122.2 (d, J = 8.7 Hz),
120.9, 118.8, 116.1, 115.9-115.6 (d, J = 23.5 Hz), 110.5-110.4 (d, J = 8.4 Hz), 109.5109.2 (d, J = 25.6 Hz) ppm; Rf = 0.67 (EtOAc/hexanes, 1:1); LC-MS (m/z): 256 (M+1).

5-Fluoro-3-(4-hydroxybenzylidene)indolin-2-one (167)
To a vial was added 5-fluoro-indolin-2-one (0.1933 g, 1.280 mmol) with 4hydroxybenzaldehyde (1.2 equiv, 1.544 mmol, 0.1884 g), piperidine (0.147 equiv, 0.1213
mmol, 0.0103 g, 0.012 mL) and EtOH (4 mL). The vial was placed on a hot plate at 60˚C
for 20 h while stirring. The vial was cooled in an ice bath and placed in the freezer
overnight to afford a bright yellow product. A bright yellow precipitate (0.2286 g,
70.0%) was collected by vacuum filtration: mp 305-308˚C; Rf = 0.27 (EtOAc/hexanes,
1:1); 1H NMR (300 MHz, DMSO-d6) 10.55 (s, N-H), 7.60 (s, 1H), 7.60 (d, J = 8.264
Hz, 3H), 7.38 (dd, J = 9.5Hz, J = 2.4 Hz, 1H), 7.07 (ddd, J = 2.5 Hz, J = 8.9 Hz, 1H),
6.93 (d, J = 8.6 Hz, 2H), 6.88 (dd, J = 4.7 Hz, J = 8.5 Hz, 1H), 3.63 (s, OH); 13C NMR :
169.1, 159.5, 158.7-155.6 (d, J = 235 Hz), 138.6 (d, J = 1.1 Hz), 138.3, 131.8, 124.5,
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124.3 (d, J = 2.8 Hz), 122.2-122.1 (d, J = 8.9 Hz), 115.7, 115.4, 110.6-110.5 (d, J =
8.5Hz), 109.0-108.7 (d, J = 25.9 Hz) ppm; MS (m/z) 255 (M+,100%). Anal. Calcd for
C15H10FNO2: C, 70.58; H, 3.95; N, 5.49; Found: C, 70.49; H, 3.90; N, 5.60.
5-Fluoro-3-(4-methoxybenzylidene)indolin-2-one144 (168)
To a vial was added 5-fluoro-indolin-2-one (0.1143 g, 0.757 mmol) with p-anisaldehyde
(1.2 equiv, 0.921 mmol, 0.112 mL), piperidine (0.1 equiv, 0.0809 mmol, 0.008 mL) and
EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 3 h while stirring. A golden
yellow precipitate (0.1178 g, 57.9%) was collected by vacuum filtration and
recrystallized with EtOH: mp 192-195˚C; Rf = 0.44 (EtOAc/hexanes, 1:1); ); 1H NMR
(300 MHz, CDCl3) 8.88 (s, 1H), 8.41 (dd, J=1.7 Hz, J=6.9 Hz, 1H), 7.85 (s, 1H), 7.51
(dd, J =2.4 Hz, J = 9.2 Hz, 1H), 7.02 (dd, J = 2.0 Hz, J = 6.8 Hz 1H), 6.98 (ddd, J = 2.4
Hz, J = 8.7 Hz , 1H), 6.88 (dd, J = 4.5 Hz, J = 8.5 Hz, 1H), 3.92 (s, 3H); 13C NMR :
170.6, 161.2, 159.9-156.8 (d, J = 237 Hz), 139.2 , 137.4 (d, J = 1.6 Hz), 134.8, 126.7,
125.4-124.4 (d, J = 3.1 Hz), 123.0-122.9 (d, J = 9.0 Hz ), 115.8-115.5 (d, J = 24.1 Hz),
114.3, 110.5-110.4 (d, J = 8.2 Hz), 110.2-109.9 (d, J = 26.0 Hz), 55.4 ppm; MS (m/z) 269
(M+,100%);

5-Fluoro-3-(3-hydroxy-4-methoxybenzylidene)indolin-2-one (169)
To a vial was added 5-fluoro-indolin-2-one (0.1889 g, 1.25 mmol) with vanillin (1.2
equiv, 1.506 mmol, 0.2289 g), piperidine (0.147 equiv, 0.1213 mmol, 12 µL) and EtOH
(4 mL). The vial was placed on a hot plate at 60˚C for 22 h while stirring. The vial was
cooled to room temperature and placed in the freezer overnight to afford a dark brown
solid. The brown precipitate (0.0523 g, 80.6%) was collected by vacuum filtration and
washed with cold EtOH: mp 218-219˚C; Rf = 0.20 (EtOAc/hexanes, 1:1); 1H NMR (300
MHz, DMSO-d6) 10.55 (s, 1H), 9.87 (s, 1H), 7.77 (dd, J = 1.5 Hz, J = 8.5 Hz, 1H),
7.63 (s, 1H), 7.51 (dd, J =2.5 Hz, J = 9.6 Hz, 1H), 7.33 (d, J =1.8 Hz, 1H), 7.29 ( dd, J =
1.5 Hz, 8.2 Hz, 1H), 7.08 (ddd, J = 2.5 Hz, J = 9.1 Hz, 1H), 6.82 (dd, J = 4.4 Hz, J =8.4
Hz, 1H), 3.87 (d, J =11.0, 3H); 13C NMR : 169.0, 158.6-155.5 (d, J = 234 Hz), 149.1,
147.5, 139.5, 138.8 (d, J = 1.2 Hz), 136.1, 128.3, 127.2-127.1 (d, J = 8.9 Hz ), 125.8,
124.4-124.3 (d, J = 2.8 Hz), 123.8, 115.9-115.7 (d, J = 17.5 Hz), 113.9-113.6 (d, J = 24.3
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Hz), 110.5-110.4 (d, J = 8.4 Hz), 109.2-108.8 (d, J = 26.0 Hz), 55.6 ppm; MS (m/z) 285
(M+, 100%),

5-Fluoro-3-(2,6 difluoro-benzylidene)indolin-2-one (170)
To a vial was added 5-fluoro-indolin-2-one (0.1025 g, 0.679 mmol) with 2,6
difluorobenzaldehyde (1.2 equiv, 0.816 mmol, 0.0881 mL), piperidine (0.1 equiv, 0.0667
mmol, 0.0066 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 3 h
while stirring. A bright yellow precipitate (0.1082 g, 58%) was collected by vacuum
filtration and recrystallized with EtOH: mp 250-255˚C; Rf = 0.27 (EtOAc/hexanes, 1:1);
1

H NMR (300 MHz, DMSO-d6) 10.75 (s, 1H), 7.68-7.58 (m, 1H), 7.44 (s, 1H), 7.32 (t,

J = 8.3 Hz, 2H), 7.16 (ddd, J = 2.6 Hz, J = 8.7 Hz, 1H), 6.92 (dd, J = 4.5 Hz, J = 8.6 Hz,
1H), 6.61 (dd, J =2.1 Hz, J = 8.8 Hz, 1H); 13C NMR : 167.5, 161.2-157.8 (dd, J = 7.0
Hz), 159.0-155.8 (d, J = 235 Hz), 139.5 (d, J = 1.6 Hz), 138.0, 132.6-132.3 (t, J =
10.4Hz), 131.8 (d, J = 2.4 Hz), 121.6, 121.5, 117.3-117.0 (d, J = 23.6 Hz), 112.4-112.0
(d, J = 8.3Hz), 110.2-110.1 (t, J = 2.8 Hz), 108.9-108.5 (d, J = 25.7 Hz) ppm; MS (m/z)
275 (M+, 100%). Anal. Calcd for C15H8F3NO: C, 65.46; H, 2.93; N, 5.09; Found: C,
65.27; H, 2.93; N, 5.10.

5-Fluoro-3-(3,5-difluorobenzylidene)indolin-2-one (171)
To a vial was added 5-fluoro-indolin-2-one (0.1118 g, 0.740 mmol) with 3,5difluorobenzaldehyde (1.2 equiv, 0.885 mmol, 0.1257 g, 0.097 mL), piperidine (0.147
equiv, 0.111 mmol, 0.0094 g, 0.011 mL) and EtOH (4 mL). The vial was placed on a hot
plate at 90˚C for 5 h while stirring. The vial was cooled in an ice bath and placed in the
freezer overnight to afford an orange product. The orange precipitate (0.1657 g, 81.4 %)
was collected by vacuum filtration: mp 218-221˚C; 1H NMR (300 MHz, DMSO-d6) δ:
10.75 (s, 1H), 10.69 (s, 1H), 8.15 (dd, J = 2.1 Hz, J = 9.4 Hz, 1H), 7.84 (s, 1H), 7.62 (s,
1H), 7.61 (dd, J = 2.6 Hz, J = 8.9 Hz, 1H), 7.43 (d, J = 6.8 Hz, 2H), 7.39 – 7.33 (m, 2H),
7.11 (dd, J = 2.8 Hz, J = 9.2 Hz, 2H), 6.89 (d, J = 8.6 Hz, 1H), 6.83 (dd, J = 4.4 Hz, J =
8.5 Hz, 1H);
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C NMR δ: 168.1, 164.2-160.9 (dd, J = 13.6 Hz), 159.5-156.3 (d, J = 236

Hz), 139.6 (d, J = 1.4 Hz), 136.8-136.7 (d, J = 10.2 Hz), 135.3, 129.2 (d, J = 3.0 Hz),
121.2, 117.2-116.9 (d, J = 23.4 Hz), 114.7-114.5 (dd, J = 8.1 Hz), 111.1-110.9 (d, J = 8.0
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Hz), 109.8-109.5 (d, J = 25.5 Hz), 105.4-104.7 (t, J = 26.3 Hz) ppm; Rf = 0.47
(EtOAc/hexanes, 1:1); MS (m/z) 275 (M+) 28 (100%).

5-fluoro-3-(4-dimethylamino-benzylidene)indolin-2-one (172)
To a vial was added 5-fluoro-indolin-2-one (0.0983 g, 0.651 mmol) with 4dimethylaminobenzaldehyde (1.2 equiv, 0.775 mmol, 0.1156 g), piperidine (0.1 equiv,
0.071 mmol, 0.007 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for
5 h while stirring. The vial was placed in the freezer overnight to afford an orange solid.
The orange precipitate (0.0.0782 g, 64.8%) was collected by vacuum filtration and
washed with cold EtOH: mp 220-223˚C; Rf = 0.14 (EtOAc/hexanes, 1:1); 1H NMR (300
MHz, DMSO-d6) 10.47 (s, 1H), 8.49 (d, J = 11.4 Hz, 1H), 7.65 (d, J = 8.6 Hz, 2H),
7.58 (s, 1H), 7.52 (dd, J = 2.0 Hz, J = 9.6 Hz), 7.06 (ddd, J = 2.3 Hz, J = 9.1 Hz, 1H),
6.82 (d, J = 8.6 Hz, 2H), 6.76 (dd, J = 4.4 Hz, J = 8.8 Hz, 1H), 3.03 (s, 6H) ; 13C NMR
(300 MHz, DMSO-d6) : 169.3, 158.7-155.6 (d, J = 234 Hz), 151.6, 138.9, 138.2, 132.0,
129.4, 122.8-122.7 (d, J = 8.8 Hz), 121.6, 120.6, 114.8-114.5 (d, J = 23.4 Hz), 111.6111.5 (d, J = 10.4 Hz), 110.2-110.1 (d, J = 8.5 Hz), 108.6-108.3 (d, J = 25.8 Hz), 39.5
ppm; LC-MS (m/z) 283 (M+1).

3-Benzylidene-1-(2,6-difluorobenzyl)-5-fluoroindolin-2-one (175)
To a vial was added 1-(2,6 difluorobenzyl)-5-fluoro-indolin-2-one (0.1925 g, 0.695
mmol) with benzaldehyde (1.2 equiv, 0.833 mmol, 0.0851 mL), piperidine (0.147 equiv,
0.1011 mmol, 0.010 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C
for 5 h while stirring. The vial was placed in an ice bath and then the freezer overnight.
Solid was not obtained so the solution was evaporated under reduced pressure to afford a
brown solid which was recrystallized with EtOH. A brown precipitate (0.0964 g, 38.0%)
was collected by vacuum filtration and washed with cold EtOH: mp 129-131˚C; Rf =0.62
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz DMSO-d6) δ: 7.84 (s, 1H), 7.72 (dd, J = 1.8
Hz, J = 7.4 Hz, 1H), 7.59 (ddd, J = 2.7 Hz, J = 7.6 Hz, 1H), 7.56 (dd, J = 1.6 Hz, J = 6.0
Hz, 2H), 7.49-7.38 (m, 1H), 7.25 (d, J = 2.6 Hz, J = 9.2 Hz, 1H), 7.18 (d, J = 2.3Hz,
1H), 7.15 (t, J = 8.3 Hz, 2H), 6.96 (dd, J = 4.4 Hz, J = 8.6 Hz, 1H), 5.05 (s, 2H); 13C
NMR δ: 166.6, 162.6-159.2 (dd, J = 8.3 Hz), 159.0-155.9 (d, J = 236 Hz), 139.1 (d, J =
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1.3 Hz), 138.6, 133.8, 130.6-130.4 (t, J = 10.6 Hz), 130.1, 129.2, 128.8, 125.8, 121.4121.3 (d, J = 8.9 Hz), 116.4-116.1 (d, J = 23.5 Hz), 111.9-111.6 (dd, J = 7.5 Hz), 111.4,
109.5-109.1 (d, J = 26.1 Hz), 109.4-109.3 (d, J = 9.6 Hz), 32.0 (d, J = 3.5 Hz) ppm ; MS
(m/z) 365 (M+), 127 (100%).

1-(2,6-Difluorobenzyl)-5-fluoro-3-(4-hydroxybenzylidene)indolin-2-one (176)
To a vial was added 1-(2,6 difluorobenzyl)-5-fluoro-indolin-2-one (0.2143 g, 0.774
mmol) with 4-hydroxybenzaldehyde (1.2 equiv, 0.928 mmol, 0.1133 g), piperidine (0.147
equiv, 0.1112 mmol, 0.011 mL) and EtOH (4 mL). The vial was placed on a hot plate at
90˚C for 3 h while stirring. The vial was placed in an ice bath and then the freezer
overnight to afford a brown-orange solid. A brown-orange precipitate (0.2131 g, 72.3%)
was collected by vacuum filtration and washed with cold EtOH: mp 253-255˚C; Rf = 0.64
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz DMSO-d6) δ: 10.35 (s, 1H), 8.84 (d, J = 8.8
Hz, 2H), 7.86 (s, 1H), 7.68 (dd, J = 2.6 Hz, J = 9.0 Hz, 1H), 7.45-7.35 (m, 1H), 7.11
(ddd, J = 2.5 Hz, J = 9.4 Hz, 1H), 7.10 (dd, J = 4.0 Hz, J = 9.5 Hz, 2H), 7.08 (d, J = 4.0
Hz, 1H), 6.91 (dd, J = 2.8 Hz, J = 9.6 Hz, 3H), 5.05 (s, 2H); 13C NMR δ: 165.1, 162.6159.2 (dd, J = 8.5 Hz), 160.7, 159.8-156.7 (d, J = 235 Hz), 139.8, 136.2 (d, J = 0.8 Hz),
135.3, 130.4-130.1 (t, J = 11.3 Hz), 126.3-126.1 (d, J = 8.9 Hz), 125.2, 120.6 (d, J = 2.6
Hz), 115.3, 113.9-113.6 (d, J = 24.0 Hz), 112.0, 111.9-111.5 (dd, J = 7.5 Hz), 108.7108.6 (d, J = 8.5 Hz), 106.6-106.3 (d, J = 25.7 Hz), 32.0-31.9 (d, J = 3.9 Hz), ppm ; LCMS (m/z) 382 (M+). Anal. Calcd for C22H14F3NO2: C, 69.29; H, 3.70; N, 3.67; Found: C,
68.96; H, 3.78; N 4.10;

1-(2,6-difluorobenzyl)-5-fluoro-3-(2-hydroxy-benzylidene)indolin-2-one (177)
To a vial was added 1-(2,6 difluorobenzyl)-5-fluoro-indolin-2-one (0.1930 g, 0.697
mmol) with salicylaldehyde (1.2 equiv, 0.838 mmol, 0.089 mL), piperidine (0.147 equiv,
0.101 mmol, 0.010 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for
6 h while stirring. The vial was placed in an ice bath and then the freezer overnight to
afford an orange solid. The orange precipitate (0.1653 g, 62.3%) was collected by
vacuum filtration and washed with cold EtOH: mp 207-211˚C; Rf = 0.54
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz DMSO-d6) δ: 10.31 (s, 1H), 7.85 (s, 1H), 7.62
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(dd, J = 1.1 Hz, J = 7.6 Hz, 1H), 7.48-7.40 (m, 1H), 7.38 (ddd, J = 1.5 Hz, J = 6.1 Hz,
1H), 7.24 (ddd, J = 2.6 Hz, J = 9.2 Hz, 1H), 7.14 (t, J = 8.3 Hz, 3H), 7.02 (ddd, J = 0.8
Hz, J = 5.6 Hz, 1H), 6.95 (dd, J = 4.5 Hz, J = 8.4 Hz, 1H), 5.05 (s, 2H); 13C NMR δ:
166.7, 162.6-159.2 (dd, J = 8.3 Hz), 159.0-155.9 (d, J = 236 Hz), 156.5, 138.7 (d, J = 1.6
Hz), 135.1, 132.1, 130.6-130.3 (t, J = 10.8 Hz), 129.6, 124.7-124.6 (d, J = 2.5 Hz), 121.9121.7 (d, J = 8.8 Hz), 120.6, 118.9, 116.1, 115.8-115.5 (d, J = 23.6 Hz), 111.9-111.6 (dd,
J = 7.4 Hz), 111.5, 109.6-109.3 (d, J = 26.1 Hz 109.2-109.1 (d, J = 8.3 Hz), 32.0-31.9 (d,
J = 3.7 Hz) ppm; MS (m/z) 381 (M+), 127 (100%). Anal. Calcd for C22H14F3NO2: C,
69.29; H, 3.70; N, 3.67; Found: C, 68.89; H, 3.98; N, 4.04;

1-(2,6-difluorobenzyl)-5-fluoro-3-(4-methoxybenzylidene)indolin-2-one (178)
To a vial was added 1-(2,6 difluorobenzyl)-5-fluoro-indolin-2-one (0.1818 g, 0.656
mmol) with p-anisaldehyde (1.5 equiv, 0.984 mmol, 116 μL), piperidine (0.147 equiv,
0.096 mmol, 0.010 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for
4 h while stirring. The vial was placed in an ice bath and then the freezer overnight.
Solid was obtained but proved to be impure thru TLC so the product was purified with
silica gel (hexanes/EtOAc, 70:30) to afford a tan solid (0.1773 g, 68.4 % ). The tan solid
was recrystallized with DCM/Hexanes to afford the pure (TLC/GCMS) product (0.1562
g, 60.3 %) was collected by vacuum filtration and washed with cold hexanes: mp 141145˚C; Rf =0.88 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz DMSO-d6) δ: 7.89 (s, 1H),
7.81 (d, J = 8.7 Hz, 2H), 7.68 (d, J = 2.5 Hz, J = 9.0 Hz, 1H), 7.44-7.34 (m,2H), 7.12
(ddd, J = 4.0 Hz, J = 8.8 Hz, 1H), 7.07 (d, J = 8.6 Hz, 1H), 6.90 (dd, J = 4.2 Hz, J = 8.5
Hz, 1H), 5.03 (s, 2H), 3.87 (s, 3H); 13C NMR δ: 165.0, 162.6-159.2 ( dd, J = 7.9 Hz),
161.7, 159.8-156.7 (d, J = 235 Hz), 139.2, 136.4, 134.8, 130.4-130.1 (t, J = 10.4 Hz),
129.9, 126.5, 126.0-125.9 (d, J = 8.9 Hz), 121.7 (d, J = 8.1 Hz), 114.3, 114.2-113.9 (d, J
= 24.1 Hz), 111.9-111.5 (dd, J = 7.4 Hz), 111.7, 108.8-108.7 (d, J = 8.2 Hz), 106.8-106.5
(d, J = 25.8 Hz), 55.3 (d, J = 4.8 Hz), 31.9-31.8 (t, J = 3.1 Hz) ppm; MS (m/z) 395 (M+),
127 (100%) 281 byproduct.

1-(2,6-difluorobenzyl)-5-fluoro-3-(4-hydroxy-3-methoxy-benzylidene)indolin-2-one
(179)
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To a vial was added 1-(2,6 difluorobenzyl)-5-fluoro-indolin-2-one (0.2142 g, 0.773
mmol) with vanillin (1.5 equiv, 1.444 mmol, 0.1764 g), piperidine (0.5 equiv, 0.3842
mmol, 0.038 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 5 h
while stirring. The vial was placed in an ice bath and then the freezer overnight. Solid
was obtained but proved to be impure thru TLC so the product was purified with silica
gel (hexanes/EtOAc, 70:30) to afford a tan solid (0.2016 g, 63.4% ). The tan solid was
recrystallized with DCM/Hexanes to afford the pure (TLC/GCMS) product (0.1433 g,
45.2%) was collected by vacuum filtration and washed with cold hexanes: mp 125129˚C; Rf =0.38 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz DMSO-d6) δ: 9.99 (s, 1H),
8.64 (d, J =1.9 Hz, 1H), 7.86 (s, 1H), 7.85 (dd, J = 1.9 Hz, J = 8.5 Hz, 1H), 7.74 (s, 1H),
7.67 (dd, J = 2.5 Hz, J = 9.0 Hz, 1H), 7.44-7.35 (m,2H), 7.29 (dd, J = 1.7 Hz, J = 8.4 Hz,
1H), 7.08 (ddd, J = 2.5 Hz, J = 9.4 Hz, 1H), 6.96 (dd, J = 8.1 Hz, J = 13.8 Hz, 1H), 6.87
(dd, J = 4.3 Hz, J = 8.5 Hz, 1H), 5.07 (s, 2H), 3.87 (s, 3H); 13C NMR δ: 167.0, 162.6159.2 (dd, J = 7.7 Hz), 150.5, 147.5, 140.3, 138.6, 136.0, 130.4-130.2 (t, J = 8.4 Hz),
128.5, 126.3-126.2 (d, J = 9.3 Hz), 125.7, 124.0, 122.7 (d, J = 2.9 Hz), 116.1-115.2 (t, J =
31.0 Hz), 111.5, 113.9-113.6 (d, J = 24.3 Hz), 111.9-111.6 (dd, J = 7.6 Hz), 108.6-108.5
(d, J = 9.0 Hz), 106.5-106.2 (d, J = 25.8 Hz), 55.6-55.5 (d, J = 7.3 Hz), 31.9 (d, J = 2.6
Hz) ppm; MS (m/z) 411 (M+), 127 (100%).

1-(2,6-difluorobenzyl)-5-fluoro-3-(pyridin-2-ylmethylene)indolin-2-one (180)
To a vial was added 1-(2,6-difluorobenzyl)-5-fluoro-indolin-2-one (0.2242 g, 0.930
mmol) with 2-pyridincarboxaldehyde (1.5 equiv, 1.219 mmol, 0.1306 g, 0.1160 mL),
piperidine (0.5 equiv, 0.4651 mmol, 0.0396 g, 0.046 mL) and EtOH (4 mL). The vial was
placed on a hot plate at 90˚C for 6 h while stirring. The vial was cooled in an ice bath and
placed in the freezer overnight. An orange precipitate (0.1128 g, 38.1%) was collected
by vacuum filtration and washed with cold EtOH: mp 205-208˚C; Rf = 0.46
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz DMSO-d6) δ: 9.06 (dd, J = 2.7 Hz, J = 10.1
Hz, 1H), 8.93 (dt, J = 1.2 Hz, J = 4.4 Hz, 1H), 8.02 (ddd, J = 1.7 Hz, J = 7.7 Hz, 1H),
7.97 (dd, J = 0.9 Hz, J = 6.6 Hz, 1H), 7.96 (d, J = 6.6 Hz, 1H), 7.74 (s, 1H), 7.53 (qd, J =
2.8 Hz, J = 8.8 Hz, 1H), 7.47 – 7.37 (m, 1H), 7.25 (ddd, J = 2.8 Hz, J = 8.8 Hz, 1H), 7.14
(t, J = 8.2 Hz, 2H), 6.93 (dd, J = 4.4 Hz, J = 8.6 Hz, 1H), 5.07 (s, 2H); 13C NMR δ:
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167.4, 162.6-159.2 (dd, J = 7.6 Hz), 159.2-156.1 (d, J = 235 Hz), 152.5, 149.7, 140.4,
139.7 (d, J = 1.6), 137.5, 136.1, 130.6-130.3 (t, J = 10.5 Hz), 129.3, 127.3-127.0 (d, J =
2.7 Hz), 124.7, 122.0, 117.0-116.6 (d, J = 24.2 Hz), 115.2-114.8 (d, J = 27.7 Hz), 111.9111.6 (dd, J = 7.4 Hz), 108.8-108.7 (d, J = 8.0 Hz), 32.1 ppm; MS (m/z) 366.1 (M+), 127
(100%). Anal. Calcd for C21H13F3N2O: C, 68.85; H, 3.58; N, 7.65; Found: C, 68.60; H,
3.76; N, 7.87.
1-(2,6-difluorobenzyl)-5-fluoro-3-(pyridin-4-ylmethylene)indolin-2-one (181)
To a vial was added 1-(2,6-difluorobenzyl)-5-fluoro-indolin-2-one (0.2037 g, 0.735
mmol) with 4-pyridincarboxaldehyde (1.2 equiv, 1.168 mmol, 0.1100 mL), piperidine
(0.147 equiv, 0.1011 mmol, 0.010 mL) and EtOH (4 mL). The vial was placed on a hot
plate at 90˚C for 3 h while stirring. A bright yellow precipitate (0.1025 g, 38.1%) was
collected by vacuum filtration and washed with cold EtOH: mp 158-161˚C; Rf = 0.38
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz DMSO-d6) δ: 8.76 (dd, J = 1.5 Hz, J = 4.4
Hz, 2H), 8.09 (dd, J = 1.4 Hz, J = 4.8 Hz, 1H), 7.94 (s, 1H), 7.77 (s, 1H), 7.74 (d, J = 2.5
Hz, 1H), 7.49 -7.37 (m, 1H), 7.26 (ddd, J = 2.6 Hz, J = 8.9 Hz, 1H), 7.15 (t, J = 8.2 Hz,
2H), 6.99 (dd, J = 4.2 Hz, J = 8.7 Hz, 1H), 5.05 (s, 2H); 13C NMR δ: 166.1, 162.6-159.2
(dd, J = 8.0 Hz), 159.9-156.7 (d, J = 236 Hz), 150.3, 141.6, 139.5 (d, J = 1.2 Hz), 135.7,
130.7-130.4 (t, J = 10.0 Hz), 128.7-128.6 (d, J = 3.2 Hz), 122.9, 120.7-120.6 (d, J = 8.8
Hz), 117.2-116.9 (d, J = 24.0 Hz), 111.9-111.6 (dd, J = 7.5 Hz), 111.2, 110.1-109.8 (d, J
= 26.4 Hz), 108.3-108.2 (d, J = 8.2 Hz), 32.1-32.0 (d, J = 3.9 Hz) ppm: MS (m/z) 366.1
(M+), 207 (100%). Anal. Calcd for C21H13F3N2O: C, 68.85; H, 3.58; N, 7.65; Found: C,
68.64; H, 3.58; N, 7.61.

1-(2,6-Difluorobenzyl)-3-(2,6-difluorobenzylidene)-5-fluoroindolin-2-one (182)
To a vial was added 1-(2,6-difluorobenzyl)-5-fluoro-indolin-2-one (0.1818 g, 0.6563
mmol) with 2,6-difluorobenzaldehyde (1.5 equiv, 1.0936 mmol, 118 µL), piperidine
(0.147 equiv, 0.1112 mmol, 11 µL) and EtOH (4 mL). The vial was placed on a hot plate
at 90˚C for 4 h while stirring. The vial was then placed in an ice bath which caused a
yellow precipitate to form. The vial was placed in the freezer overnight to induce more
crystallization. A yellow solid was collected by vacuum filtration but the product was
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impure thru TLC. The product was evaporated under reduced pressure and purified with
silica gel (hexanes/EtOAc, 70:30) to afford a yellow solid. The yellow solid was then
recrystallized from EtOH to afford the pure (TLC, GC/MS) product as a golden yellow
product (0.0720 g, 25.2%): mp 142-144 ºC; Rf = 0.94 (EtOAc/hexanes, 1:1); 1H NMR
(300 MHz DMSO-d6) δ: 7.71-7.61 (m, 1H), 7.55 (s, 1H), 7.48-7.38 (m, 1H), 7.36 ( t, J
=8.3 Hz, 2H), 7.26 (ddd, J = 2.7 Hz, J = 9.1 Hz, 1H), 7.15 (t, J = 8.2 Hz, 2H), 6.98 (dd,
J = 4.3 Hz, J = 8.7 Hz, 1H), 6.69 (dd, J =2.1 Hz, J = 8.7 Hz, 1H) , 5.06 (s, 2H); 13C
NMR δ: 165.6, 162.6-159.2 (dd, J = 7.8 Hz), 161.2-157.8 (dd, J = 6.7 Hz), 159.3-156.2
(d, J = 237 Hz), 139.4 (d, J = 1.4 Hz), 132.8-132.5 (t, J = 10.6 Hz), 130.7-130.4 (t, J =
10.6 Hz), 130.1 (d, J = 2.2 Hz), 122.6, 121.1-121.0 (d, J = 8.8 Hz), 117.2-116.9 (d, J =
23.6 Hz), 112.4-112.1 (dd, J = 6.3 Hz), 112.0-111.6 (dd, J = 7.3 Hz), 111.4-110.9 (t, J =
18.7 Hz), 111.3, 110.3-109.9 (d, J = 25.6 Hz), 109.7-109.6 (d, J = 7.4 Hz), 32.2-32.1 (t, J
= 2.7 Hz) ppm; MS (m/z) 401 (M+), 127 (100%).

1-(2,6-Difluorobenzyl)-3-(3,5-difluorobenzylidene)-5-fluoroindolin-2-one (183)
To a vial was added 1-(2,6-difluorobenzyl)-5-fluoro-indolin-2-one (0.1904 g, 0.687
mmol) with 3,5-difluorobenzaldehyde (1.5 equiv, 1.031 mmol, 0.1130 mL), piperidine
(0.5 equiv, 0.3438 mmol, 0.034 mL) and EtOH (4 mL). The vial was placed on a hot
plate at 90˚C for 8 h while stirring. The vial was placed in an ice bath which caused a
yellow precipitate to form. The vial was placed in the freezer overnight to induce more
crystallization. A yellow solid (0.1634 g, 59.3%) was collected by vacuum filtration and
washed with cold EtOH: mp 175-176˚C; Rf = 0.79 (EtOAc/hexanes, 1:1); 1H NMR (300
MHz DMSO-d6) δ: 8.13 (dd, J = 2.1 Hz, J = 9.3 Hz, 2H), 7.94 (s, 1H), 7.69 (dd, J = 2.5
Hz, J = 8.7 Hz, 1H), 7.44-7.36 (m, 2H), 7.20( ddd, J = 2.5 Hz, J = 9.3 Hz, 1H), 7.13 (t,
J = 8.2 Hz, 2H), 6.95 (dd, J =4.2 Hz, J = 8.6 Hz, 1H) , 5.04 (s, 2H); 13C NMR δ: 164.5,
163.6-160.3 (dd, J = 13.6 Hz), 162.6-159.2 (dd, J = 7.9 Hz), 159.9-156.7 (d, J = 236 Hz),
139.1 (d, J = 0.8 Hz), 137.4, 136.2-136.1 (d, J = 2.6 Hz), 130.6-130.3 (t, J = 10.0 Hz),
127.0-126.9 (d, J = 3.0 Hz), 124.8-124.7 (d, J = 9.1 Hz), 116.1-115.8 (d, J = 24.5 Hz),
114.7-114.4 (dd, J = 8.3 Hz), 111.9-111.6 (dd, J = 7.4 Hz), 111.4, 109.5-109.4 (d, J = 8.6
Hz), 107.9-107.5 (d, J = 25.8 Hz), 106.4-105.2 (t, J = 25.8 Hz), 32.1-32.0 (t, J = 3.5 Hz)
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ppm; MS (m/z) 401 (M+), 127 (100%); Anal. Calcd for C22H12F5NO: C, 65.84; H, 3.01;
N, 3.49; Found: C, 65.89; H, 3.06; N, 3.75.

1-(2,6-difluorobenzyl)-5-fluoro-3-(4-fluoro-benzylidene)indolin-2-one (184)
To a vial was added 1-(2,6-difluorobenzyl)-5-fluoro-indolin-2-one (0.2196 g, 0.792
mmol) with 4-fluorobenzaldehyde (1.2 equiv, 0.951 mmol, 0.102 mL), piperidine (0.147
equiv, 0.121 mmol, 0.012 mL) and EtOH (4 mL). The vial was placed on a hot plate at
90˚C for 5 h while stirring. The vial was cooled to rt and placed in the freezer overnight
to induce crystallization but was unsuccessful. The reaction mixture was then evaporated
under reduced pressure to afford an orange oil. The oil was then recrystallized from
DCM/hexanes to afford the pure (TLC, GC/MS) product as brown-orange powder
(0.1352 g, 44.5 %): mp 135-138 ºC; 1H NMR (300 MHz, DMSO-d6)  8.51 (dd, J = 5.7
Hz, .J = 8.8 Hz, 1H), 7.97 (s, 1H), 7.81 (d, J = 3.8 Hz , J = 4.4 Hz, 1H), 7.72 (dd, J = 2.5
Hz, J = 8.8 Hz, 1H), 7.47-7.33 (m, 3H), 7.21(ddd, J = 2.5 Hz, J = 8.8 Hz, 1H), 7.14 (t,
(dd, J = 8.1, 2H), 6.96 (dd, J = 4.25 Hz, J = 8.6 Hz, 1H), 5.04 (s, 2H); 13C NMR : 166.5,
165.0-164.8 (d, J = 16.3 Hz), 162.6-159.2 (dd, J = 7.4 Hz), 159.9-156.7 (dd, J = 235 Hz),
139.1 (d, J = 1.9 Hz), 137.9-137.5 (d, J = 34.9 Hz), 136.9, 134.9 (d, J = 8.7 Hz), 130.6130.3 (t, J = 10.4 Hz), 130.2 (d, J = 3.1 Hz), 124.2-124.1 (t, J = 2.7 Hz), 121.3-121.1 (d,
J = 9.0 Hz), 116.1-115.8 (d, J = 21.2 Hz), 115.1-114.8 (d, J = 23.9 Hz), 111.9-111.5 (dd,
J = 8.4 Hz), 109.5-109.0 (d, J = 9.8 Hz), 107.4-107.1 (d, J = 26.1 Hz), 32.0 ppm: Rf =
0.81 (EtOAc/hexanes, 1:1); MS (m/z) 383 (M+), 28 (100%);

1-(2,6-difluorobenzyl)-5-fluoro-3-(4-dimethylamino-benzylidene)indolin-2-one (185)
To a vial was added 1-(2,6- difluorobenzyl)-5-fluoro-indolin-2-one (0.2061 g, 0.744
mmol) with 4-dimethylaminobenzaldehyde (1.2 equiv, 0.899 mmol, 0.1341 g), piperidine
(0.1 equiv, 0.101 mmol, 0.010 mL) and EtOH (4 mL). The vial was placed on a hot plate
at 90˚C for 3 h while stirring. The vial was placed in the freezer overnight to afford an
orange solid. The orange precipitate (0.1369 g, 45.1%) was collected by vacuum
filtration and washed with cold EtOH: mp 174-176˚C; Rf = 0.81 (EtOAc/hexanes, 1:1);
1

H NMR (300 MHz, DMSO-d6) 8.48 (d, J = 9.0 Hz, 1H), 7.78 (s, 1H), 7.67 (dd, J =

4.5 Hz, J = 8.9 Hz, 1H), 7.45-7.35 (m, 2H), 7.13 (ddd, J = 4.0 Hz, J = 8.0 Hz, 2H), 7.02
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(ddd, J = 2.5 Hz, J = 9.4 Hz, 1H), 6.88 (ddd, J = 2.5 Hz , J = 6.8 Hz, 1H), 6.80 (t, J = 9.4
Hz ), 5.05 (s, 1H), 3.05 (s, 6H);

13

C NMR (300 MHz, DMSO-d6) : 165.2, 162.6-159.8

(dd, J =8.0 Hz), 159.8-156.6 (d, J =235 Hz), 151.9, 140.3, 138.0 (d, J =1.4 Hz), 135.2,
130.3-130.1 (t, J =10.6 Hz), 129.4, 126.9-126.8 (d, J =9.3 Hz), 121.5 (d, J =4.5 Hz),
120.3, 117.6 (d, J =3.0 Hz), 112.8-112.5 (d, J =23.7 Hz), 112.0-111.7 (dd, J =11.0 Hz),
108.3-108.2 (d, J =7.2 Hz), 105.8-105.5 (d, J =25.3 Hz), 39.6, 31.9-31.8 (t, J =3.9 Hz)
ppm; LC-MS (m/z) 409 (M+1).

1-(2,6 difluorobenzyl)-5-chloro-3-(4-(hydroxy)-benzylidene)indolin-2-one (186)
To a vial was added 1-(2,6-difluorobenzyl)-5-chloro-indolin-2-one (0.1829 g, 0.624
mmol) with 4-hydroxybenzaldehyde (1.2 equiv, 0.798 mmol, 0.0974 g), piperidine (0.147
equiv, 0.091 mmol, 0.009 mL) and EtOH (4 mL). The vial was placed on a hot plate at
90˚C for 4 h while stirring. The vial was cooled to rt and placed in the freezer overnight
to induce crystallization. A yellow precipitate (0.1700 g, 68.6%) was collected by
vacuum filtration and washed with cold EtOH: mp 250-255 ˚C; 1H NMR (300 MHz,
DMSO-d6) 10.35 (s, 1H), 8.44 (d, J = 8.1 Hz, 2H), 7.90 (d, J = 16.7 Hz, 2H), 7.73 (s,
1H), 7.64 (d, J = 8.0 Hz, 1H), 7.42-7.32 (m, 2H), 7.26 (d, J = 7.8 Hz, 1H), 7.11 (t, J = 7.6
Hz, 3H), 6.93 (t, J = 8.6 Hz, 4H), 5.04 (s, 2H); 13C NMR : 165.8, 162.5, 159.8, 139.8,
138.6, 133.7, 130.3, 127.8, 126.2, 125.4, 124.3, 122.3, 120.0, 119.8, 115.5, 111.7, 109.3,
31.9 ppm: Rf = 0.56 (EtOAc/hexanes, 1:1); LC-MS (m/z): 398 (M+);
1-(2,6 difluorobenzyl)-5-chloro-3-(2-hydroxy-benzylidene)indolin-2-one (187)
To a vial was added 1-(2,6 difluorobenzyl)-5-chloro-indolin-2-one (0.1577 g, 0.538
mmol) with salicyclaldehyde (1.2 equiv, 0.650 mmol, 0.069 mL), piperidine (0.147
equiv, 0.081 mmol, 0.008 mL) and EtOH (4 mL). The vial was placed on a hot plate at
90˚C for 5 h while stirring. The vial was cooled to rt and placed in the freezer overnight
to induce crystallization. No solid precipitated so the solution was evaporated under
reduced pressure and recrystallized with DCM/hexanes. A brown precipitate (0.1389 g,
68.6%) was collected by vacuum filtration and washed with cold EtOH: mp 149-151 ˚C;
Rf = 0.56 (EtOAc/hexanes, 1:1); LC-MS (m/z): 398 (M+).
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1-Benzyl-5-fluoro-3-(2-hydroxybenzylidene)indolin-2-one (190)
To a vial was added 1-(Benzyl)-5-fluoro-indolin-2-one (0.2039 g, 0.846 mmol) with
salicylaldehyde (1.5 equiv, 1.271 mmol, 135 µL), piperidine (0.5 equiv, 0.4146 mmol, 41
µL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 6 h while stirring.
The vial was then placed in an ice bath which caused a brown precipitate to form. The
vial was placed in the freezer overnight to induce more crystallization. A brown solid
(0.1756 g, 69.9%) was collected by vacuum filtration and washed with cold EtOH: mp
185-187˚C; Rf = 0.43 (EtOAc/hexanes, 1:1); ); 1H NMR (300 MHz DMSO-d6) δ : 9.00 (s,
1H), 8.59 (d, J = 9.4 Hz, 1H), 8.12 (s,1H), 7.71 (d, J = 9.4 Hz, 1H), 7.65 (d, J = 9.0 Hz,
1H), 7.43 (d, J = 1.7 Hz, 1H), 7.41-7.36 (m, 1H), 7.35 (d, J = 4.1 Hz, 2H), 7.31 (d, J =
10.0 Hz, 1H), 7.29 ( d, J = 8.6, 1H), 7.25 (d, J = 9.2 Hz, 1H), 7.13 (dd, J = 2.6 Hz, J =
17.9 Hz, 1H), 7.10 (d, J = 2.4 Hz, 1H), 7.03 (s, 1H), 7.00-6.93 (m, 1H), 4.99 (s, 2H) ;13C
NMR δ: 167.3, 159.1-156.0 (d, J = 236 Hz), 156.5, 138.9 (d, J = 1.2 Hz), 136.3, 135.3,
132.2, 129.6, 128.6, 127.4, 127.2, 125.0-124.9 (d, J = 2.7 Hz), 121.9-121.8 (d, J = 8.9
Hz), 120.7, 118.9, 116.1, 115.7-115.4 (d, J = 23.8 Hz), 110.0-109.9 (d, J = 8.3 Hz),
109.6-109.3 (d, J = 25.9 Hz), 42.7 ppm:; MS (m/z) 345 (M+), 91 (100%). Anal. Calcd for
C22H16FNO2: C, 76.51; H, 4.67; N, 4.06; Found: C, 76.64; H, 4.68; N, 4.06.
1-Benzyl-5-fluoro-3-(4-hydroxybenzylidene)indolin-2-one (191)
To a vial was added 1-(benzyl)-5-fluoro-indolin-2-one (0.2927 g, 1.214 mmol) with 4hydroxybenzaldehyde (1.2 equiv, 1.439 mmol, 0.1758 g), piperidine (0.147 equiv, 0.1719
mmol, 17 µL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 5 h while
stirring. The vial was then cooled to room temperature and placed into the freezer
overnight.. A yellow solid was collected by vacuum filtration and washed with EtOH to
afford the pure (TLC, GC/MS) product as a bright yellow solid (0.3413 g, 81.4 %): mp
236-238 ºC; Rf = 0.33 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz DMSO-d6) δ: 10.35 (s,
1H), 8.48 (dd, J = 2.5 Hz , J = 11.3 Hz, 2H), 7.90 (s, 1H), 7.69 (dd, J = 2.5 Hz, J = 9.0
Hz, 1H), 7.83 (s, 1H), 7.33 (d, J = 4.4 Hz, 5H), 7.27 (dd, J = 3.3 Hz, J = 4.7 Hz, 2H),
7.04 (ddd, J = 2.5 Hz, J = 8.6 Hz, 1H), 6.91 (dd, J = 4.5 Hz, J = 8.8 Hz, 1H) 13C NMR δ:
165.5, 160.8, 159.9-156.8 (d, J = 235 Hz), 140.0, 136.7, 136.3 (d, J = 0.7 Hz), 135.3,
128.6, 127.3, 127.2, 126.3-126.1 (d, J = 9.1 Hz), 125.2, 120.9-120.8 (d, J = 2.9 Hz),
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115.3, 113.9- 113.6 (d, J = 24.2 Hz), 109.4-109.3 (d, J = 8.2 Hz), 106.6-106.3 (d, J =25.2
Hz), 42.6 ppm: MS (m/z) 345 (M+), 91(100%). Anal. Calcd for C22H16FNO2: C, 76.51;
H, 4.67; N, 4.06; Found: C, 76.46; H, 4.62; N, 4.15.
1-Benzyl-5-fluoro-3-(4-methoxybenzylidene)indolin-2-one (192)
To a vial was added 1-(benzyl)-5-fluoro-indolin-2-one (0.1920 g, 0.797 mmol) with panisaldehyde (1.5 equiv, 1.1917 mmol, 145 µL), piperidine (0.5 equiv, 0.3944 mmol, 39
µL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 3 h while stirring.
The vial was then placed in an ice bath which caused a yellow precipitate to form. The
vial was placed in the freezer overnight to induce more crystallization. A yellow solid
was collected by vacuum filtration but the product was very gummy. The product was
dissolved combined with the filtrate and evaporated under reduced pressure to afford a
solid and recrystallized from EtOH to afford the pure (TLC, GC/MS) product as a dark
brown product (0.0720 g, 25.2%): mp 140-142 ºC; Rf = 0.63 (EtOAc/hexanes, 1:1); ); 1H
NMR (300 MHz DMSO-d6) δ: 7.76 (dd, J = 2.6 Hz, J = 11.1 Hz, 2H), 7.83 (s, 1H), 7.44
(dd, J = 2.5 Hz, J = 9.3 Hz, 1H), 7.32 (d, J = 4.0 Hz, 5H), 7.09 (dd, J = 3.2 Hz, J=9.1 Hz,
1H), 7.09 (d, J=9.1 Hz, 2H), 7.04 (ddd, J =2.4 Hz, J=9.4 Hz, 1H), 6.97 (dd, J = 4.5 Hz,
J=8.6 Hz, 1H), 6.92 (d, J=8.6 Hz, 1H), 4.98 (s, 2H), 3.85 (s,3H)

13

C NMR δ: 167.5,

161.0, 159.1-156.0 (d, J = 236 Hz), 138.9, 136.5 (d, J =1.3 Hz), 136.3, 131.7, 128.6,
127.3, 127.1, 126.0, 123.9-123.8 (d, J = 3.0 Hz), 121.7-121.6 (d, J = 9.0 Hz), 115.8-115.4
(d, J = 23.5 Hz), 114.4, 110.1-110.0 (d, J = 8.3 Hz), 109.2-108.9 (d, J =26.0 Hz), 55.4,
42.7 ppm; MS (m/z) 359 (M+), 91(100%). Anal. Calcd for C23H18FNO2: C, 76.86; H,
5.05; N, 3.90; Found: C, 76.66; H, 4.99; N, 3.96.

1-Benzyl-5-fluoro-3-(pyridin-2-ylmethylene)indolin-2-one (193)
To a vial was added 1-(benzyl)-5-fluoro-indolin-2-one (0.1889 g, 0.784 mmol) with 2pyridincarboxaldehyde (1.5 equiv, 1.177 mmol, 0.1120 mL), piperidine (0.5 equiv,
0.3944 mmol, 39 µL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 5
h while stirring. The vial was then placed in an ice bath which caused a brown
precipitate to form. The vial was placed in the freezer overnight to induce more
crystallization. A brown solid (0.1921 g, 74.3%) was collected by vacuum filtration and
washed with cold EtOH: mp 126-127˚C; Rf =0.51 (EtOAc/hexanes, 1:1); %).1H NMR
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(300 MHz, DMSO-d6) δ: 9.06 (dd, J = 2.7 Hz, J = 10.1Hz, 1H), 8.94 (dd, J = 1.8 Hz, J
= 8.1 Hz, 1H), 8.03 (dd, J = 1.7 Hz, J = 7.8 Hz, 1H), 7.98 (d, J =1.5 Hz, 1H), 7.80 (s,
1H), 7.54-7.51 (m, 1H), 7.34 (d, J= 4.4Hz, 4H), 7.30-7.23 (m, 1H), 7.20 (ddd, J = 2.8 Hz,
J =8.8 Hz,1H), 6.97 (dd, J =4.5 Hz, J = 8.6 Hz, 1H), 5.01 (s, 2H);13C (300 MHz, DMSOd6): δ 167.9, 159.3-156.2 (d, J = 235 Hz), 152.6, 149.7, 139.9 (d, J = 1.4 Hz), 137.5,
136.2 (d, J = 4.2 Hz), 129.3, 128.6, 127.6-127.5 (d, J = 2.6 Hz), 127.4, 127.1, 124.7,
122.2-122.0 (d, J = 10.2 Hz), 116.9-116.6 (d, J = 24.1 Hz), 115.2-114.9 (d, J = 27.2 Hz),
109.6-109.5 (d, J = 8.5 Hz), 42.8 ppm; MS (m/z) 330.1 (M+), 91 (100%). Anal. Calcd for
C21H15FN2O: C, 76.35; H, 4.58; N, 8.48 Found: C, 76.60; H, 4.67; N, 8.45.

1-Benzyl-5-fluoro-3-(pyridin-4-ylmethylene)indolin-2-one (194)
To a vial was added 1-(benzyl)-5-fluoro-indolin-2-one (0.2032 g, 0.843 mmol) with 4pyridincarboxaldehyde (1.2 equiv, 1.274 mmol, 0.1200 mL), piperidine (0.147 equiv,
0.1315 mmol, 0.013 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C
for 3 h while stirring. The vial was then placed in an ice bath which caused a bright
yellow precipitate to form. The vial was placed in the freezer overnight to induce more
crystallization. A bright yellow solid (0.1405 g, 50.5%) was collected by vacuum
filtration and washed with cold EtOH: mp 157-158˚C; Rf = 0.29 (EtOAc/hexanes, 1:1);
1

H NMR (300 MHz DMSO-d6) δ: 8.77(dd, J = 1.5 Hz, J = 4.4 Hz, 2H), 7.82 (s, 1H),

7.78 (dd, J = 2.5Hz, J=8.7 Hz, 1H), 7.67 (dd, J = 1.5 Hz, J = 6.0 Hz, 1H), 7.35 (d, J =
4.4 Hz, 4H), 7.31-7.25 (m, 1H), 7.13 (ddd, J = 2.6 Hz, J = 9.2 Hz, 1H), 7.01 (dd, J=4.5
Hz, 8.9 Hz, 1H), 7.01-6.92 (m, 1H), 4.99 (d, J = 9.6 Hz, 2H); 13C NMR δ: 166.6, 159.1156.0 (d, J = 236 Hz), 150.3, 141.7, 139.7 (d, J = 1.4 Hz), 136.2, 135.8, 129.0 (d, J = 2.9
Hz), 127.4 (d, J = 4.0 Hz), 124.7, 124.6-124.5 (d, J = 8.9 Hz), 117.1-116.8 (d, J = 23.5
Hz), 110.6-110.5 (d, J = 8.6 Hz), 110.1 (d, J = 2.5 Hz), 110.0-109.8 (d, J = 14.8 Hz),
108.4-108.0 (d, J = 25.6 Hz), 42.8-42.7 (d, J = 8.1 Hz) ppm; MS (m/z) 330.1 (M+), 207.1
(100%). Anal. Calcd for C21H15FN2O: C, 76.35; H, 4.58; N, 8.48; Found: C, 76.35; H,
4.53; N, 8.59.

1-Benzyl-3-(3,5-difluorobenzylidene)-5-fluoroindolin-2-one (195)
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To a vial was added 1-(benzyl)-5-fluoro-indolin-2-one (0.2169 g, 0.900 mmol) with 3,5difluorobenzaldehyde (1.5 equiv, 1.351 mmol, 0.1480 mL), piperidine (0.5 equiv, 0.4550
mmol, 45 µL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 5 h while
stirring. The vial was then placed in an ice bath which caused a yellow precipitate to
form. The vial was placed in the freezer overnight to induce more crystallization. A
yellow solid (0.1624 g, 49.4%) was collected by vacuum filtration and washed with cold
EtOH: mp 161-164˚C; Rf =0.69 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz DMSO-d6) δ:
8.18 (dd, J =2.1 Hz, J =9.4 Hz, 1H), 7.98 (s, 1H), 7.70 (dd, J =2.5 Hz, J =8.7 Hz, 1H),
7.43 (dt, J =2.3Hz ,J =9.4 Hz 1H), 7.35 (d, J =4.4 Hz, 4H), 7.31-7.24 (m, 1H), 7.13 (ddd,
J =2.5 Hz, J =9.4 Hz, 1H), 6.96 (dd, J =3.9 Hz, J =8.6 Hz, 1H), 4.98 (s, 2H)

13

C NMR δ:

166.8, 164.2-160.7 (dd, J = 13.6 Hz), 159.1-156.0 (d, J = 236 Hz), 139.6 (d, J = 1.0 Hz),
137.5-137.4 (d, J = 10.2 Hz), 136.2, 136.0, 128.6, 127.9 (d, J = 2.8 Hz), 127.4 (d, J = 3.9
Hz), 127.2, 124.9-124.7 (d, J = 9.0 Hz),116.9-116.6 (d, J = 23.5 Hz), 114.8-114.5 (d, J =
26.2 Hz), 112.4-112.0 (dd, J = 8.5 Hz), 110.5-110.4 (d, J = 8.2 Hz), 105.6-104.9 (t, J =
25.8 Hz), 42.8 ppm; MS (m/z) 365 (M+), 91 (100%).

1-Benzyl-3-(2,6-difluorobenzylidene)-5-fluoroindolin-2-one (196)
To a vial was added 1-(benzyl)-5-fluoro-indolin-2-one (0.1804 g, 0.749 mmol) with 2,6difluorobenzaldehyde (1.2 equiv, 0.878 mmol, 0.096 mL), piperidine (0.147 equiv, 0.111
mmol, 11 µL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 6 h while
stirring. The vial was then placed in an ice bath which caused a yellow precipitate to
form. The vial was placed in the freezer overnight to induce more crystallization. A
yellow solid (0.1099 g, 49.4%) was collected by vacuum filtration and washed with cold
EtOH: mp 162-164˚C; Rf =0.69 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz DMSO-d6) δ:
7.69 (m,1Ht, J =8.2 Hz, 1H), 7.61 (s, 1H), 7.36 (d, J =4.4 Hz, 5H), 7.32-7.26 (m, 2H),
7.20 (ddd, J = 2.5 Hz, J = 8.9 Hz, 1H), 7.02 (dd, J = 4.4 Hz, J = 8.6 Hz, 1H), 6.71 (dd, J
= 2.0 Hz, J = 8.7 Hz,1H), 4.99 (s, 2H);

13

C NMR δ: 166.1, 161.2-157.8 (dd, J = 6.9 Hz),

159.4-156.3 (d, J = 237 Hz), 139.6 (d, J = 1.5 Hz), 136.1, 132.8-132.5 (t, J = 10.5 Hz),
130.4 (d, J = 2.5 Hz), 128.7, 127.5, 127.2, 122.8, 121.2-121.0 (J = 8.8 Hz), 117.1-116.8
(d, J = 23.7 Hz), 112.4-112.1 (dd, J = 22.7 Hz), 111.6 – 111.4 (d, J = 19.6 Hz), 110.5110.4 (d, J = 8.3 Hz), 110.3 -110.0 (d, J = 23.5 Hz), 42.8 ppm; MS (m/z) 365 (M+), 91
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(100%). Anal. Calcd for C22H14F3NO: C, 72.32; H, 3.86; N, 3.83 Found: C, 72.22; H,
4.00; N, 3.92.

1-Benzyl-5-fluoro-3-(3-hydroxy-4-methoxybenzylidene)indolin-2-one (197)
To a vial was added 1-(benzyl)-5-fluoro-indolin-2-one (0.1843 g, 0.765 mmol) with
vanillin (1.2equiv, 0.914 mmol, 0.1389 g), piperidine (0.147 equiv, 0.121 mmol, 0.0103
g, 12 µL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 4 h while
stirring. The vial was cooled to room temperature then placed in the freezer overnight
but crystallization did not occur. The solution was evaporated under reduced pressure to
afford a red oil. The oil dissolved with DCM and the Biotage Horizon HPFC
(hexanes/EtOAc, 70:30) was used to separate the product from impurities to give a
yellow solid. The solid was dissolved in DCM then recrystallized from hexanes to afford
the pure (TLC, GC/MS) product as a yellow-orange product (0.1387 g, 48.4%): mp 145149 ºC; Rf = 0.43 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz DMSO-d6) δ: 10.02 (s, 1H),
7.91 (s, 1H), 7.57 (dd, J =2.5 Hz, J = 9.4 Hz, 1H), 7.46 (dd, J =1.8 Hz, J = 7.9 Hz, 1H),
7.32 (d, J =4.8 Hz, 5H), 7.29 – 7.23 (m, 2H), 7.09 (ddd, J =2.5 Hz, J =8.3 Hz, 1H), 6.89
(d, J = 4.2 Hz, J =8.3 Hz, 1H), 5.01 (d, J = 7.1 Hz, 2H), 3.87 (s, 3H); 13C NMR δ: 165.6,
159.9-156.8 (d, J = 235 Hz), 150.5, 147.6, 140.4, 138.8, 136.6, 128.6, 127.2, 127.1,
126.3, 124.8, 124.1, 123.0-122.9 (d, J = 2.9 Hz), 115.9, 115.3-115.2 (t, J = 5.4 Hz),
113.8-113.5 (d, J = 23.9 Hz), 109.4-109.3 (d, J = 8.4 Hz), 106.5-106.2 (d, J = 25.9 Hz)
55.5, 42.6 ppm; MS (m/z) 375 (M+), 28 (100%).

1-(Benzyl)-5-fluoro-3-(4-dimethylamino-benzylidene)indolin-2-one (198)
To a vial was added 1-(benzyl)-5-fluoro- indolin-2-one (0.2131 g, 0.884 mmol) with 4dimethylaminobenzaldehyde (1.2 equiv, 1.023 mmol, 0.1527 g), piperidine (0.1 equiv,
0.121 mmol, 0.012 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for
5 h while stirring. The vial was placed in the freezer overnight to afford a red solid. The
orange precipitate (0.2711g, 82.4%) was collected by vacuum filtration and washed with
cold EtOH: mp 139-140˚C; Rf = 0.80 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz,
DMSO-d6) 8.53 (d, J = 9.0 Hz, 2H), 7.82 (s, 1H), 7.64 (dd, J =2.4 Hz, J = 9.2 Hz, 1H),
7.32 (d, J = 4.3 Hz, 4H), 7.28-7.22 (m, 1H), 6.97 (ddd, J =2.5 Hz, J =8.7 Hz, 1H), 6.87
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(dd, J = 4.5 Hz, J =8.5 Hz, 1H), 6.80 (d, J = 9.1 Hz, 2H), 4.99 (s, 2H), 3.05 (s, 6H); 13C
NMR (300 MHz, DMSO-d6) : 165.7, 159.9-156.7 (d, J = 235 Hz), 152.2, 140.4, 136.9,
135.7, 135.3, 128.5, 127.2, 127.1, 126.9-126.8 (d, J = 9.1 Hz), 121.6, 117.9-117.8 (d, J =
3.0 Hz), 112.7-112.4 (d, J = 24.0 Hz), 111.0, 109.0-108.9 (d, J = 8.4 Hz), 105.8-105.5 (d,
J = 25.5 Hz), 42.5, 39.5 ppm; LC-MS (m/z) 373 (M+), 100%). Anal. Calcd for
C24H21FN2O: C, 77.40; H, 5.68; N, 7.52; Found: C, 77.20; H, 5.74; N, 7.61.

1-Benzyl-5-chloro-3-(4-hydroxy-benzylidene)indolin-2-one (199)
To a solution of 1-(benzyl)-5-chloro-indolin-2-one (0.2833 g, 1.102 mmol) with EtOH
(45 mL) was added 4-hydroxybenzaldehyde (1.2 equiv, 1.322 mmol, 0.1615 g) and
piperidine (0.147 equiv, 0.1617 mmol, 0.0137 g, 0.016 mL). The mixture was heated
under reflux and stirred for 5 h or until the solution went from yellow to orange in color.
The solution was cooled to room temperature and evaporated under reduced pressure to
afford an orange oil. The orange oil was recrystallized with DCM/Hexanes to afford the
pure (TLC, GC/MS) product as a yellow solid (0.3246 g, 68.6%): mp 255-257 ˚C; 1H
NMR (300 MHz, DMSO-d6) 10.32 (s, 1H), 8.50 (d, J =8.8 Hz, 1H), 7.96 (s, 1H), 7.88
(d, J = 2.0 Hz, 1H), 7.81 (s, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.34 (d, 3.7 Hz, 1H), 7.32 (d, J
= 2.6 Hz, 3H), 7.30 (d, J = 8.6 Hz, 1H), 7.23 (dd, J = 2.1 Hz, J = 8.3 Hz, 1H), 6.98 (t, J =
4.3 Hz, 1H), 6.94 (d, J = 8.7 Hz, 1H), 4.99 (s, 2H); 13C NMR : 166.3, 160.4, 140.0,
139.9, 136.4, 133.7, 128.6, 127.3, 127.1, 127.0, 126.3, 125.4, 124.4, 121.3, 120.1, 115.5,
110.1, 42.6 ppm: Rf = 0.64 (EtOAc/hexanes, 1:1); LC-MS (m/z): 362 (M+1);
1-(Benzyl)-3-(4-dimethylamino-benzylidene)indolin-2-one (200)
To a vial was added 1-(benzyl)- indolin-2-one (0.1977 g, 0.886 mmol) with 4dimethylaminobenzaldehyde (1.2 equiv, 0.952 mmol, 0.1421 g), piperidine (0.1 equiv,
0.121 mmol, 0.012 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for
4 h while stirring. The vial was placed in the freezer overnight to afford an orange solid.
The orange precipitate (0.2377g, 75.7%) was collected by vacuum filtration and washed
with cold EtOH: mp 139-140˚C; Rf = 0 75 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz,
DMSO-d6) d, J = 9.0 Hz, 2H), 7.75 (s, 1H), 7.70 (d, J = 7.0 Hz, 1H), 7.33-7.23
(m, 5H), 7.15 (dd, J = 0.9 Hz, J = 15.2 Hz, 1H), 7.02 (dd, J = 0.7 Hz, J = 7.5 Hz, 1H),
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6.90 (d, J = 7.6 Hz, 1H), 6.79 (d, J = 9.0 Hz, 2H), 5.00 (s, 2H), 3.04 (s, 6H); 13C NMR
(300 MHz, DMSO-d6) : 165.6, 151.9, 139.5, 138.8, 137.1, 134.9, 128.5, 127.2, 127.2,
126.8, 125.1, 121.8, 121.2, 118.5, 118.2, 111.0, 108.3, 42.4, 39.5 ppm; LC-MS (m/z): 355
(M+1). Anal. Calcd for C24H22N2O: C, 81.33; H, 6.26; N, 7.90 Found: C, 81.15; H, 6.20;
N, 7.92.

1-(3,5-difluorobenzyl)-5-fluoro-3-(pyridin-2-ylmethylene)indolin-2-one (203)
To a vial was added 1-(3,5-difluorobenzyl)-5-fluoro-indolin-2-one (0.1758 g, 0.635
mmol) with 2-pyridincarboxaldehyde (1.2 equiv, 0.767 mmol, 0.073 mL), piperidine
(0.147 equiv, 0.091 mmol, 0.009 mL) and EtOH (4 mL). The vial was placed on a hot
plate at 90˚C for 5 h while stirring. A tan precipitate (0.0861 g, 37.1%) was collected by
vacuum filtration and washed with cold EtOH: mp 165-166˚C; Rf = 0.73
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6) δ: 9.05 (dd, J = 2.7 Hz, J = 10.1
Hz 1H), 8.92 (d, J = 5.2 Hz,1H), 8.00 (ddd, J =1.8 Hz, J =7.6 Hz, 1H), 7.94 (d, J = 7.3
Hz), 7.76 (s, 1H), 7.51 (qd, J =1.4 Hz , J = 4.7 Hz, 1H), 7.20 (ddd, J =2.8 Hz, J = 8.8
Hz), 7.15 (dd, J =2.2 Hz, J =9.4 Hz 1H), 7.05 (d, J = 8.3 Hz, 2H), 6.87 (dd, J =4.6 Hz, J
= 8.6 Hz, 1H), 5.01 (s, 2H); 13C (300 MHz, DMSO-d6) δ: 168.1, 164.2-160.7, 159.4156.3, 152.5, 149.7, 141.1-140.8, 139.5-139.4, 137.4, 136.4, 129.3, 127.3, 124.7, 122.2122.1, 116.9-116.6 (d, J = 24.0 Hz), 115.3-114.9 (d, J = 27.5 Hz), 110.4-110.1 (dd, J =
8.1 Hz), 109.5-109.4 (d, J = 8.4 Hz), 103.3-102.6 (t, J = 25.9 Hz), 42.6 MS (m/z) 366
(M+), 127 (100%); Anal. Calcd for C21H13F3N2O: C, 68.85; H, 3.58; N, 7.65 Found: C,
68.72; H, 3.82; N, 7.49.

1-(3,5-Difluorobenzyl)-5-fluoro-3-(pyridin-4-ylmethylene)indolin-2-one (204)
To a vial was added 1-(3,5-difluorobenzyl)-5-fluoro-indolin-2-one (0.1887 g, 0.681
mmol) with 4-pyridincarboxaldehyde (1.2 equiv, 0.8174 mmol, 77 µL), piperidine (0.147
equiv, 0.1011 mmol, 10 µL) and EtOH (4 mL). The vial was placed on a hot plate at
90˚C for 5 h while stirring. The vial was then placed in the freezer overnight but
crystallization did not occur. The solution was evaporated under reduced pressure and
purified with silica gel (hexanes/EtOAc, 70:30) to afford a yellow solid (0.1461 g,
58.6%). The yellow solid was recrystallized from DCM/ hexanes to afford the pure (TLC,
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GC/MS) product as a yellow-orange product (0.0574 g, 23.0%): mp 138-141 ºC; Rf =
0.25 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6) δ: 8.77 (dd, J = 1.3 Hz, J =
4.5 Hz, 2H), 8.12 (d, J = 6.0 Hz, 1H) 7.98 (s, 1H), 7.79 (dd, J = 2.5 Hz, J = 8.7 Hz, 1H),
7.67 (d, J = 5.5 Hz, 2H), 7.15 (ddd, J =2.5 Hz, J =8.8 Hz, 1H), 7.05 (dd, J =2.5 Hz, J =
8.8 Hz, 2H), 6.99 (dd, J =4.5 Hz, J = 8.6 Hz, 1H), 5.01 (s, 2H); 13C (300 MHz, DMSOd6) δ: 166.8, 164.2-160.7 (dd, J = 13.1 Hz), 159.2-156.1 (d, J = 236 Hz), 150.3, 141.6,
140.8, 139.4-139.3 (d, J = 1.3 Hz), 135.9, 128.5-128.4 (d, J = 3.0 Hz), 122.9, 121.0-120.8
(d, J = 8.8 Hz), 117.2-116.9 (d, J = 23.5 Hz), 110.6-110.2 (dd, J = 7.8 Hz), 110.0-109.9
(d, J = 8.9 Hz), 108.4-108.1 (d, J = 24.6 Hz), 103.4-102.6 (dt, J = 4.7, J = 25.8 Hz), 42.1
(d, J = 7.0 Hz) ppm; MS (m/z) 366 (M+) 28 (100%). Anal. Calcd for C21H13F3N2O: C,
68.85; H, 3.58; N, 7.65; Found: C, 68.78; H, 3.74; N, 7.37.

1-(3,5-difluorobenzyl)-5-fluoro-3-(4-methoxy-benzylidene)indolin-2-one (205)
To a solution of 1-(3,5 difluorobenzyl)-5-fluoro-indolin-2-one (0.3303 g, 1.192 mmol)
with EtOH (45 mL) was added p-anisaldehyde (1.2 equiv, 1.430 mmol, 0.174 mL) and
piperidine (0.147 equiv, 0.1719 mmol, 0.017 mL). The mixture was heated under reflux
and stirred for 26 h. The solution was cooled to room temperature and evaporated under
reduced pressure to afford a yellow oil which was purified with silica gel
(hexanes/EtOAc, 70:30) to produce a yellow oil/solid (0.4662 g, 98.9 %). The yellow oil
was recrystallized with EtOH to afford the pure (TLC/GCMS) yellow solid product
(0.3664 g, 77.8 %): ); 1H NMR (300 MHz DMSO-d6) δ: 8.54 (d, J = 8.9 Hz, 1H), 7.84 (s,
1H), 7.78 (d, 8.5 Hz, 2H), 7.73 (d, J = 9.1 Hz, 1H), 7.46 (dd, J = 2.5 Hz, J = 9.3 Hz, 1H),
7.19 (d, J = 4.6 Hz, 1H), 7.14 (ddd, J =2.5 Hz, J =8.8 Hz, 1H), 7.06 (dd, J =2.5 Hz, J
=8.7 Hz, 2H), 6.98 (dd, J = 4.4 Hz, J = 8.5 Hz, 1H), 5.02 (s, 2H), 3.86 (s, 3H) ;13C NMR
(DMSO-d6) δ: 167.6, 164.1, 161.0, 157.7, 141.2, 139.2, 138.6, 133.3, 126.3, 123.7, 121.8,
115.7, 114.1, 110.4, 109.9, 109.1, 102.8, 55.4, 42.1 ppm; mp 125-126˚C; Rf = 0.76
(EtOAc/hexanes, 1:1); MS (m/z) 395 (M+), 268 (100%). C23H16F3NO2; C, 69.87; H, 4.08;
N, 3.54; Found C, 69.52; H, 3.91; N, 3.47.

1-(3,5-difluorobenzyl)-5-fluoro-3-(2,6-difluorobenzylidene)-indolin-2-one (206)
To a vial was added 1-(3,5-difluorobenzyl)-5-fluoro-indolin-2-one (0.1931 g, 0.697
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mmol) with 2,6 difluorobenzaldehyde (1.2 equiv, 0.834 mmol, 0.090 mL), piperidine
(0.147 equiv, 0.081 mmol, 0.008 mL) and EtOH (4 mL). The vial was placed on a hot
plate at 90˚C for 4 h while stirring. The vial was cooled to rt and placed in the freezer
overnight to induce crystallization. An orange precipitate (0.0802 g, 28.7 %) was
collected by vacuum filtration and washed with cold EtOH: mp 162-164˚C; 1H NMR
(300 MHz, DMSO-d6) dd, J =2.0 Hz, J =9.0 Hz, 1Hm, 2H), 7.61 (s,
1H), 7.36 (t, J = 8.2 Hz, 3H), 7.19 (ddd, J =2.5 Hz, J =8.7 Hz, 1H), 6.92 (dd, J =4.4 Hz,
J =8.7 Hz, 1H) 6.72 (dd, J = 2.1 Hz, J = 8.7 Hz, 1H), 5.01 (s, 2H); 13C NMR : 168.3,
164.2-160.7 (dd, J = 13.1 Hz), 161.2-157.8 (dd, J = 6.9 Hz), 159.5-156.4 (d, J = 237 Hz),
140.9-140.7 (t, J = 9.0 Hz), 139.3 (d, J = 1.4 Hz), 132.8-132.5 (t, J = 10.5 Hz), 130.2 (d,
J = 2.2 Hz), 129.9, 122.9, 121.3-121.2 (d, J = 9.2 Hz), 117.2-116.9 (d, J = 23.7 Hz),
112.4-112.1 (dd, J = 6.8 Hz), 110.6-110.3 (dd, J = 8.2 Hz), 110.1-110.0 (d, J = 7.9 Hz),
109.1-108.7 (d, J = 25.8 Hz), 103.4-102.7 (t, J = 25.6 Hz), 42.2-41.8 (d, J = 1.8 Hz) ppm:
Rf = 0.79 (EtOAc/hexanes, 1:1); MS (m/z): 401 (M+), 127 (100%); Calcd for
C22H12F5NO: C, 65.84; H, 3.01; N, 3.49; Found: C, 65.57, H, 3.27, N, 3.48.
5-Chloro-1-(3,5-difluorobenzyl)-3-(pyridin-2-ylmethylene)indolin-2-one (207)
To a vial was added 1-(3,5-difluorobenzyl)-5-chloro-indolin-2-one (0.1842 g, 0.629
mmol) with 2-pyridincarboxaldehyde (1.2 equiv, 0.757 mmol, , 0.072 mL), piperidine
(0.147 equiv, 0.1011 mmol, 0.010 mL) and EtOH (4 mL). The vial was placed on a hot
plate at 90˚C for 5 h while stirring. A green precipitate (0.1661 g, 69.2%) was collected
by vacuum filtration and washed with cold EtOH: mp 157-159˚C; Rf = 0.55
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz, CDCl3): 9.27 (d, J = 2.2 Hz, 1H), 8.95 (d, J
= 4.7 Hz, 1H), 7.88 (d, J = 15.4 Hz, 1H), 7.85 (s, 1H), 7.68 (d, J = 7.7 Hz, 1H), 7.41 (dd,
J = 1.0 Hz, J = 7.5 Hz, 1H), 7.39 (d, J = 7.6 Hz, 1H), 7.28 (s, 1H), 7.26 (d, J =8.3Hz,
1H), 6.84 (d, J =7.7 Hz, 2H), 6.76 (tt, J =8.8 Hz, 1H), 6.61 (d, J = 8.3 Hz, 1H), 4.98 (s,
2H); 13C NMR (CDCl3) : 168.8, 165.0-161.6 (dd, J = 12.7 Hz), 158.4, 153.2, 149.7,
141.7, 141.1, 136.8 (d, J = 3.7 Hz), 130.0, 128.7, 128.5, 128.0, 127.7, 124.2, 123.1,
110.1-109.8 (dd, J = 8.2 Hz), 109.1, 103.3-102.9 (t, J = 25.3 Hz), 43.2 ppm; MS (m/z):
382 (M+), 28 (100%); Anal. Calcd for C21H13ClF2N2O: C, 65.89; H, 3.42; N, 7.32;
Found: C, 65.66; H, 3.24; N, 7.20.
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5-chloro-1-(3,5-difluorobenzyl)-3-(pyridin-4-ylmethylene)indolin-2-one (208)
To a vial was added 1-(3,5-difluorobenzyl)-5-chloro-indolin-2-one (0.2077 g, 0.677
mmol) with 4-pyridincarboxaldehyde (1.2 equiv, 0.8492 mmol, 0.0910 g, 80 µL),
piperidine (0.147 equiv, 0.1011 mmol, 0.0086 g, 10 µL) and EtOH (4 mL). The vial was
placed on a hot plate at 90˚C for 5 h while stirring. The vial was then placed in the
freezer overnight but crystallization did not occur. The solution was evaporated under
reduced pressure and purified with silica gel (hexanes/EtOAc, 70:30) to afford a yellow
solid (0.1475 g, 54.5%). The yellow solid was recrystallized from DCM/hexanes to
afford the pure (TLC, GC/MS) product as a yellow-orange product (0.0275 g, 10.2%):
mp 130-133 ºC; Rf = 0.24 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6): 8.75
(d, J = 5.7 Hz, 2H), 8.11 (d, J = 5.7 Hz, 2H), 7.92 (d, J = 1.7 Hz, 1H), 7.80 (s, 1H), 7.34
(m, 1H), 7.06 (d, 4H), 7.00 (t, 2H), 4.99 (s, 2H); 13C NMR : 166.5, 164.2-160.7 (dd, J =
13.6 Hz), 150.2, 141.7, 140.8-140.5 (dd, J = 8.9Hz), 140.1, 136.1, 130.2, 128.2, 126.7,
124.9, 124.7, 122.2, 110.9, 110.5-110.2 (d, J = 26.0 Hz), 103.9-102.6 (td, J = 4.8 Hz, J =
25.7 Hz), 42.1-42.0 (d, J = 6.8 Hz) ppm; MS (m/z): 382 (M+), 28 (100%); Anal. Calcd
for C21H13ClF2N2O: C, 65.89; H, 3.42; N, 7.32; Found: C, 65.64; H, 3.53; N, 7.12.

1-(3,5-difluorobenzyl)-5-chloro-3-(2,6-difluoro-benzylidene)indolin-2-one (209)
To a vial was added 1-(3,5-difluorobenzyl)-5-chloro-indolin-2-one (0.1237 g, 0.422
mmol) with 2,6-difluorobenzaldehyde (1.2 equiv, 0.556 mmol, 0.060 mL), piperidine
(0.147 equiv, 0.090 mmol, 0.008 mL) and EtOH (4 mL). The vial was placed on a hot
plate at 90˚C for 4 h while stirring. The vial was cooled to rt and placed in the freezer
overnight to induce crystallization. A gold-yellow precipitate (0.1204 g, 68.4%) was
collected by vacuum filtration and washed with cold EtOH: mp 165-167˚C; 1H NMR
(300 MHz, DMSO-d6)  (m, 1H), 7.61 (s, 1H), 7.39 (m, 2H), 7.35 (d, J = 8.2 Hz,
1H), 7.07 (d, J = 8.2 Hz, 2H), 7.15 (m, 3H), 7.01 (d, J = 10.2 Hz, 1H), 6.90 (d, J = 1.4
Hz, 1H), 5.02 (s, 2H); 13C NMR : 166.1, 164.2-160.7 (dd, J = 13.0 Hz), 161.2-157.8 (dd,
J = 6.8 Hz), 141.8, 140.8-140.5 (t, J = 8.9 Hz), 140.2, 132.9-132.6 (t, J = 10.3 Hz), 130.2129.7 (d, J = 38.7 Hz), 126.7-126.4 (d, J = 25.0 Hz), 123.1-122.6 (d, J = 31.7 Hz), 121.7,
121.3, 112.4-112.1 (d, J = 6.5 Hz), 111.7-111.1 (t, J = 19.5 Hz), 110.8, 110.6-110.3 (d, J
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= 10.1 Hz), 103.4-102.7 (t, J = 25.6 Hz), 42.2 ppm: Rf = 0.80 (EtOAc/hexanes, 1:1); MS
(m/z) 417 (M+), 28 (100%); Anal. Calcd for C22H12ClF4NO: C, 63.25; H, 2.90; N, 3.35;
Found: C, 63.17; H, 3.01; N, 3.35.

1-(4-Methoxy-benzyl)-5-fluoro-3-(pyridin-2-ylmethylene)-indolin-2-one (213)
To a vial was added 1-(4-methoxy-benzyl)-5-fluoro-indolin-2-one (0.1488 g, 0.549
mmol) with 2-pyridinecarboxaldehyde (1.2 equiv, 0.652 mmol, 0.062 mL), piperidine
(0.147 equiv, 0.090 mmol, 0.008 mL) and EtOH (4 mL). The vial was placed on a hot
plate at 90˚C for 4 h while stirring. The vial was cooled to rt and placed in the freezer
overnight to induce crystallization. A brown-green precipitate (0.1476 g, 74.7%) was
collected by vacuum filtration and washed with cold EtOH: mp 139-140˚C; 1H NMR
(300 MHz, DMSO-d6)  9.04 (dd, J = 2.7 Hz, J = 10.1 Hz, 1H), 8.93 (d, J = 4.4 Hz, 1H),
8.02-7.94 (m, 2H), 7.79 (s, 1H), 7.53-7.48 (m, 1H), 7.30-7.27 (d, J = 8.7 Hz, 2H), 7.19
(ddd, J = 2.5 Hz, J = 8.6 Hz, 1H), 6.98 (dd, J = 4.5 Hz, J = 8.6 Hz, 1H), 6.90 (dd, J =2.5
Hz, J = 8.7 Hz, 2H), 4.92 (s, 2H), 3.70 (s, 3H); 13C NMR : 167.9, 159.3-156.1 (d, J =
234 Hz), 158.5, 152.6, 149.7, 139.9, 137.3, 136.1, 129.2, 128.6, 128.1, 127.6, 124.6,
122.2-122.0 (d, J = 10.0 Hz), 116.8-116.5 (d, J = 23.9 Hz), 115.2-114.8 (d, J = 27.9 Hz),
114.0, 109.6-109.5 (d, J = 8.2 Hz), 55.0, 42.3 ppm: Rf = 0.41 (EtOAc/hexanes, 1:1); LCMS (m/z): 361 (M+1); Anal. Calcd for C22H17FN2O2: C, 73.32; H, 4.80; N, 7.60; Found:
C,73.22; H, 4.80; N, 7.60.
1-(4-Methoxy-benzyl)-5-fluoro-3-(pyridin-4-ylmethylene)-indolin-2-one (214)
To a vial was added 1-(4-methoxy-benzyl)-5-fluoro-indolin-2-one (0.1562 g, 0.576
mmol) with 4-pyridinecarboxaldehyde (1.2 equiv, 0.689 mmol, 0.065 mL), piperidine
(0.147 equiv, 0.090 mmol, 0.009 mL) and EtOH (4 mL). The vial was placed on a hot
plate at 90˚C for 4 h while stirring. The vial was cooled to rt and placed in the freezer
overnight to induce crystallization. A yellow precipitate (0.1370 g, 66.1%) was collected
by vacuum filtration and washed with cold EtOH: mp 135-139˚C; Rf = 0.41
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6)  8.76 (dd, J = 1.4 Hz, J = 4.5
Hz, 2H), 8.13 (d, J = 4.7 Hz, 1H), 7.80 (s, 1H), 7.31 (d, J = 8.7 Hz, 2H), 7.19 (ddd, J =
2.5 Hz, J = 8.6 Hz, 1H), 6.98 (dd, J = 4.5 Hz, J = 8.6 Hz, 2H), 6.91 (d, J = 8.6 Hz, 1H),
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4.90 (s, 2H), 3.71 (s, 3H); 13C NMR : 166.6, 159.1-156.0 (d, J = 235 Hz), 158.6, 150.3,
141.7, 139.7 (d, J = 1.5 Hz), 135.7, 128.8, 128.6, 128.0, 124.7, 120.8-120.7, 117.1-116.8
(d, J = 23.9 Hz), 114.0 (d, J = 2.3 Hz), 110.6-110.5 (d, J = 8.2 Hz), 108.3-108.0 (d, J =
25.6 Hz), 55.0, 42.2 ppm; LC-MS (m/z): 361 (M+1);
1-(4-Methoxy-benzyl)-5-fluoro-3-(4-dimethylamino-benzylidene)indolin-2-one (215)
To a vial was added 1-(4-methoxy-benzyl)-5-fluoro-indolin-2-one (0.1301 g, 0.480
mmol) with 4-dimethylaminobenzaldehyde (1.2 equiv, 0.576 mmol, 0.0861 g), piperidine
(0.1 equiv, 0.061 mmol, 0.006 mL) and EtOH (4 mL). The vial was placed on a hot plate
at 90˚C for 4 h while stirring. The vial was placed in the freezer overnight but
crystallization did not occur. The solution was evaporated under reduced pressure and
purified with silica gel (hexanes/EtOAc, 70:30) to afford an orange oil (0.1398 g, 72.4%).
The orange oil was recrystallized from DCM/hexanes to afford the pure (TLC, GC/MS)
product as a orange product (0.0306 g, 15.8%):mp 140-143˚C; Rf =0.76 (EtOAc/hexanes,
1:1); 1H NMR (300 MHz, Acetone-d6) 8.63 (d, J = 9.0 Hz, 2H), 7.75 (s, 1H), 7.48 (d, J
= 8.9 Hz, 1H), 7.35 (d, J = 4.5 Hz, 3H), 7.19 (ddd, J = 2.5 Hz, J = 8.6 Hz, 1H), 6.98 (dd,
J = 4.5 Hz, J = 8.6 Hz, 2H), 6.91 (d, J = 8.6 Hz, 1H), 4.98 (s, 2H), 3.71 (s, 3H), 3.12 (s,
6H); 13C NMR (300 MHz, DMSO-d6) : 167.0, 160.0-156.8 (d, J =235 Hz), 153.4, 140.8,
137.3-137.2 (d, J =1.4 Hz), 136.4, 130.0, 129.7, 129.6 (d, J =2.1 Hz ), 123.2, 119.8-119.7
(d, J =2.9 Hz), 118.1, 114.8 (d, J =3.4 Hz), 113.5-113.2 (d, J =24.0 Hz), 112.4-111.9 (d, J
=36.1 Hz),109.8-109.7 (d, J =8.3 Hz), 106.4-106.0 (d, J =25.5 Hz), 55.4, 42.4, 40.0 ppm;
LC-MS (m/z) 403 (M+1).

1-(4-Methoxy-benzyl)-5-chloro-3-(pyridin-2-ylmethylene)-indolin-2-one (216)
To a vial was added 1-(4-methoxy-benzyl)-5-chloro-indolin-2-one (0.1741 g, 0.607
mmol) with 2-pyridinecarboxaldehyde (1.2 equiv, 0.728 mmol, 0.070 mL), piperidine
(0.147 equiv, 0.090 mmol, 0.008 mL) and EtOH (4 mL). The vial was placed on a hot
plate at 90˚C for 5 h while stirring. The vial was cooled to rt and placed in the freezer
overnight to induce crystallization. A brown/green precipitate (0.2281 g, 99.7%) was
collected by vacuum filtration and washed with cold EtOH: mp 152-155˚C; 1H NMR
(300 MHz, DMSO-d6)  9.20 (d, J = 2.0 Hz, 1H), 8.90 (d, J = 4.4 Hz, 1H), 8.02 (d, J =
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7.8 Hz, 1H), 7.78 (s, 1H), 7.55-7.48 (m, 1H), 7.37 (d, J = 8.3 Hz, 1H), 7.29 (d, J =8.6 Hz,
2H), 6.99 (d, J = 8.3 Hz, 1H), 6.90 (dd, J = 1.9 Hz, J = 6.7 Hz, 1H), 4.92 (s, 2H); 13C
NMR : 167.7, 158.6, 152.5, 149.6, 142.3, 137.5, 136.3, 129.9, 129.3, 128.6, 128.0,
127.5, 127.0, 125.9, 124.7, 122.5, 114.0, 110.3, 55.0, 42.3 ppm: Rf = 0.60
(EtOAc/hexanes, 1:1); LC-MS (m/z): 377 (M+); Anal. Calcd for C22H17ClN2O2: C, 70.12;
H, 4.55; N, 7.43; Found: C, 70.06; H, 4.56; N, 7.46.
1-(4-methoxy-benzyl)-5-chloro-3-(2,6-difluoro-benzylidene)indolin-2-one (217)
To a vial was added 1-(4-methoxy-benzyl)-5-chloro-indolin-2-one (0.1858 g, 0.647
mmol) with 2,6-difluorobenzaldehyde (1.2 equiv, 0.768 mmol, 0.084 mL), piperidine
(0.147 equiv, 0.101 mmol, 0.010 mL) and EtOH (4 mL). The vial was placed on a hot
plate at 90˚C for 5 h while stirring. The vial was cooled to rt and placed in the freezer
overnight to induce crystallization. A yellow precipitate (0.2006 g, 75.4%) was collected
by vacuum filtration and washed with cold EtOH: mp 159-162˚C; 1H NMR (300 MHz,
DMSO-d6)  8.00 (d, J = 2.0 Hz, 1H), 7.69-7.64 (m, 1H), 7.61 (s, 1H), 7.38-7.32 (m,
3H), 7.31 (d, J = 8.7 Hz, 2H), 7.07 (d, J = 8.4 Hz, 1H), 6.91 (d, J = 8.7 Hz, 2H), 4.91 (s,
2H), 3.71 (s, 3H); 13C NMR : 165.9, 161.2-157.8 (dd, J = 6.9 Hz), 158.6 (d, J = 5.2 Hz),
142.0, 140.6, 132.9-132.6 (t, J = 10.3 Hz), 130.2-129.6 (d, J = 43.7 Hz), 128.7-128.6 (d, J
= 7.4 Hz), 127.8, 126.4-126.1 (d, J = 21.5 Hz), 129.9, 122.8-122.5 (d, J = 24.7 Hz),
F121.6, 121.2, 114.1-114.0 (d, J = 5.0 Hz), 112.4-112.1 (d, J = 6.7 Hz), 111.4-110.6 (d, J
= 29.6 Hz) 55.0, 42.3 ppm: Rf =0.68 (EtOAc/hexanes, 1:1); MS (m/z) 411 (M+), 121
(100%); Anal. Calcd for C23H16ClF2NO2: C, 67.08; H, 3.92; N, 3.40; Found: C, 66.89;
H, 4.03; N, 3.15.

3-(Benzylidene)indolin-2-one (226)
To a vial was added indolin-2-one (0.6001 g, 4.51 mmol) with benzaldehyde (1.2 equiv,
5.39 mmol, 0.550 mL), piperidine (0.147 equiv, 0.657 mmol, 0.065 mL) and EtOH (4
mL). The vial was placed on a hot plate at 90˚C for 3 h while stirring. The vial was
cooled to rt and placed in the freezer overnight to induce crystallization. A goldenyellow precipitate (0.8030 g, 80.6%) was collected by vacuum filtration and washed with
cold EtOH: mp 169-172˚C (lit.139 mp. 175-176); 1H NMR (300 MHz, DMSO166
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d6)(s, 1H), 7.73 (d, J = 6.8 Hz, 2H), 7.67 (s, 1H), 7.57-7.48 (m, 4H), 7.27 (t, J =
7.6 Hz, 1H), 6.92 (d, J = 7.6 Hz, 1H), 6.88-6.83 (t, J = 7.6 Hz, 1H); 13C NMR : 168.5,
142.9, 135.7, 134.4, 130.1, 129.6, 129.2, 128.7, 127.6, 122.3, 121.0, 120.2, 110.1 ppm:
Rf = 0.40 (EtOAc/hexanes, 1:1); MS (m/z): 221 (M+), 28 (100%);

3-(4-chlorobenzylidene)indolin-2-one (227)
To a vial was added indolin-2-one (0.3192 g, 2.400 mmol) with 4-chlorobenzaldehyde
(1.2 equiv, 2.876 mmol, 0.4044 g), piperidine (0.147 equiv, 0.354 mmol, 0.035 mL) and
EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 5 h while stirring. The vial
was cooled to rt and placed in the freezer overnight to induce crystallization. An orange
precipitate (0.5084 g, 82.9%) was collected by vacuum filtration and washed with cold
EtOH: mp 186-188˚C (lit.140 mp. 188-190˚C); 1H NMR (300 MHz, DMSO-d6) : 10.64
(s, 1H), 8.42 (d, J = 8.6 Hz, 1H), 7.75 (d, 8.4 Hz, 2H), 7.60 (d, J = 2.1 Hz, 2H), 7.57 (s,
1H), 7.51 (d, J = 7.6 Hz, 1H), 7.27 (t, J = 7.7 Hz, 1H), 6.90-6.83 (m, 2H),

C NMR :
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168.4, 143.0, 134.2, 134.0, 133.3, 131.0, 130.3, 128.8, 128.1, 122.4, 121.1, 120.6, 110.1
ppm: Rf = 0.38 (EtOAc/hexanes, 1:1); MS (m/z): 255 (M+), 28 (100%);

3-(2,3- Dichlorobenzylidene)indolin-2-one (228)
To a vial was added indolin-2-one (0.3304 g, 2.484 mmol) with 2,3dichlorobenzaldehyde (1.2 equiv, 2.977 mmol, 0.5211 g), piperidine (0.147 equiv, 0.364
mmol, 0.036 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 3 h
while stirring. The vial was cooled to rt and placed in the freezer overnight to induce
crystallization. A golden-yellow precipitate (0.6071 g, 84.3%) was collected by vacuum
filtration and washed with cold EtOH: mp 205-207˚C; 1H NMR (300 MHz, DMSO-d6)
(s, 1H), 10.58 (s, 1H), 7.94 (dd, J = 0.9 Hz, J = 7.8 Hz, 1H), 7.80 (s, 1H), 7.78
(d, J = 8.0 Hz, 1.5H), 7.74 (d, J = 7.7 Hz, 1.5H), 7.67 (dd, J = 1.0 Hz, J = 8.0 Hz, 1H),
7.56 (s, 1H), 7.54 (t, J = 7.9 Hz, 1H), 7.40 (t, J = 7.9 Hz, 1H), 7.29-7.22 (m, 2H), 7.09 (d,
J = 7.5 Hz, 1H), 7.02 (t, J = 7.5 Hz, 1H), 6.90 (d, J = 7.6 Hz, 1H), 6.84 (d, J = 1.0 Hz,
1H), 6.81 (dd, J = 0.9 Hz, J = 7.6 Hz, 1H); 13C NMR : 167.1, 142.4, 135.1, 131.8,
167

[Type text]
131.2, 130.8, 130.3, 129.7, 128.7, 127.2, 123.2, 122.7, 121.0, 120.2, 109.9 ppm: Rf =
0.45 (EtOAc/hexanes, 1:1); MS (m/z): 289 (M+), 254 (100%);
3-(2-chlorobenzylidene)indolin-2-one (229)
To a vial was added indolin-2-one (0.4797 g, 3.60 mmol) with 2-chlorobenzaldehyde (1.2
equiv, 4.31 mmol, 0.486 mL), piperidine (0.147 equiv, 0.526 mmol, 0.052 mL) and EtOH
(4 mL). The vial was placed on a hot plate at 90˚C for 4 h while stirring. The vial was
cooled to rt and placed in the freezer overnight to induce crystallization. A goldenyellow precipitate (0.8168 g, 88.7%) was collected by vacuum filtration and washed with
cold EtOH: mp 174-176˚C; 1H NMR (300 MHz, DMSO-d6):10.69 (s, 1H), 7.79 (d, J =
7.5 Hz, 2H), 7.60 (s, 1H), 7.53-7.49 (m, 2H), 7.27 (t, J = 7.7 Hz, 1H), 7.16 (d, J = 7.5 Hz,
1H), 6.90 (d, J = 7.7 Hz, 1H), 6.84-6.79 (t, J = 7.6 Hz, 1H) ; 13C NMR : 168.0, 143.1,
132.9, 132.8, 131.4, 131.2, 130.5, 130.2, 129.7, 129.5, 127.3, 122.5, 121.2, 120.4, 110.2
ppm: Rf = 0.43 (EtOAc/hexanes, 1:1); MS (m/z): 255 (M+), 28 (100%);

3-(2,6-Dichlorobenzylidene)indolin-2-one (230)
To a vial was added oxindole (0.5524 g, 4.153 mmol) with 2,6-dichlorobenzaldehyde
(1.2 equiv, 4.15 mmol, 0.7269 g), piperidine (0.147 equiv, 0.6067 mmol, 0.060 mL) and
EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 4 h while stirring. The vial
was cooled to rt and placed in the freezer overnight to induce crystallization. A brown
precipitate was collected but was shown as impure through TLC. The filtrate was
evaporated under reduced pressure to afford a yellow oil and recrystallized from
DCM/hexanes to afford the pure (TLC, GC/MS) product (0.3512 g, 29.3%) was collected
by vacuum filtration and washed with cold hexanes; mp. 181-183˚C (lit141mp.188189˚C); Rf = 0.42 (EtOAc/hexanes, 1:1); MS (m/z): 289 (M+), 254 (100%);

3-(4-Methoxybenzylidene)indolin-2-one (231)
To a vial was added oxindole (0.8542 g, 6.422 mmol) with p-anisaldehyde (1.2 equiv,
7.79 mmol, 0.948 mL), piperidine (0.147 equiv, 0.940 mmol, 0.093 mL) and EtOH (4
mL). The vial was placed on a hot plate at 90˚C for 5 h while stirring. The vial was
cooled to rt and placed in the freezer overnight to induce crystallization. A golden yellow
precipitate (1.4619 g, 90.7%) was collected by vacuum filtration and washed with cold
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EtOH: mp 154-157˚C (lit142mp.158-159˚C); Rf = 0.21 (EtOAc/hexanes,1:1); MS (m/z):
251 (M+), 207 (100%).

3-(2,6-Difluorobenzylidene)indolin-2-one (232)
To a vial was added oxindole (0.8579 g, 6.450 mmol) with 2,6-difluorobenzaldehyde (1.2
equiv, 7.73 mmol, 0.835 mL), piperidine (0.147 equiv, 0.920 mmol, 0.091 mL) and EtOH
(4 mL). The vial was placed on a hot plate at 90˚C for 4 h while stirring. The vial was
cooled to rt and placed in the freezer overnight to induce crystallization. A golden yellow
precipitate (1.3029 g, 78.6%) was collected by vacuum filtration and washed with cold
EtOH: mp 217-220˚C (lit143mp.213-218˚C); Rf = 0.39 (EtOAc/hexanes, 1:1); MS (m/z):
257 (M+), 28 (100%).

3-(3,5-difluorobenzylidene)indolin-2-one (233)
To a vial was added indolin-2-one (0.6357 g, 4.77 mmol) with 3,5 -difluorobenzaldehyde
(1.2 equiv, 5.75 mmol, 0.630 mL), piperidine (0.147 equiv, 0.647 mmol, 0.064 mL) and
EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 4 h while stirring. The vial
was cooled to rt and placed in the freezer overnight to induce crystallization. A bright
yellow precipitate (0.6652 g, 54.2 %) was collected by vacuum filtration and washed with
cold EtOH: mp 197-199˚C (lit143 mp.202-205˚C); 1H NMR (300 MHz, DMSO-d6) δ:
10.66 (s, 1H), 7.54 (s, 1H), 7.40-7.37 (d, J = 6.9 Hz, 3H), 7.33-7.29 (dd, J = 2.2 Hz, J =
9.2 Hz, 1H), 7.26-7.21 (M, 1H), 6.88-6.85 (d, J = 8.7 Hz, 2H) 13C NMR δ: 168.1, 164.1160.6 (dd, J = 13.5 Hz), 143.3, 138.2-137.9 (t, J = 10.0 Hz), 132.7-132.6 (t, J = 2.3 Hz),
130.7, 129.4, 122.6, 121.2, 120.2, 112.3-111.9 (dd, J = 8.4 Hz), 110.2, 105.0-104.4 (t, J =
25.8 Hz) ppm: Rf = 0.5 (EtOAc/hexanes, 1:1); MS (m/z): 257 (M+,100%);
3-(3-hydroxy-4-methoxybenzylidene)-indolin-2-one (234)
To a vial was added indolin-2-one (0.3151 g, 2.369 mmol) with vanillin (1.2 equiv, 2.840
mmol, 0.4321 g), piperidine (0.147 equiv, 0.344 mmol, 0.034 mL) and EtOH (4 mL). The
vial was placed on a hot plate at 90˚C for 3 h while stirring. The vial was cooled to rt and
placed in the freezer overnight to induce crystallization. A yellow precipitate (0.5448 g,
86.0 %) was collected by vacuum filtration and washed with cold EtOH: mp 218-220˚C;
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H NMR (300 MHz, DMSO-d6) 10.54 (s, 1H), 9.86 (s, 1H), 8.72-8.71 (d, J = 1.8 Hz,

1H), 7.76-7.73 (d, J = 8.4 Hz, 1H), 7.70 (s, 1H), 7.66-7.63 (d, J = 7.4 Hz, 1H), 7.19-7.13
(dd, J = 7.6 Hz, J = 15.2 Hz, 1H), 6.99-6.93 (t, J = 7.5 Hz, 1H), 6.89-6.82 (m, 2H), 3.86
(s, 3H); 13C NMR :167.5, 149.7, 146.9, 139.9, 137.8, 127.9, 127.8, 126.1, 125.6, 122.9,
120.7, 118.8, 115.7, 115.1, 109.1, 55.4 ppm: Rf = 0.19 (EtOAc/hexanes, 1:1); LC-MS
(m/z): 268 (M+1).
5-Chloro-3-(benzylidene)-indolin-2-one (236)
To a vial was added 5-chloro-indolin-2-one (0.1886 g, 1.039 mmol) with benzaldehyde
(1.2 equiv, 1.352 mmol, 0.230 mL), piperidine (0.147 equiv, 0.162 mmol, 0.016 mL) and
EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 3 h while stirring. The vial
was cooled to rt and placed in the freezer overnight to induce crystallization. A yellow
precipitate (0.2580 g, 97.4%) was collected by vacuum filtration and washed with cold
EtOH: mp 204-205˚C (lit.126mp 210oC); 1H NMR (300 MHz, DMSO-d6) 10.77 (s, 1H),
8.43 (d, J = 7.5 Hz, 1H), 7.95 (s, 1H), 7.86 (d, J = 2.0 Hz, 1H), 7.74 (s, 1H), 7.71 (d, 7.5
Hz, 2H), 7.59 – 7.48 (m, 4H), 7.41 (d, J = 2.0 Hz, 1H), 7.30 (d, J = 8.3 Hz, 1H), 7.24 (d,
J = 2.0 Hz, 1H), 6.91 (d, J = 16.9 Hz, 1H); 13C NMR : 167.1, 140.5, 138.1, 133.8,
131.4, 129.7, 128.9, 128.2, 126.8, 125.5, 123.6, 120.7, 111.0 ppm: Rf = 0.35
(EtOAc/hexanes, 1:1); MS (m/z): 255 (M+), 28 (100%);
5-Chloro-3-(2-chlorobenzylidene)-indolin-2-one (237)
To a vial was added 5-chloro-indolin-2-one (0.2849 g, 1.569 mmol) with 2chlorobenzaldehyde (1.2 equiv, 2.042 mmol, 0.230 mL), piperidine (0.147 equiv, 0.253
mmol, 0.025 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 3 h
while stirring. The vial was cooled to rt and placed in the freezer overnight to induce
crystallization. A yellow precipitate (0.4470 g, 90.4%) was collected by vacuum
filtration and washed with cold EtOH: mp 249-250˚C; 1H NMR (300 MHz, DMSO-d6)
10.84 (s, 1H), 7.95 (s, 1H), 7.88 (d, J = 2.0 Hz, 1H), 7.79 (d, J = 6.4 Hz, 1H), 7.69 ( d,
J = 2.2 Hz, 1H), 7.67 (s, 1H), 7.59-7.50 (m, 2H), 7.32 (dd, J = 2.1 Hz, J = 8.3 Hz, 1H),
7.02 (d, J = 2.091 Hz, 1H), 6.91 (d, J = 8.3 Hz, 1H), 6.84 (d, J = 8.3 Hz, 1H); 13C NMR
: 167.6, 141.9, 133.3, 132.8, 132.5, 131.6, 130.2, 130.1, 129.9, 128.7, 127.4, 125.0,
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122.1, 122.0, 111.6 ppm: Rf = 0.49 (EtOAc/hexanes, 1:1); MS (m/z): 289 (M+), 28
(100%);
5-chloro-3-(4-chlorobenzylidene)-indolin-2-one (238)
To a vial was added 5-chloro-indolin-2-one (0.2925 g, 1.612 mmol) with 4chlorobenzaldehyde (1.2 equiv, 2.101 mmol, 0.2954 g), piperidine (0.147 equiv, 0.253
mmol, 0.025 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 3 h
while stirring. The vial was cooled to rt and placed in the freezer overnight to induce
crystallization. A yellow precipitate (0.3980 g, 78.3%) was collected by vacuum
filtration and washed with cold EtOH: mp 247-248˚C (lit.126 mp. 252-254˚C); 1H NMR
(300 MHz, DMSO-d6)  10.77 (s, 1H), 8.43 (d, J = 8.6 Hz, 1H), 7.93 (s, 1H), 7.84 (d, J
= 2.0 Hz, 1H), 7.74 (d, J = 8.4 Hz, 2H), 7.68 (s, 1H), 7.63 (d, J = 8.4 Hz, 2H), 7.56 (d, J
=8.6 Hz, 1H) 7.38 (d, J = 1.9 Hz, 1H), 7.31 (dd, J =2.0 Hz, J = 12.5 Hz, 1H), 7.28 (d, J =
12.5 Hz, 1H), 6.91 (d, J =18.5 Hz, 2H); 13C NMR :167.4, 140.6, 136.6, 134.9, 132.7,
132.4, 129.3, 128.4, 126.9, 125.8, 123.6, 120.9, 111.2 ppm; Rf = 0.44(EtOAc/hexanes,
1:1); MS (m/z): 257 (M+, 100%);
5-chloro-3-(2,3-dichlorobenzylidene)-indolin-2-one (239)
To a vial was added 5-chloro-indolin-2-one (0.3005 g, 1.654 mmol) with 2,3dichlorobenzaldehyde (1.2 equiv, 2.159 mmol, 0.3779 g), piperidine (0.147 equiv, 0.263
mmol, 0.026 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 3 h
while stirring. The vial was cooled to rt and placed in the freezer overnight to induce
crystallization. A yellow precipitate (0.4968 g, 85.2%) was collected by vacuum
filtration and washed with cold EtOH: mp 273-276˚C; 1H NMR (300 MHz, DMSO-d6)
s, 1H)dd, J = 0.9 HzJ = 8.0 Hz, 7.62 (s, 1H), 7.55-7.50 (t, J
= 7.886 Hz, ),7.30-7.26 (d, J = 8.3 Hz, 1H), 6.98 (d, J = 2.0 Hz, 1H), 6.90-6.80 (dd, J =
8.3 Hz, J = 20.4 Hz,1H) 13C NMR :167.5, 142.0, 134.9, 133.0, 132.5, 131.6, 130.8,
130.6, 129.5, 129.1, 128.5, 125.6, 122.2, 121.8, 111.7 ppm; Rf =0.47 (EtOAc/hexanes,
1:1); MS (m/z): 323 (M+), 28 (100%); Anal. Calcd for C15H8Cl3NO: C, 55.50; H, 2.48; N,
4.32 Found: C, 55.70; H, 2.60; N, 4.32.
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5-chloro-3-(4-methyl-benzylidene)-indolin-2-one (240)
To a vial was added 5-chloro-indolin-2-one (0.2876 g, 1.584 mmol) with tolualdehyde
(1.2 equiv, 2.205 mmol, 0.260 mL), piperidine (0.147 equiv, 0.253 mmol, 0.025 mL) and
EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 3 h while stirring. The vial
was cooled to rt and placed in the freezer overnight to induce crystallization. A greenyellow precipitate (0.2373 g, 51.2%) was collected by vacuum filtration and washed with
cold EtOH: 218-220˚C (lit.126 mp. 220-223˚C); 13C NMR : 168.2, 141.6, 138.8, 138.1,
133.9, 132.6, 130.6, 129.3, 126.8, 125.9, 124.8, 121.7, 111.4, 20.7 ppm: Rf = 0.41
(EtOAc/hexanes, 1:1); MS (m/z): 269 (M+), 28 (100%);
5-Chloro-3-(4-methoxybenzylidene)indolin-2-one (241)
To a solution of 5-chloroindolin-2-one (0.8840 g, 5.29 mmol) in EtOH (3 mL), was
added

-anisaldehyde (1.2 equiv, 779 µL, 6.40 mmol) and piperidine (0.1 equiv, 53 µL,

0.536 mmol). The solution was placed on a hot plate at 90˚C for 3 h while stirring after
which time was cooled to rt and placed in the freezer overnight. A yellow precipitate
(1.3347 g, 88%) was collected by vacuum filtration: mp 218-220˚C (lit.126 mp. 219220˚C); Rf = 0.24 (EtOAc/hexanes, 1:1); MS (m/z) 285 (M+, 100 %).
5-Chloro-3-(2,6-dichlorobenzylidene)indolin-2-one (242)
To a vial was added 5-chloro-indolin-2-one (0.2204 g, 1.32 mmol) with 2,6dichlorobenzaldehyde (1.2 equiv, 1.58 mmol, 0.2772 g), piperidine (0.147 equiv, 0.1921
mmol, 0.019 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 4 h
while stirring. The vial was cooled to rt and placed in the freezer overnight to induce
crystallization. A bright yellow precipitate (0.2734 g, 64.3 %) was collected by vacuum
filtration and washed with cold EtOH: mp 215-218˚C (lit.148 mp. 197-199˚C);; Rf = 0.42
(EtOAc/hexanes, 1:1); MS (m/z) 291(M+, 100%);

5-Chloro-3-(2,6-difluorobenzylidene)indolin-2-one (243)
To a vial was added 5-chloro-indolin-2-one (0.2374 g, 1.42 mmol) with 2,6difluorobenzaldehyde (1.2 equiv, 1.71 mmol, 0.1841 mL), piperidine (0.147 equiv, 0.212
mmol, 0.021 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 3 h
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while stirring. The vial was cooled to rt and placed in the freezer overnight to induce
crystallization. A bright yellow precipitate (0.3290 g, 79.5 %) was collected by vacuum
filtration and washed with cold EtOH: mp 245-246˚C(lit.126 mp. 242-244˚C); Rf = 0.39
(EtOAc/hexanes, 1:1); MS (m/z) 291 (M+,100%);

5-Chloro-3-(3,5-difluorobenzylidene)indolin-2-one (244)
To a vial was added 5-chloro-indolin-2-one (0.4754 g, 2.84 mmol) with 3,5 difluorobenzaldehyde (1.2 equiv, 3.41 mmol, 0.375 mL), piperidine (0.147 equiv, 0.414
mmol, 0.041 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 4 h
while stirring. The vial was cooled to rt and placed in the freezer overnight to induce
crystallization. A bright yellow precipitate (0.4883 g, 58.9 %) was collected by vacuum
filtration and washed with cold EtOH: mp 158-162 ˚C; 1H NMR (300 MHz, DMSO-d6) δ;
10.85 (s, 1H), 8.67 (s, 1H), 8.16 (d, J = 9.4 Hz, 1H), 7.89 (s, 1H), 7.79 (d, J = 2.0 Hz,
1H), 7.64 (s, 1H), 7.45 (d, J = 6.7 Hz, 1H), 7.40 (d, J = 2.2 Hz, 1H), 7.36 (t, J = 2.3 Hz,
1H), 7.32 -7.26 (m, 2H), 6.91 (d, J = 7.7 Hz, 1H), 6.85 (d, J = 8.2 Hz, 1H); 13C NMR δ:
167.2, 162.1, 140.9, 136.7, 137.6, 135.0, 129.6, 128.4, 125.5, 121.1, 113.3, 111.3, 105.6
ppm: Rf = 0.41 (EtOAc/hexanes, 1:1); MS (m/z): 2 peaks both: 291 (M+), 28 (100%);
C15H8ClF2NO; C, 61.77; H, 2.76; N, 4.80; Found C, 61.66; H, 2.81; N, 4.86.
5-Chloro-3-(3-(hydroxy)-4-(methoxy)-benzylidene)indolin-2-one (245)
To a vial was added 5-chloro-indolin-2-one (0.2224 g, 1.33 mmol) with vanillin (1.2
equiv, 1.29 mmol, 0.1975 g), piperidine (0.147 equiv, 0.192 mmol, 0.019 mL) and EtOH
(4 mL). The vial was placed on a hot plate at 90˚C for 4 h while stirring. The vial was
cooled to rt and placed in the freezer overnight to induce crystallization. An orange
precipitate (0.3342 g, 83.4%) was collected by vacuum filtration and washed with cold
EtOH: mp 227-231˚C; 1H NMR (300 MHz, DMSO-d6) s, 1H), 8.69 (d, J = 1.9
Hz, 1H), 7.79 (s, 1H), 7.78 (d, J = 1.9 Hz, 1H), 7.75 (d, J = 4.5 Hz, 2H), 7.62 (s, 1H),
7.33 (d, 1.9 Hz, 1H), 7.26 (dd, J = 2.1Hz, J = 8.3 Hz, 1H), 7.25 (d, J = 8.5 Hz, 1H), 7.17
(dd, J = 2.0 Hz, 8.2 Hz, 1H), 6.91 (d, J = 8.3 Hz, 2H), 6.83 (d, J = 8.3 Hz, 2H), 3.84 (d, J
= 5.3 Hz, 5H), 3.48 (q, J = 7.0 Hz, 2H) ; 13C NMR : 168.0, 152.0, 147.6, 139.4, 128.7,
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127.9, 125.6, 125.0, 124.2, 122.9, 121.3, 120.1, 118.5, 115.8, 111.5, 55.9 ppm: Rf = 0.29
(EtOAc/hexanes, 1:1); MS (m/z): 301 (M+), 28 (100%);
5-Chloro-3-(4-(hydroxy)-benzylidene)indolin-2-one (246)
To a vial was added 5-chloro-indolin-2-one (0.2004 g, 1.20 mmol) with 4hydroxybenzaldehyde (1.2 equiv, 1.44 mmol, 0.1758 g), piperidine (0.147 equiv, 0.172
mmol, 0.017 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for 4 h
while stirring. The vial was cooled to rt and placed in the freezer overnight to induce
crystallization. A yellow precipitate (0.2121 g, 65.2%) was collected by vacuum
filtration and washed with cold EtOH: mp 288-290˚C; Rf = 0.64 (EtOAc/hexanes, 1:1);1H
NMR (300 MHz, DMSO-d6) 10.67 (s, 1H), 10.31 (s, 1H), 8.45 (d, J = 8.7 Hz, 2H),
7.84 (s, 1H), 7.80 (d, J = 1.9 Hz, 1H), 7.64 (d, J = 10.7 Hz, 1H), 7.20 (dd, J = 2.0 Hz, J =
8.2 Hz, 1H), 6.89 (d, J = 8.7 Hz, 2H), 8.82 (d, J = 8.2 Hz, 1H) ; 13C NMR : 167.1,
160.5, 139.3, 136.6, 135.2 127.5, 127.1, 125.4, 125.1, 121.1, 119.0, 115.2, 110.3 ppm:
LC-MS (m/z): 272 (M+).
5-chloro-3-(4-dimethylamino-benzylidene)indolin-2-one (247)
To a vial was added 5-chloro-indolin-2-one (0.2461 g, 1.473 mmol) with 4dimethylaminobenzaldehyde (1.2 equiv, 1.768 mmol, 0.2641 g), piperidine (0.1 equiv,
0.212 mmol, 0.021 mL) and EtOH (4 mL). The vial was placed on a hot plate at 90˚C for
6 h while stirring. The vial was placed in the freezer overnight to afford an orange solid.
The orange precipitate (0.2846 g, 64.8%) was collected by vacuum filtration and washed
with cold EtOH: mp 250-253˚C (lit.151mp 257-260oC); Rf = 0.28 (EtOAc/hexanes, 1:1);
1

H NMR (300 MHz, DMSO-d6) 10.59 (s, 1H), 7.70 (d, J = 1.8 Hz, 1H), 7.63 (s, 1H),

7.60-7.59 (d, J = 3.3 Hz, 1H), 7.22-7.19 (dd, J = 1.9 Hz, J = 8.2 Hz, 1H), 6.87-6.79 (m,
3H), 3.02 (s, 2H) ; 13C NMR (300 MHz, DMSO-d6) : 169.0, 151.6, 140.6, 139.1, 132.1,
127.9, 124.6, 123.5, 120.9, 120.8, 120.5, 111.4, 110.9, 39.5 ppm; MS (m/z): 299 (M+1).

1-(2,6-Difluorobenzyl)-3-(4-methoxybenzylidene)indolin-2-one (248)
Route A
To a solution of 3-(4-methoxy-benzylidene)-indolin-2-one (0.2332 g, 0.929 mmol) in
acetonitrile (45 mL) was added 6 equiv of KF/alumina (0.8544 g, 5.59 mmol) and the
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resulting mixture was allowed to stir at rt for 5 min, the solution stayed a bright yellow
color. To the mixture 1.5 equiv. of 2,6-difluorobenzyl bromide (0.2885 g, 1.39 mmol,)
was then added to the stirred solution after which time the mixture was refluxed for 24 h.
The mixture was then allowed to cool to rt and the suspended KF/alumina was removed
by vacuum filtration. The filtrate was evaporated under reduced pressure and purified
with silica gel (hexanes/EtOAc, 70:30) to afford the desired product as a yellow solid
(0.1565 g, 44.7 %). The solid was recrystallized from DCM/hexanes to afford the pure
(TLC, GC/MS) product as bright yellow crystals (0.0638 g, 18.2%): mp 139-141 ºC; Rf =
0.68 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6) d, Jz, 1H),
s, 1H) (s, 1H), 7.72 (d, J = 6.8 Hz, 1H), 7.47-7.37 (m, 1H), 7.29 (dd, J = 0.966
Hz, J = 15.493 Hz, 1H), 7.27 (d, J = 0.8 Hz, 1H), 7.14 (t, J = 8.9 Hz, 4H), 6.95-6.90 (m,
2H), 5.05 (s, 2H), 3.85 (s, 3H); 13C NMR δ 167.0, 162.6-159.2 (dd, J = 7.9 Hz), 160.6,
142.4, 137.1, 131.6, 130.5-130.2 (t, J = 10.5 Hz), 129.5, 126.3, 124.0, 121.9, 121.6,
120.6, 114.2, 111.9-111.6 (dd, J = 7.2 Hz), 111.4, 108.4, 55.3, 31.8 ppm; MS (m/z): 377
(M+, 100 %).
Route B
To a solution of 3-(4-methoxy-benzylidene)-indolin-2-one (0.2881g, 1.15 mmol) in EtOH
(45 mL) was added DBU (2 equiv, 340 µL, 2.27 mmol) and the resulting mixture was
allowed to stir at rt for 5 min, the solution turned a golden-yellow color. To the mixture
2,6 difluorobenzyl bromide (3 equiv, 0.6912 g, 3.33 mmol,) was then added to the stirred
solution after which time the mixture was refluxed for 27 h. The mixture was then
allowed to cool to rt and evaporated under reduced pressure and purified with silica gel
(hexanes/EtOAc, 70:30) to afford the desired product as a yellow solid (0.1127 g, 68.3
%). The solid was recrystallized from DCM/hexanes to afford the pure (TLC, GC/MS)
product as bright yellow crystals (0.1286 g, 41.1%): mp 135-138ºC; Rf = 0.69
(EtOAc/hexanes, 1:1); MS (m/z): 377 (M+, 100 %).
Route C
To a solution of 3-(4-methoxy-benzylidene)-indolin-2-one (0.2091 g, 0.833 mmol) in
EtOH (3 mL) was added 2.0 equiv. of DBU (0.243 mL, 1.62 mmol) and the resulting
mixture was allowed to stir at rt for 5 min, the solution changed to an orange color. To
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the mixture 3.0 equiv. of 2,6-difluorobenzyl bromide (0.5041 g, 2.44 mmol,) was then
added to the stirred solution after which time the mixture was placed in the microwave at
180ºC for 20 min. The mixture was then allowed to cool to rt and placed in the freezer
overnight. A solid precipitate did not form so the mixture was evaporated under reduced
pressure and purified with silica gel (hexanes/EtOAc, 70:30) to afford the desired product
as a yellow oil (0.2145 g, 50.6 %). The yellow oil was recrystallized from DCM/hexanes
to afford the pure (TLC, GC/MS) product as bright yellow crystals (0.3388 g, 40.3%): mp
139-141ºC; Rf = 0.71 (EtOAc/hexanes, 1:1); MS (m/z): 377 (M+, 100 %).
1-(2,6-Dichlorobenzyl)-3-(4-methoxybenzylidene)indolin-2-one (249)
Route A
To a solution of 3-(4-methoxy-benzylidene)-indolin-2-one (0.2075 g, 0.827 mmol) in
acetonitrile (45 mL) was added 6 equiv of KF/alumina (0.7566 g, 4. 94 mmol) and the
resulting mixture was allowed to stir at rt for 5 min, the solution stayed a bright yellow
color. To the mixture 2,6 dichlorobenzyl bromide (1.5 equiv, 0.2988 g, 1.25 mmol,) was
then added to the stirred solution after which time the mixture was refluxed for 24 hr..
The mixture was then allowed to cool to rt and the suspended KF/alumina was removed
by vacuum filtration. The filtrate was evaporated under reduced pressure and purified
with silica gel (hexanes/EtOAc, 70:30) to afford the desired product as a yellow solid
(0.2137 g, 63.2 %). The solid was recrystallized from DCM/hexanes to afford the pure
(TLC, GC/MS) product as bright yellow crystals (0.0942 g, 27.9%): mp:135-138ºC; Rf =
0.64 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6) 8.49 (d, J = 8.9 Hz, 1H),
7.84 (s, 1H), 7.74 (s, 1H), 7.72 (d, J = 7.5 Hz, 3H), 7.52 (d, J = 7.5 Hz, 1H) 7.41-7.35 (m,
1H), 7.23 (dd, J = 1.0 Hz, 15.5 Hz, 1H), 7.20 (d, J = 0.954 Hz, 1H), 7.11 (d, J =8.7 Hz,
2H), 6.93 (d, J = 0.8 Hz, 1H), 6.90 (dd, J =0.9 Hz, J = 15.2 Hz, 1H), 6.77 (dd, J = 7.7
Hz, J = 12.7 Hz, 1H) 5.20 (s, 1H), 3.85 (s, 1H) ; 13C NMR : 167.2, 160.6, 142.6, 137.1,
135.3, 131.6, 130.6, 130.4, 129.4, 129.0, 126.3, 123.9, 121.8, 121.5, 120.7, 114.2, 108.8,
55.3, 39.8 ppm; MS (m/z) 410 (M+, 100 %). Anal. Calcd for C23H17Cl2NO2: C, 67.33; H
,4.18 ; N, 3.41 Found: C, 66.97; H, 4.21; N, 3.46.
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Route B
To a solution of 3-(4-methoxy-benzylidene)-indolin-2-one (0.2881g, 1.15 mmol) in EtOH
(45 mL) was added DBU (2 equiv, 340 µL, 2.27 mmol) and the resulting mixture was
allowed to stir at rt for 5 min, the solution turned a golden-yellow color. To the mixture
2,6 difluorobenzyl bromide (3 equiv, 0.6912 g, 3.33 mmol,) was then added to the stirred
solution after which time the mixture was refluxed for 27 h. The mixture was then
allowed to cool to rt and evaporated under reduced pressure and purified with silica gel
(hexanes/EtOAc, 70:30) to afford the desired product as a yellow solid (0.1127 g, 68.3
%). The solid was recrystallized from DCM/hexanes to afford the pure (TLC, GC/MS)
product as bright yellow crystals (0.1286 g, 41.1%): mp 140-142ºC; Rf = 0.66
(EtOAc/hexanes, 1:1); MS (m/z): 410 (M+, 100 %).
Route C
1-(2,6-Dichlorobenzyl)-3-(4-methoxybenzylidene)indolin-2-one (KJK-4-135)
To a solution of 3-(4-methoxybenzylidene)indolin-2-one (0.4694 g, 0.929 mmol) in
EtOH (3 mL) was added 1.7 equiv. of DBU (0.475 mL, 3.17 mmol) and the resulting
mixture was allowed to stir at rt for 5 min, the solution changed to an orange color. To
the mixture 2.2 equiv. of 2,6-dichlorobenzyl bromide (0.9758 g, 4.08 mmol,) was then
added to the stirred solution after which time the mixture was placed in the microwave at
130ºC for 40 min. The mixture was then allowed to cool to rt and placed in the freezer
overnight. A pure solid precipitate did not form so the mixture was evaporated under
reduced pressure to afford a yellow oil and purified with silica gel (hexanes/EtOAc,
70:30) to afford the desired product as a yellow oil (0.3322 g, 43.3 %). The yellow oil
was recrystallized from DCM/hexanes to afford the pure (TLC, GC/MS) product as
bright yellow crystals (0.1914 g, 24.9%): mp 147-149 ºC; Rf = 0.69 (EtOAc/hexanes,
1:1); 1H NMR (300 MHz, DMSO-d6) 8.49 (d, J = 8.9 Hz, 1H), 7.83 (s, 1H), 7.74-7.68
(m, 4H), 7.52 (dd, J = 1.0 Hz, J = 2.5 Hz, 2H), 7.49 (d, J = 2.5 Hz, 1H), 7.40 (dd, J = 1.7
Hz, J = 2.8 Hz, 1H), 7.22 (t, J = 7.7 Hz, 1H), 7.18 (t, J = 7.6 Hz, 1H), 7.10 (d, J = 8.7 Hz,
2H), 7.06 (d, J = 8.9 Hz, 1H), 7.02 (t, J = 7.6 Hz, 1H), 6.92 (t, J = 7.6 Hz, 1H), 6.76 (dd,
J = 7.7 Hz, J = 12.7 Hz, 1H), 5.75 (s, 1H), 5.21 (d, J = 2.9 Hz, 2H), 3.84 (s, 3H)
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NMR : 166.2, 160.9, 141.4, 137.5, 135.3, 133.0, 130.7, 130.3, 129.2, 128.0, 126.5,
124.2, 121.6, 121.4, 120.2, 113.7, 108.5, 55.3, 38.9 ppm; MS m/z 410 (M+, 100 %).
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1-(2,6-Dichlorobenzyl)-3-(2,6-difluorobenzylidene)indolin-2-one (250)
Route A
To a solution of 3-(2,6-difluorobenzylidene)indolin-2-one (0.2853 g, 1.11 mmol) in
acetonitrile (45 mL) was added 6 equiv of KF/alumina (1.0869 g, 7.11mmol) and the
resulting mixture was allowed to stir at rt for 5 min, the solution stayed a bright yellow
color. To the mixture 2,6 dichlorobenzyl bromide (1.5 equiv, 0.8162 g, 3.34 mmol,) was
then added to the stirred solution after which time the mixture was refluxed for 24 hr..
The mixture was then allowed to cool to rt and the suspended KF/alumina was removed
by vacuum filtration. The filtrate was evaporated under reduced pressure and purified
with silica gel (hexanes/EtOAc, 70:30) to afford the desired product as a yellow solid
(0.2736 g, 59.2 %). The solid was recrystallized from DCM/hexanes to afford the pure
(TLC, GC/MS) product as bright yellow crystals (0.2644 g, 57.3%): mp:137-139ºC; Rf =
0.67 (EtOAc/hexanes, 1:1); MS (m/z) 415 (M+, 100 %).
Route B
To a solution of 3-(2,6-difluorobenzyl)-indolin-2-one (0.4487 g, 1.75 mmol) in EtOH (45
mL) was added DBU (1.1 equiv, 290 µL, 1.94 mmol) and the resulting mixture was
allowed to stir at rt for 5 min, the solution turned a golden-yellow color. To the mixture
2,6 dichlorobenzyl bromide (1.5 equiv, 0.6283 g, 2.62 mmol,) was then added to the
stirred solution after which time the mixture was refluxed for 28 h. The mixture was then
allowed to cool to rt and evaporated under reduced pressure and purified with silica gel
(hexanes/EtOAc, 70:30) to afford the desired product as a yellow solid (0.4056 g, 61.8
%). The solid was recrystallized from DCM/hexanes to afford the pure (TLC, GC/MS)
product as bright yellow crystals (0.0942 g, 14.4%): mp 135-138ºC; Rf = 0.69
(EtOAc/hexanes, 1:1); MS (m/z) 415 (M+, 100 %).
Route C
To a solution of 3-(2,6-difluorobenzylidene)indolin-2-one (0.5202 g, 2.025 mmol) in
EtOH (3 mL) was added 2.0 equiv. of DBU (0.605 mL, 4.05 mmol) and the resulting
mixture was allowed to stir at rt for 5 min, the solution changed to an orange color. To
the mixture 3.0 equiv. of 2,6-dichlorobenzyl bromide (1.4569 g, 6.07 mmol,) was then
added to the stirred solution after which time the mixture was placed in the microwave at
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125ºC for 30 min. The mixture was then allowed to cool to rt and placed in the freezer
overnight. A solid precipitate did not form so the mixture was evaporated under reduced
pressure and purified with silica gel (hexanes/EtOAc, 70:30) to afford the desired product
as a yellow oil (0.4255 g, 50.6 %). The yellow oil was recrystallized from DCM/hexanes
to afford the pure (TLC, GC/MS) product as bright yellow crystals (0.3388 g, 40.3%): mp
139-141ºC; Rf = 0.48 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6) 7.68 –
7.58 (m, 1H), 7.42 (dd, J = 7.2 Hz, J = 8.9 Hz, 2H), 7.33 (t, J = 8.2 Hz, 2H), 7.26 (d, J =
7.9 Hz, 1H), 6.97 (d, J = 7.7 Hz, 1H), 6.93 (t, J = 7.3 Hz, 1H) 5.21 (s, 2H) ; 13C NMR :
165.8, 161.2-157.8 (dd, J = 6.8 Hz), 143.2, 135.3, 132.2-132.0 (t, J = 10.6 Hz), 130.7,
130.6, 130.5, 130.3, 129.0, 122.9, 122.0, 120.8 (t, J = 1.8 Hz), 120.2, 112.3-112.0 (dd, J
= 6.9 Hz), 111.8, 109.1, 39.9 ppm; MS (m/z) 415 (M+, 100 %). Anal. Calcd for
C22H13F2Cl2NO2: C, 63.48; H, 3.15; N, 3.36 Found: C, 63.45; H, 3.20; N, 3.37
5-Chloro-1-(2,6-difluorobenzyl)-3-(4-methoxybenzylidene)indolin-2-one (251)
Route A
To a solution of 5-chloro-3-(4-methoxy-benzylidene)indolin-2-one (0.4038 g, 1.42
mmol) in acetonitrile (45 mL) was added 6 equiv of KF/alumina (1.294 g, 8.47 mmol)
and the resulting mixture was allowed to stir at rt for 5 min, the solution stayed a bright
yellow color. To the mixture 1.5 equiv. of 2,6 difluorobenzyl bromide (0.4389 g, 1.25
mmol,) was then added to the stirred solution after which time the mixture was refluxed
for 24 h.. The mixture was then allowed to cool to rt and the suspended KF/alumina was
removed by vacuum filtration. The filtrate was evaporated under reduced pressure and
purified with silica gel (hexanes/EtOAc, 70:30) to afford the desired product as a yellow
solid (0.4468 g, 76.7 %). The yellow solid was recrystallized from DCM/hexanes to
afford the pure (TLC, GC/MS) product as bright yellow crystals (0.3479 g, 59.7%): mp
167-170 ºC; Rf = 0.69 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz DMSO-d6) δ: 8.52 (d, J
= 8.9 Hz, 1H), 7.97 (s, 1H), 7.89 (d, J = 2.0,1H), 7.78 (s, 1H), 7.74 (d, J = 8.5 Hz, 1H),
7.61 (d, J = 2.1 Hz, 1H), 7.45-7.38 (m, 1H), 7.37 (d, J = 8.4 Hz, 1H), 7.30 (dd, J = 2.1 J
= 8.3 Hz, 1H), 7.14-7.06 (m, 4H), 6.98 (d, J = 8.3 Hz, 1H), 5.75 (s, 1H), 5.05 (s, 2H),
3.86 (d, J = 1.3 Hz, 3H);
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C NMR (DMSO-d6) δ: 166.7, 161.8, 161.0, 141.2, 139.6,

134.9, 130.5-130.2 (t, J = 10.6 Hz), 129.0, 126.6, 126.0, 125.6, 123.1, 121.3, 121.0,
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114.4, 111.9-111.6 (dd, J = 4.0 Hz), 109.9, 55.4, 32.0 ppm: MS (m/z) 411 (M+), 28 (100
%). Anal. Calcd for C23H16ClF2NO2: C, 67.08; H, 3.92; N, 3.40 Found: C, 66.85; H, 3.92;
N, 3.41
Route B
To a solution of 5-chloro-3-(4-methoxy-benzylidene)indolin-2-one (0.2413 g, 0.847
mmol) in EtOH (45 mL) was added DBU (2.0 equiv, 260 µL, 1.74 mmol) and the
resulting mixture was allowed to stir at rt for 5 min, the solution turned a golden-yellow
color. To the mixture 2, 6 dichlorobenzyl bromide (3.0 equiv, 0.5312 g, 2.57 mmol,) was
then added to the stirred solution after which time the mixture was refluxed for 24 h. The
mixture was then allowed to cool to rt and evaporated under reduced pressure and
purified with silica gel (hexanes/EtOAc, 70:30) to afford the desired product as a yellow
solid (0.1675 g, 48.1 %). The solid was recrystallized from DCM/hexanes to afford the
pure (TLC, GC/MS) product as bright yellow crystals (0.0801g, 23.8%): mp 162-165 ºC;
Rf = 0.65 (EtOAc/hexanes, 1:1); MS (m/z): 411 (M+), 28 (100 %).
Route C
To a solution of 5-chloro-3-(4-methoxy-benzylidene)indolin-2-one (0.1899 g, 0.666
mmol) in EtOH (3 mL) was added DBU (2.0 equiv, 260 µL, 1.74 mmol) and the
resulting mixture was allowed to stir at rt for 5 min, the solution turned a golden-yellow
color. To the mixture 2, 6 dichlorobenzyl bromide (3.0 equiv, 0.4731 g, 1.97 mmol,) was
then added to the stirred solution after which time the mixture was placed in the
microwave at 180ºC for 20 min. The mixture was then allowed to cool to rt and placed in
the freezer overnight. A solid precipitate did not form so the mixture was evaporated
under reduced pressure and purified with silica gel (hexanes/EtOAc, 70:30) to afford the
desired product as a yellow oil (0.2849 g, 72.6 %). The yellow oil was recrystallized
from DCM/hexanes to afford the pure (TLC, GC/MS) product as bright yellow crystals
(0.0743g, 18.9%): mp 160-165 ºC; Rf = 0.62 (EtOAc/hexanes, 1:1); MS (m/z): 411 (M+),
28 (100 %).
5-Chloro-1-(2,6-dichlorobenzyl)-3-(4-methoxybenzylidene)indolin-2-one (252)
Route B
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To a solution of 5-chloro-3-(4-methoxy-benzylidene)indolin-2-one (0.2564 g, 0.900
mmol) in EtOH (45 mL) was added 2.2 equiv of DBU (295 µL, 1.97 mmol) and the
resulting mixture was allowed to stir at rt for 5 min, the solution turned a orange color.
To the mixture 2.2 equiv. of 2,6-dichlorobenzyl bromide (0.5792 g, 2.41 mmol,) was then
added to the stirred solution after which time the mixture was refluxed for 24 h. The
mixture was then allowed to cool to rt and evaporated under reduced pressure and
purified with silica gel (hexanes/EtOAc, 70:30) to afford the desired product as a yellow
solid (0.2016 g, 50.6 %). The solid was recrystallized from DCM/hexanes to afford the
pure (TLC, GC/MS) product as bright yellow crystals (0.1083 g, 27.2%): mp (214-216
ºC); Rf = 0.71 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6): 8.50 (d, J = 8.9
Hz, 1H), 7.97 (s, 1H), 7.88 (d, J = 2.0 Hz, 1H), 7.75 (s, 1H), 7.74 (d, J = 8.7 Hz, 1H),
7.62 (d, J = 2.1 Hz, 1H), 7.53 (dd, J = 1.0 Hz, J = 2.6 Hz, 1H), 7.50 (d, J = 2.6 Hz, 1H),
7.41 (d, J = 8.9 Hz, 1H), 7.39 (dd, J = 3.1 Hz, J = 8.9 Hz, 1H), 7.31 (dd, J = 2.1 Hz, J =
8.4 Hz, 1H), 7.24 (d, J = 8.4 Hz, 1H), 7.13 (d, J = 15.8 Hz, 2H), 6.80 (d, J = 15.8 Hz,
1H), 5.21 (d, J = 3.8 Hz, 2H), 3.86 (d, J = 2.4 Hz, 3H)
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C (300 MHz, DMSO-d6): δ

165.9, 161.4, 141.3, 139.2, 138.9, 135.3, 134.8, 130.4, 128.9, 127.3, 126.5, 125.7, 122.6,
120.9, 120.2, 114.1, 109.9, 55.4, 38.6 ppm; LC-MS (m/z) 444 (M+). Anal. Calcd for
C23H16Cl3NO2: C, 62.11; H, 3.63 ; N, 3.15 Found: C, 62.21; H, 3.86; N, 3.06. Exact
Mass: 443.02
Route C
To a solution of 5-chloro-3-(4-methoxybenzylidene)indolin-2-one (0.1899 g, 0.666
mmol) in EtOH (3 mL) was added 2.0 equiv of DBU (200 µL, 1.34 mmol) and the
resulting mixture was allowed to stir at rt for 5 min, the solution turned an orange color.
To the mixture 3.0 equiv. of 2,6 dichlorobenzyl bromide (0.4731 g, 1.97 mmol,) was then
added to the stirred solution after which time the mixture was placed in the microwave at
180ºC for 20 min and placed in the freezer overnight. A solid precipitate did not form so
the mixture was evaporated under reduced pressure and purified with silica gel
(hexanes/EtOAc, 70:30) to afford the desired product as a yellow oil (0.2849 g, 73 %).
The yellow oil was recrystallized from DCM/hexanes to afford the pure (TLC, GC/MS)
product as bright yellow crystals (0.0743 g, 18.9 %): mp 215-217 ºC; Rf = 0.43
(EtOAc/hexanes, 1:1); MS (m/z): 417 (M+, 100 %).
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5-Chloro-1-(2,6-difluorobenzyl)-3-(2,6-difluorobenzylidene)indolin-2-one (254)
Route A
To a solution of 5-chloro-3-(2,6-diflouro-benzylidene)indolin-2-one (0.2883 g, 0.991
mmol) in EtOH (45 mL) was added 2.2 equiv of DBU (320 µL, 2.14 mmol) and the
resulting mixture was allowed to stir at rt for 5 min, the solution turned an orange color.
To the mixture 2.2 equiv. of 2,6 difluorobenzyl bromide (0.4497 g, 2.17 mmol,) was then
added to the stirred solution after which time the mixture was refluxed for 24 hr.. The
mixture was then allowed to cool to rt and evaporated under reduced pressure and
purified with silica gel (hexanes/EtOAc, 70:30) to afford the desired product as a yellow
oil (0.1693 g, 40.9 %). The yellow oil was recrystallized from DCM/hexanes to afford
the pure (TLC, GC/MS) product as bright yellow crystals (0.0738 g, 17.9 %): mp 163166 ºC; Rf = 0.47 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz DMSO-d6) 7.73 –7.65 (m,
2H), 7.57 (s, 1H), 7.50-7.33 (m, 5H), 7.26 (d, J = 7.9 Hz, 1H), 7.16 (t, J = 7.9 Hz, 2H),
7.02 (d, J = 8.4 Hz, 1H) 6.89 (s, 1H), 5.08 (s, 2H); 13C NMR : 165.4, 162.6-159.2 (dd, J
= 7.8 Hz), 161.2-157.8 (dd, J = 6.7 Hz), 141.9, 132.9-132.6 (t, J = 10.8 Hz), 130.7-130.4
(t, J = 10.8 Hz), 130.3, 129.6, 126.1, 122.8, 122.5, 121.6, 112.4-112.1 (d, J = 24.1 Hz),
112.0-111.6 (dd, J = 7.4 Hz), 111.4, 111.1, 110.2, 32.2-32.1 (t, J = 2.6 Hz) ppm; MS
(m/z): 417 (M+, 100 %). Anal. Calcd for C22H12ClF4NO: C, 63.25; H, 2.90; N, 3.35
Found: C, 62.83; H, 3.02; N, 3.36
Route B
To a solution of 5-chloro-3-(2,6-diflouro-benzylidene)indolin-2-one (0.1944 g, 0.668
mmol) in EtOH (3 mL) was added 2.0 equiv of DBU (204µL, 1.34 mmol) and the
resulting mixture was allowed to stir at rt for 5 min, the solution turned an orange color.
To the mixture 3.0 equiv. of 2,6 difluorobenzyl bromide (0.4238 g, 2.00 mmol,) was then
added to the stirred solution after which time the mixture was placed in the microwave at
180ºC for 20 min and placed in the freezer overnight. A solid precipitate did not form so
the mixture was evaporated under reduced pressure and purified with silica gel
(hexanes/EtOAc, 70:30) to afford the desired product as a yellow oil (0.0825 g, 40.9 %).
The yellow oil was recrystallized from DCM/hexanes to afford the pure (TLC, GC/MS)
product as bright yellow crystals (0.0452 g, 17.9 %): mp 169-171 ºC; Rf = 0.43
(EtOAc/hexanes, 1:1); MS (m/z): 417 (M+, 100 %).
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Route C
To a solution of 5-chloro-3-(2,6-diflouro-benzylidene)indolin-2-one (0.2399 g, 0.824
mmol) in acetonitrile (45 mL) was added 6 equiv of KF/alumina (0.7657 g, 5.00 mmol)
and the resulting mixture was allowed to stir at rt for 5 min, the solution stayed a bright
yellow color. To the mixture 3 equiv. of 2,6 difluorobenzyl bromide (0.5120 g, 2.47
mmol,) was then added to the stirred solution after which time the mixture was refluxed
for 24 h.. The mixture was then allowed to cool to rt and the suspended KF/alumina was
removed by vacuum filtration. The filtrate was evaporated under reduced pressure and
purified with silica gel (hexanes/EtOAc, 70:30) to afford the desired product as a yellow
solid (0.2249 g, 65.4 %). The yellow solid was recrystallized from DCM/hexanes to
afford the pure (TLC, GC/MS) product as bright yellow crystals (0.1253 g, 36.4%): mp
167-169 ºC; Rf = 0.45 (EtOAc/hexanes, 1:1); MS (m/z): 417 (M+, 100 %).
1-(Propargyl)-3-(benzylidene)indolin-2-one ( 254)
To a solution of 3-(benzylidene)indolin-2-one (0.3682 g, 1.666 mmol) in EtOH (3 mL)
was added 1.7 equiv of DBU (427 µL, 2.85 mmol) and the resulting mixture was allowed
to stir at rt for 5 min, the solution turned a orange color. To the mixture 3 equiv. of
propargyl bromide (460 µL, 5.02 mmol,) was then added to the stirred solution after
which time the mixture was placed in the microwave for 20 min at 180 ºC. The mixture
was then allowed to cool to rt and placed in the freezer overnight. The solution was
evaporated under reduced pressure and purified by silica gel (hexanes/EtOAc, 70:30) to
afford the desired product as yellow oil (0.1919 g, 44.5 %). The oil was dissolved in
DCM and then recrystallized from hexanes to afford the pure (TLC, GC/MS) product as
yellow/gold crystals (0.1002 g, 23.2 %): mp (121-124 ᵒC); Rf = 0.77 (EtOAc/hexanes,
1:1); 1H NMR (300 MHz, DMSO-d6): δ 8.37 (d, J = 7.4 Hz, 1H), 7.79 (d, J = 5.4 Hz,
1H), 7.77 (s, 1H), 7.59-7.46 (m, 5H), 7.38 (t, J = 7.7 Hz, 1H), 7.14 (d, J = 7.5 Hz, 1H ),
6.98 (t, J =7.6 Hz, 1H), 4.63 (d, J = 2.5 Hz, 2H);
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C (300 MHz, DMSO-d6): δ 166.4,

142.0, 137.6, 133.9, 131.9, 130.1, 129.2, 128.1, 126.1, 122.2, 122.1, 120.2, 109.5, 78.1,
74.2, 28.7 ppm; MS (m/z) 2 peaks at 259 (M+, 100 %).
1-(Propargyl)-3-(2-chloro-benzylidene)indolin-2-one (255)
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To a solution of 3-(2-chloro-benzylidene)indolin-2-one (0.3286 g, 1.285 mmol) in EtOH
(3 mL) was added 2.0 equiv of DBU (326 µL, 2.18 mmol) and the resulting mixture was
allowed to stir at rt for 5 min, the solution turned a orange color. To the mixture 3 equiv.
of propargyl bromide (360 µL, 3.93 mmol,) was then added to the stirred solution after
which time the mixture was placed in the microwave for 20 min at 180 ºC. The mixture
was then allowed to cool to rt and placed in the freezer overnight. The solution was
evaporated under reduced pressure and purified by silica gel (hexanes/EtOAc, 70:30) to
afford the desired product as yellow oil (0.1918 g, 50.8 %). The oil was recrystallized
from DCM/hexanes to afford the pure (TLC, GC/MS) product as bright yellow crystals
(0.1081g, 28.6 %): mp (174-177 ᵒC); Rf = 0.71 (EtOAc/hexanes, 1:1); ); 1H NMR (300
MHz, DMSO-d6) δ: 8.09 (d, J = 7.6 Hz, 1H), 7.95 (s, 1H), 7.80 (d, J = 6.9 Hz, 1H), 7.72
(s, 1H), 7.68 (d, J =7.3 Hz, 1H), 7.57-7.48 (m, 3H), 7.40 (t, J = 7.7 Hz, 2H), 7.20 (t, J =
8.3 Hz, 2H), 7.13 (d, J =7.6 Hz, 1H), 6.96 (dd, J =0.9 Hz, J =7.5 Hz, 1H), 5.75 (s, 1H),
4.64 (dd, J = 2.4 Hz, J = 25.9 Hz, 2H);
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C (300 MHz, DMSO-d6 ) δ: 165.8, 142.2,

132.9, 132.8, 132.4, 131.3, 130.5, 130.2, 129.8, 128.5, 127.3, 126.3, 122.3, 120.1, 109.7,
77.9, 74.3, 28.7 ppm; MS (m/z) 293(M+), 28 (100 %).
1-(Propargyl)-3-(2,3-dichlorobenzylidene)indolin-2-one (256)
To a solution of 3-(2,3-dichloro-benzylidene)indolin-2-one (0.3467 g, 1.20 mmol) in
EtOH (3 mL) was added 2.0 equiv of DBU (357 µL, 2.39 mmol) and the resulting
mixture was allowed to stir at rt for 5 min, the solution turned an orange color. To the
mixture 3 equiv. of propargyl bromide (305 µL, 3.57 mmol,) was then added to the
stirred solution after which time the mixture was placed in the microwave for 20 min at
180 ºC. The mixture was then allowed to cool to rt and placed in the freezer overnight.
The solution was evaporated under reduced pressure and purified by silica gel
(hexanes/EtOAc, 70:30) to afford the desired product as a yellow oil (0.1282 g, 32.7 %).
The oil was recrystallized from DCM/hexanes to afford the pure (TLC, GC/MS) product
as bright yellow crystals (0.0497 g, 12.7 %): mp (151-155 ᵒC); Rf = 0.68 (EtOAc/hexanes,
1:1); 1H NMR (300 MHz, DMSO-d6)  7.89 (dd, J =0.5 Hz J1.4 Hz, 1H), 7.82-7.66
(m, 2H), 7.61 (s, 1H), 7.54 (t, J =7.9 Hz, 1H), 7.41-7.35 (m, 1H), 7.17 (d, Jz, 1H),
7.13 (d, J =7.5 Hz, 1H), 6.95 (t, J =7.6 Hz, 1H), 4.63 (d, J =2.4 Hz, 2H); 13C NMR :
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165.7, 142.3, 135.1, 132.4, 132.3, 131.4, 130.7, 130.6, 128.8, 128.5, 122.6, 122.3, 120.8,
119.6, 109.7, 78.8, 74.4, 28.8 ppm: MS (m/z) 327(M+), 292(100 %). C18H11Cl2NO; C,
65.87; H, 3.38; N, 4.27; Found C, 65.76; H, 3.42; N, 4.22.
1-(Propargyl)-3-(4-chlorobenzylidene)indolin-2-one (257)
To a solution of 3-(4-chlorobenzylidene)indolin-2-one (0.3302 g, 1.29 mmol) in EtOH (3
mL) was added 2.0 equiv of DBU (397 µL, 2.65 mmol) and the resulting mixture was
allowed to stir at rt for 5 min, the solution turned an yellow color. To the mixture 3
equiv. of propargyl bromide (360 µL, 3.93 mmol,) was then added to the stirred solution
after which time the mixture was placed in the microwave for 20 min at 180 ºC. The
mixture was then allowed to cool to rt and placed in the freezer overnight. The solution
was evaporated under reduced pressure and purified by silica gel (hexanes/EtOAc, 70:30)
to afford the desired product as a yellow oil (0.1269 g, 33.5 %). The oil was
recrystallized from DCM/hexanes to afford the pure (TLC, GC/MS) product as bright
yellow crystals (0.0923 g, 24.4 %): mp (125-128 ᵒC); Rf = 0.75 (EtOAc/hexanes, 1:1); 1H
NMR (300 MHz, DMSO-d6) 8.41 (d, J = 8.6 Hz, 1H), 7.81 (d, J = 7.7 Hz, 1H), 7.71 (s,
1H), 7.61-7.51 (m, 3H), 7.25 (t, J = 7.4 Hz, 1H), 7.16 (d, J = 7.7 Hz, 1H), 7.02-6.95 (m,
1H), 6.84 (d, J = 7.6 Hz, 1H), 4.63 (d, J = 2.5 Hz, 2H); 13C NMR : 167.0, 142.1, 135.1,
135.0, 133.6, 133.5, 131.1 130.2, 128.8, 128.1, 121.0, 119.9, 109.6, 78.0, 74.2, 28.7 ppm:
MS (m/z) 293(M+), 28 (100 %). C18H12ClNO;
1-(Propargyl)-3-(4-methoxybenzylidene)indolin-2-one (258)
To a solution of 3-(4-methoxy-benzylidene)-indolin-2-one (0.3103 g, 1.236 mmol) in
EtOH (3 mL) was added 1.7 equiv of DBU (304 µL, 2.03 mmol) and the resulting
mixture was allowed to stir at rt for 5 min, the solution turned a orange color. To the
mixture 2.5 equiv. of propargyl bromide (280 µL, 3.05 mmol,) was then added to the
stirred solution after which time the mixture was placed in the microwave for 15 min at
150 ºC. The mixture was then allowed to cool to rt and placed in the freezer overnight.
The solution was evaporated under reduced pressure and purified by silica gel column
(hexanes/EtOAc, 70:30) to afford the desired product as a yellow oil (0.1815 g, 50.8 %).
The solid was recrystallized from DCM/hexanes to afford the pure (TLC, GC/MS)
product as bright yellow crystals (0.0253 g, 7.08%): mp (95-98 ᵒC); Rf =0.72
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(EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6): δ 8.50 (d, J = 8.9 Hz, 1H), 7.88
(s, 1H), 7.76 (d, J = 8.9 Hz, 4H), 7.38-7.28 (m, 2H), 7.16 (s, 1H), 7.12 (d, J = 8.7 Hz,
3H), 7.07 (d, J = 9.0 Hz, 1H), 7.02 (d, J = 0.9, 1H), 7.00 (dd, J = 0.9 Hz, J = 7.6 Hz,
1H), 5.75 (s, 1H), 4.62 (d, J = 2.3 Hz, 2H), 3.85 (s, 3H);
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C (300 MHz, DMSO-d6): δ

166.7, 160.7, 141.7, 138.1, 134.5, 129.6, 126.7, 124.3, 122.1, 121.9, 114.3, 109.4, 78.3,
74.1, 55.3, 28.6 ppm; MS m/z 289 (M+, 100 %).
1-(Propargyl)-3-(2,6-dichloro-benzylidene)indolin-2-one (259)
To a solution of 3-(4-methoxy-benzylidene)-indolin-2-one (0.3398 g, 1.236 mmol) in
EtOH (3 mL) was added 1.7 equiv of DBU (298 µL, 1.99 mmol) and the resulting
mixture was allowed to stir at rt for 5 min, the solution turned a orange color. To the
mixture 2.7 equiv. of propargyl bromide (290 µL, 3.17 mmol,) was then added to the
stirred solution after which time the mixture was placed in the microwave for 15 min at
165 ºC. The mixture was then allowed to cool to rt and placed in the freezer overnight.
The solution was evaporated under reduced pressure and purified with silica gel
(hexanes/EtOAc, 70:30) to afford the desired product as yellow oil (0.0974 g, 25.6 %).
The solid was recrystallized from DCM/hexanes to afford the pure (TLC, GC/MS)
product as bright yellow crystals (0.0882 g, 22.9%): mp (167-169 ºC); Rf = 0.64
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6): δ 7.69 (d, J = 1.0 Hz, 1H), 7.66
(s, 1H), 7.59 (s, 1H), 7.56 (d, J = 1.9 Hz, 1H), 7.53 (d, J = 0.6 Hz, 1H), 7.40 (td, J = 1.0
Hz, J = 15.5 Hz, 1H), 7.38 ( d, J = 1.010 Hz, 1H), 7.17 (d, J = 7.8 Hz, 1H), 6.95 (dd, J =
0.8 Hz, J = 15.2 Hz, 1H), 6.93 (d, J = 0.8 Hz, 1H), 6.57 (d, J = 7.3 Hz, 1H), 5.75 (s,
1H), 4.64 (d, J = 2.4Hz, 2H);
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C (300 MHz, DMSO-d6): δ 165.2, 142.1, 133.1, 132.1,

131.4, 130.8, 130.3, 129.7, 128.6, 122.6, 120.0, 109.7, 77.8, 74.5, 28.8 ppm; MS (m/z)
327(M+), 292 (100 %). Anal. Calcd for C18H11Cl2NO: C, 65.87; H, 3.38; N, 4.27; Found:
C, 65.70; H, 3.41; N, 4.32.

1-Propargyl-3-(2,6 difluoro-benzylidene)-indolin-2-one (260)
To a solution of 3-(2,6 difluoro-benzylidene)indolin-2-one (0.4410 g, 1.71 mmol) in
acetonitrile (45 mL) was added 6 equiv of KF/alumina (1.5727 g, 10.3 mmol) and the
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resulting mixture was allowed to stir at rt for 5 min, the solution stayed a bright yellow
color. Propargyl bromide 80% (235 µL, 2.57 mmol, 1.5 equiv.) was then added dropwise
to the stirred solution of the preformed anion after which time the mixture was refluxed
for 24 h. The mixture was then allowed to cool to rt and the suspended KF/alumina was
removed by vacuum filtration. The filtrate was evaporated under reduced pressure and
purified with silica gel (hexanes/EtOAc, 70:30) to afford the desired product as a yellow
solid. The solid was then recrystallized from EtOH to afford the pure (TLC, GC/MS)
product as bright yellow crystals (0.0836 g, 16.5%): mp 123-125 ˚C ; Rf = 0.54
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz DMSO-d6)  7.87 ppm (d, J = 7.95Hz, 1H),
7.74 (s, 1H), 7.69 (t, J = 15.054Hz, 1H), 7.67 (d, J = 14.9 Hz, 1H), 7.49 (s, 1H), 7.447.37 (m,1H), 7.34 (t, J = 8.2 Hz, 2H), 7.18 (d, J =14.0 Hz, 1H), 7.00 (d, J = 5.0 Hz, 2H),
4.63 (d, J = 2.5 Hz, 1H) ; 13C NMR δ: 165.3, 161.2-157.8 (dd, J = 7.0 Hz), 142.3, 132.3132.1 (t, J = 10.4 Hz), 130.8, 130.7, 123.0-122.9 (t, J = 2.2 Hz), 122.5, 121.3, 120.0,
112.3-112.0 (dd, J = 6.7 Hz), 111.7, 109.6, 77.8, 74.4, 28.8 ppm; MS (m/z) 295 (M+, 100
%). Anal. Calcd for C18H11F2NO: C, 73.22; H, 3.75; N, 4.74. Found: C, 72.96 ; H, 3.69;
N, 4.60 .
1-(Propargyl)-3-(3,5-difluoro-benzylidene)indolin-2-one (261)
To a solution of 3-(3,5-difluoro-benzylidene)indolin-2-one (0.3665 g, 1.236 mmol) in
EtOH (3 mL) was added 1.7 equiv of DBU (338 µL, 2.26 mmol) and the resulting
mixture was allowed to stir at rt for 5 min, the solution turned a orange color. To the
mixture 3 equiv. of propargyl bromide (365 µL, 3.99 mmol,) was then added to the
stirred solution after which time the mixture was placed in the microwave for 15 min at
170 ºC. The mixture was then allowed to cool to rt and placed in the freezer overnight.
The solution was evaporated under reduced pressure and purified with silica gel
(hexanes/EtOAc, 70:30) to afford the desired product as a yellow oil (0.2387 g, 56.7 %).
The solid recrystallized from DCM/hexanes to afford the pure (TLC, GC/MS) product as
bright yellow crystals (0.1002 g, 23.8%): mp (107-110 ºC); Rf = 0.77 (EtOAc/hexanes,
1:1); 1H NMR (300 MHz DMSO-d6)  8.15 (d, J = 9.5 Hz, 1H), 7.70 (s, 1H), 7.47-7.33
(m, 3H), 7.17-7.11 (m, 2H), 7.02 (td, J = 0.9 Hz, J = 7.6 Hz, 1H), 6.85 (d, J = 8.1 Hz,
1H), 4.62 (d, J = 2.4 Hz, 2H) ;
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C NMR δ: 166.0, 164.1-160.7 (dd, J = 13.4 Hz), 142.3,
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137.9-137.6 (t, J = 10.3 Hz), 134.9-134.8 (t, J = 2.2 Hz), 130.6, 128.0, 123.2, 122.5,
120.0, 112.4-112.0 (dd, J = 8.1 Hz), 109.7, 105.7-105.0 (t, J = 26.6 Hz), 77.9, 74.3, 28.7
ppm; MS (m/z) 295 (M+), 28 (100 %). Anal. Calcd for C18H11F2NO: C, 73.22; H, 3.75; N,
4.74. Found: C, 72.88; H, 4.02; N, 4.72.
1-(Propargyl)-5-chloro-3-(2-chloro-benzylidene)indolin-2-one (262)
To a solution of 5-chloro-3-(2-chloro-benzylidene)indolin-2-one (0.3875 g, 1.10 mmol)
in EtOH (3 mL) was added 2.0 equiv of DBU (330 µL, 2.21 mmol) and the resulting
mixture was allowed to stir at rt for 5 min, the solution turned an orange color. To the
mixture 3 equiv. of propargyl bromide (305 µL, 3.33 mmol,) was then added to the
stirred solution after which time the mixture was placed in the microwave for 20 min at
180 ºC. The mixture was then allowed to cool to rt and placed in the freezer overnight.
The solution was evaporated under reduced pressure and purified by silica gel
(hexanes/EtOAc, 70:30) to afford the desired product as a yellow oil (0.2182 g, 49.8 %).
The oil was recrystallized from DCM/hexanes to afford the pure (TLC, GC/MS) product
as bright yellow crystals (0.2015 g, 45.9 %): mp (106-109 ᵒC); Rf = 0.73 (EtOAc/hexanes,
1:1); 1H NMR (300 MHz, DMSO-d6) 8.08 (s, 1H), 8.06 (d, J7.7 Hz, 1H), 8.01 (d,
Jz, 1H), 7.70 (d, J=7.8 Hz, 1H), 7.61-7.51 (m, 2H), 7.48 (dd, J =2.1 Hz, J = 8.4
Hz, 1H), 7.41 (d, J =7.6 Hz, 1H), 7.21 (d, J =19.1 Hz, 1H), 7.08 (d, J = 2.0 Hz, 1H), 4.65
(dd, J = 28.2 Hz, 2H) ; 13C NMR : 165.5, 141.0, 134.9, 132.5, 131.6, 130.2, 130.0,
129.0, 127.5, 127.2, 126.7, 126.2, 121.7, 120.7, 111.2, 77.6, 74.6, 28.9 ppm: MS (m/z)
327(M+), 292(100 %). C18H11Cl2NO; C, 65.87; H, 3.38; N, 4.27; Found C, 65.76; H,
3.47; N, 4.30.
5-Chloro-1-(prop-2-yn-1-yl)-3-((4)-methoxy-benzylidene)indolin-2-one (263)
To a solution of 3-(4-methoxy-benzylidene)-5-chloro-indolin-2-one (0.5246 g, 1.83
mmol) in acetonitrile (45 mL) was added 6 equiv of KF/alumina (1.6884 g, 11.0 mmol)
and the resulting mixture was allowed to stir at rt for 5 min, the solution stayed a bright
yellow color. Propargyl bromide 80% (260 µL, 2.84 mmol, 1.5 equiv.) was then added
dropwise to the stirred solution of the preformed anion after which time the mixture was
refluxed for 49 h. The mixture was then allowed to cool to rt and the suspended
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KF/alumina was removed by vacuum filtration. The filtrate was evaporated under
reduced pressure and purified with silica gel (hexanes/EtOAc, 70:30) to afford the
desired product as a yellow solid. The solid was then recrystallized from EtOH to afford
the pure (TLC, GC/MS) product as bright yellow crystals (0.3905 g, 66%): mp 127-129
ºC; Rf = 0.54 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6): 8.85 (d, J = 8.9 Hz,
1H), 8.01 (s, 1H), 7.92 (J = 2.0 Hz, 1H), 7.80 (s, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.64 (d, J
= 2.0 Hz, 1H), 7.45 (dd, J = 2.0 Hz, J = 8.4 Hz, 1H), 7.37 (dd, J = 2.0 Hz, J = 8.3 Hz,
1H), 7.19 (d, J = 8.4 Hz, 1H), 7.15-7.06 (m, 4H), 4.63 (s, 2H), 3.86 (s, 3H)

13

C (300

MHz, DMSO-d6): δ 166.4, 161.9, 140.4, 140.0, 134.9, 129.0, 126.5-126.3 (t, J = 9.4 Hz),
126.0, 123.0, 121.3, 120.9, 114.4, 110.8, 78.0, 74.4, 55.4, 28.8 ppm; MS (m/z ) 323 (M+,
100 %).
1-(Propargyl)-5-chloro-3-(2,6-dichloro-benzylidene)indolin-2-one (264)
To a solution of 5-chloro-3-(2,6-dichloro-benzylidene)indolin-2-one (0.3568 g, 1.336
mmol) in EtOH (3 mL) was added 2.0 equiv of DBU (370 µL, 2.47 mmol) and the
resulting mixture was allowed to stir at rt for 5 min, the solution turned an orange color.
To the mixture 3 equiv. of propargyl bromide (370 µL, 4.04 mmol,) was then added to
the stirred solution after which time the mixture was placed in the microwave for 20 min
at 180 ºC. The mixture was then allowed to cool to rt and placed in the freezer overnight.
The solution was evaporated under reduced pressure and purified by silica gel
(hexanes/EtOAc, 70:30) to afford the desired product as yellow oil (0.2182 g, 74.0 %).
The oil was recrystallized from DCM/hexanes to afford the pure (TLC, GC/MS) product
as bright yellow crystals (0.2015 g, 46.8 %): mp (106-109 ᵒC); Rf = 0.73 (EtOAc/hexanes,
1:1); 1H NMR (300 MHz, DMSO-d6)  7.97 (s, 1H), 7.72 (m, 3H), 7.61 (dd, J = 0.6 Hz,
J = 7.1 Hz, 1H), 7.58 (dd, J = 0.7 Hz, J = 7.1 Hz, 1H), 7.21 (d, J = 8.4 Hz, 1H), 5.75 (s,
1H), 4.65 (d, J = 2.4 Hz, 2H) ; 13C NMR : 164.8, 140.9, 133.0, 131.8, 131.7, 131.5,
130.4, 129.4, 128.7, 126.5, 122.1, 121.5, 111.3, 76.1, 29.0 ppm: MS (m/z): 362 (M+), 326
(100 %). C18H10Cl3NO; C, 59.62; H, 2.78; N, 3.86; Found C, 60.01; H, 2.91; N, 3.90.
1-(Propargyl)-5-chloro-3-(2,6-difluoro-benzylidene)indolin-2-one (265)
To a solution of 5-chloro-3-(2,6-difluoro-benzylidene)indolin-2-one (0.3210 g, 1.110
mmol) in acetonitrile (45 mL) was added 6 equiv of KF/alumina (1.012 g, 6.62 mmol)
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and the resulting mixture was stirred at rt for 5 min., the solution stayed a bright yellow
color. Propargyl bromide 80% (303 µL, 3.311 mmol, 3 equiv) was then added dropwise
to the stirred solution of the preformed anion after which time the mixture was refluxed
for 23 h. The mixture was then allowed to cool to rt and the suspended KF/alumina was
removed by vacuum filtration. The filtrate was evaporated under reduced pressure and
purified with silica gel (hexanes/EtOAc, 70:30) to afford the desired product as a yellow
solid (0.0837, 23.1%). The solid was then recrystallized from EtOH to afford the pure
(TLC, GC/MS) product as bright yellow crystals (0.0536 g, 14.8%): mp 119-121 ºC; Rf =
0.57 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6): 7.72-7.62 (m, 1H), 7.59 (s,
1H), 7.51 (dd, J =2.0 Hz, J =8.4 Hz, 1H), 7.38 (t, J =8.2 Hz, 3H), 7.22 (d, J =8.40 Hz,
1H), 6.91 (d, J =1.9 Hz, 1H), 4.64 (d, J =2.4 Hz, 2H);13C NMR : 165.0, 161.2-157.8
(dd, J = 7.1 Hz), 141.1, 133.0-132.7 (t, J = 10.5 Hz), 130.3, 129.6, 126.5, 123.3, 122.5,
121.6, 112.4-112.1 (dd, J =6.8 Hz), 111.3, 111.1, 77.5, 74.7, 29.0 ppm; MS (m/z) 329
(M+), 28 (100 %). Anal. Calcd for C18H10ClFNO: C, 65.57; H, 3.06; N, 4.25; Found: C,
65.58; H, 3.20; N, 4.51.
1-(Propargyl)-5-chloro-3-(3,5-difluoro-benzylidene)indolin-2-one (266)
To a solution of 5-chloro-3-(3,5-difluoro-benzylidene)-indolin-2-one (0.4061 g, 1.396
mmol) in EtOH (3 mL) was added 1.7 equiv of DBU (355 µL, 2.56 mmol) and the
resulting mixture was allowed to stir at rt for 5 min, the solution turned a orange color.
To the mixture 3 equiv. of propargyl bromide (383 µL, 4.19 mmol,) was then added to
the stirred solution after which time the mixture was placed in the microwave for 15 min
at 170 ºC. The mixture was then allowed to cool to rt and placed in the freezer overnight.
The solution was evaporated under reduced pressure and purified with silica gel
(hexanes/EtOAc, 70:30) to afford the desired product as a yellow oil/solid (0.2860 g, 62.3
%). The oil/solid was recrystallized from DCM/hexanes to afford the pure (TLC,
GC/MS) product as bright yellow crystals (0.0554 g, 12.1%): mp (177-179 ºC); Rf = 0.76
(EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6): 8.14 (dd, J = 2.1 Hz, J = 9.3 Hz,
2H), 8.05 (s, 1H), 7.93 (d, J = 2.0 Hz, 1H), 7.47 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.1 Hz,
1H), 7.17 (d, J = 8.3 Hz, 1H), 4.63 (d, J = 2.4 Hz, 2H); 13C NMR (DMSO-d6) δ: 166.5,
163.6-160.1 (dd, J = 10.3 Hz), 139.0, 136.7-136.3 (t, J = 10.8 Hz), 129.1, 128.6, 126.0,
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125.1, 120.2, 114.8-114.3 (dd, J = 8.4 Hz), 110.6, 106.1-105.8 (t, J = 25.6 Hz), 77.7,
74.4, 28.8 ppm; MS (m/z) 329(M+), 28 (100 %).
1-(Propargyl)-5-fluoro-3-(2,6-difluoro-benzylidene)indolin-2-one (267)
To a solution of 5-fluoro-3-(2,6-difluoro-benzylidene)indolin-2-one (0.2704 g, 0.983
mmol) in acetonitrile (45 mL) was added 6 equiv of KF/alumina (0.9146 g, 5.98 mmol)
and the resulting mixture was stirred at rt for 5 min., the solution stayed a bright yellow
color. Propargyl bromide 80% (270 µL, 2.94 mmol, 3 equiv) was then added dropwise to
the stirred solution of the preformed anion after which time the mixture was refluxed for
27 h. The mixture was then allowed to cool to rt and the suspended KF/alumina was
removed by vacuum filtration. The filtrate was evaporated under reduced pressure and
purified with silica gel (hexanes/EtOAc, 70:30) to afford the desired product as a yellow
solid (0.1636, 53.2%). The solid was then recrystallized from EtOH to afford the pure
(TLC, GC/MS) product as bright yellow crystals (0.1280 g, 41.6%): mp 171-175 ºC; Rf =
0.69 (EtOAc/hexanes, 1:1); 1H NMR (300 MHz, DMSO-d6): 7.71-7.61 (m, 1H), 7.57 (s,
1H), 7.36 (t, J =8.3 Hz, 2H), 7.33 (d, J =2.6 Hz, 1H), 7.30 (d, J =9.2 Hz, 1H) 7.20 (dd, J
=4.4 Hz, J =8.6 Hz, 1H), 6.71 (dd, J =2.0 Hz, J =4.5 Hz, 1H), 4.64 (d, J =2.4 Hz, 2H)
;13C NMR : 165.2, 161.2-157.8 (dd, J =6.9 Hz), 159.6-156.4 (d, J =237 Hz), 138.7 (d, J
=1.3 Hz), 132.9-132.6 (d, J =10.6 Hz), 130.2-130.1 (t, J =1.0 Hz), 123.1, 121.1-121.0 (d,
J =9.0 Hz), 117.3-116.9 (d, J =23.7 Hz), 112.4-112.1 (dd, J =6.8 Hz), 111.5-111.3 (t, J
=19.3 Hz), 110.6-110.5 (d, J =8.3 Hz), 110.4-109.9 (d, J =25.5 Hz), 77.7, 74.5, 28.9 ppm;
MS (m/z) 313 (M+), 28 (100 %). Anal. Calcd for C18H10F3NO: C, 69.01; H, 3.22; N, 4.47;
Found: C, 68.86; H, 3.27; N, 4.60.

3-(2,6-Difluoro-benzylidene)-5-fluoro-1-[1-(2-fluoro-ethyl)-1H-[1,2,3]triazol-4ylmethyl]-1,3-dihydro-indol-2-one (284)
To a solution of 2-fluoroethyltosylate (1 equiv., 0.224 mmol, 0.0488 g) in N, Ndimethylformamide (5 mL) was added sodium azide (1.1 equiv., 0.2456 mmol, 0.0159 g)
and the resulting mixture was heated at 50 ºC for 30 min. in which the solution stayed
clear. After 30 min., 5 mol % 1M Cu (II) sulfate (12 μL) and 10 mol % (5 mg) sodium
ascorbate were added to the mixture turning the solution brown/orange. The mixture was
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stirred for 1-2 min. in which the solution changed back to a clear color. 1-(Propargyl)-5fluoro-3-(2,6-difluoro-benzylidene)indolin-2-one (1 equiv., 0.0700g, 0.223 mmol) was
added to the mixture and heated at 80 ºC for 24 h. The reaction was cooled in an ice bath
and transferred to a beaker with 30 mL cold water after which 10% NH4OH (5 mL) was
added to the reaction with stirring. The reaction mixture then washed with DCM (30 mL)
and brine solution (30 mL). The solution was dried with sodium sulfate and the filtrate
was evaporated under reduced pressure and purified with silica gel (hexanes/EtOAc,
70:30) to afford the desired product as a orange oil (0.0709 g, 78.9 %). The oil was then
recrystallized from DCM/Hexanes to afford the pure (TLC, GC/MS) product as
orange/brown solid (0.0679 g, 75.5%): mp 171-174ºC; Rf = 0.30; MS (m/z) 402 (M+), 28
(100 %).
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